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Abstract 
Approximately half the world’s human population is at risk of infection from 
mosquito-borne arboviruses. Currently, interactions between the mosquito 
antiviral response and infecting arboviruses remains poorly understood; 
deciphering these will be crucial to the development of novel methods to limit 
replication and transmission that could help control future outbreaks. Previous 
mammalian studies have shown that the Homo sapiens Small Ubiquitin-related 
Modifier (SUMO) pathway plays a fundamental role in multiple aspects of cell 
biology, including the regulation of host cell immunity. However, this pathway 
and its impact on arbovirus replication remain uncharacterised in mosquito hosts 
such as Aedes aegypti (Ae. aegypti; Aa). 
Comparison between the Ae. aegypti and H. sapiens (Hs) SUMOylation pathways 
demonstrated a high degree of amino acid sequence and structural similarity. 
The most notable predicted difference is the lack of ability of AaSUMO to form 
poly-SUMO chains, which have important functions in H. sapiens. Biochemical 
analysis of the AaSUMOylation pathway identified a conserved function, and 
confirmed that AaSUMO could not efficiently form poly-SUMO chains, unlike 
HsSUMO3 (its closest H. sapiens homologue) due to the absence of an internal 
SUMO conjugation motif. Catalytically inactive mutants revealed the necessity of 
AaPIAS (Protein inhibitor of activated STAT) to induce the formation of poly-
SUMO chains. Confocal microscopy confirmed that AaSUMO protein is expressed 
in haemocytes, the salivary glands, ovaries, and midgut, all of which are sites of 
arboviral replication. Q-PCR investigations have also revealed the AaSUMOylation 
pathway to be ubiquitously expressed. In vitro depletion of the AaSUMOylation 
pathway led to significantly enhanced levels of Zika, Semliki Forest, and 
Bunyamwera virus replication, identifying a vital role for AaSUMOylation in the 
suppression of these arboviruses. Subsequent studies in H. sapiens cells have also 
identified a significant role for HsPIAS1 in suppressing the replication of Zika, 
Semliki Forest, and Bunyamwera viruses. Furthermore, depletion of HsSUMO1 
significantly enhanced the replication of Bunyamwera virus, indicating that 
SUMOylation suppresses arbovirus in a virus dependent manner. Collectively, 
these data have identified a novel role for the SUMOylation pathway in 
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suppressing arbovirus replication in both the vertebrate and invertebrate species 
in which arboviruses replicate.  
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MIDV   Middleburg virus 
Min  minutes 
miRNA micro RNA 
ML  Median lobe 
ml  millilitres 
mm  millimeter 
MOI  Multiplicity of Infection 
mRNA  messenger RNA 
MyD88  Myeloid differentiation primary response 88 
N  Nucelocapsid protein 
NaCl  Sodium Chloride 
NDUV  Ndumu virus 
NEDD8 Neural-precursor-cell-expressed developmentally down-regulated 8 
NEMO  NF-κB essential modulator 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
ng  Nanogram  
nl  Nano-luciferase 
nm  Nanometres 
nM  nanomolar 
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NOD  Nucleotide-binding oligomerization domain 
NRIV  Ngari virus 
ns  Not significant 
NS1-5  Non-structural protein 1-5 
NSm  Non-structural protein encoded by the Medium segment 
nsP1-4 Non-structural protein 1-4 
NSs  Non-structural protein encoded by the Small segment 
o/n  Over night 
ONNV  O’nyong-nyong virus 
P  Phosphate 
P; Pro  Proline 
PAMPS Pathogen associated molecular patterns 
PBS  Phosphate buffered saline 
PCR  Polymerase Chain Reaction 
pfu  Plaque forming units 
PGRP  Peptidoglycan recognition proteins 
PIAS  Protein inhibitor of activated STAT 
piRNA  Piwi-interacting RNA 
PKR  Protein kinase R 
PL  Proximal lateral lobe 
PML  Promyelocytic leukemia protein 
PML-NB PML-nuclear body 
PRRs  Pattern recognition receptors  
PTM  Post-translational modification 
Pup  prokaryotic ubiquitin-like protein 
Q; Gln  Glutamine 
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QPCR  Quantitative Polymerase Chain Reaction 
R; Arg  Arginine 
RDRP  RNA-dependent RNA polymerase 
RIDL  Release of insects carrying a dominant lethal genetic system  
RIG-I  Retinoic acid inducible gene I 
RISC  RNA induced silencing complex 
RNA  Ribonucleic acid 
RNAi  RNA interference 
RNC  Ribonucleocapsid 
RPB1  RNA polymerase binding protein 1 
rpm  Revolutions per minute 
RT  Room temperature  
s  Seconds 
S; Ser  Serine 
SAE1/2 SUMO activating enzyme 1 / SUMO activating enzyme 2 
SAP  Scaffold associating region/Acinus/PIAS 
SARS  Severe acute respiratory syndrome 
SCM  SUMO conjugation motif 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SENP  Sentrin specific protease 
SESV  Southern elephant seal virus 
sfRNA  subgenomic flavivirus RNA 
SFV  Semliki forest Virus 
SIM  SUMO interaction motif 
siRNA  small interfering RNA 
SLEV   St Louis encephalitis virus 
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SOCS  Suppressors of cytokine signalling 
SPDV  Salmon pancreas disease virus 
SP-RING SP- Really Interesting New Gene 
STAT  Signal transducer and activator of transcription 
STUbLs SUMO targeted Ubiquitin Ligase 
SUMO  Small ubiquitin-like modifier 
T; Thr  Threonine 
TAM  Tyro3/Axl/Mer 
TCV  Trocara virus 
TLR  Toll-like receptor 
TPB  Tryptose phosphate broth  
TRAF  TNF receptor-associated factor 
TRIM  Tripartite Motif family 
TYK2  Tyrosine Kinase 2 
Ubc9  Ubiquitin conjugating enzyme 9 
UFM1  ubiquitin-fold modifier 1 
Upd  Unpaired 
UV  Ultraviolet 
V; Val  Valine 
VEEV  Venezuelan equine encephalitis virus 
Vero  African green monkey kidney epithelial cells 
vRNA  Viral RNA 
WEEV   Western equine encephalitis virus 
WNV  West Nile virus 
XRN1  Exoribonuclease 1 
YFV  Yellow Fever virus  
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ZIKV  Zika virus 
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1. Introduction 
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1.1. Overview 
This chapter aims to inform the reader about the importance of studying 
mosquito vector species and the arboviruses they transmit. The clinical 
importance of vector-borne diseases will be covered, before describing the 
distribution of Aedes aegypti (Ae. aegypti), the vector responsible for the 
transmission of many clinically and economically important arboviruses. Further 
details about alphaviruses, flaviviruses, and orthobunyaviruses will be provided, 
including their clinical significance, epidemiology of disease, genome structure, 
and replication. The introduction will then cover post-translational modification 
by ubiquitin-related modifiers, specifically the Small Ubiquitin-like Modifier 
(SUMO) pathway. What is known about arbovirus interactions with the cellular 
immune response will be described, followed by what is known about SUMO-virus 
interactions and SUMO-arbovirus interactions. 
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1.2. Importance of studying vector-borne 
diseases  
Vector-borne diseases cause of one-sixth of the human illness and disabilities 
suffered worldwide (WHO 2014). Diseases transmitted by vectors are also widely 
reported to threaten global food security. They can be a significant threat to 
plant health, including commercially important crops, and can lead to outbreaks 
of diseases amongst livestock, which result in illness, loss of productivity, and 
the death of large numbers of animals (Kilpatrick and Randolph 2012, Whitfield, 
Falk et al. 2015).  
Vector-borne diseases are ubiquitous around the world, including areas inhabited 
by Homo sapiens, where ticks, midges, flies, sandflies, and mosquitoes are 
highly prevalent. The only areas where vector-borne diseases are not found is 
the Polar Regions. Each individual species of arthropod vector possess its own 
unique geographical distribution (Borkent 2014, WHO 2014).  
Mosquitoes act as vector species to a wide range of pathogens. This includes 
malaria, caused by the parasite Plasmodium falciparum, and tularemia, caused 
by the bacteria Francisella tularensis (Ulu-Kilic and Doganay 2014). Mosquitoes 
are also known to be prominent vectors of viral diseases, including dengue virus 
(DENV), chikungunya virus (CHIKV), and Japanese Encephalitis virus (JEV). Viral 
diseases transmitted by the mosquito species Aedes aegypti will be the focus of 
the study. 
 
1.2.1. Aedes aegypti  
Aedes aegypti (Ae. aegypti) is amongst the most clinically important vector-
species, it is known to be the primary vector for DENV, yellow fever virus (YFV), 
Zika virus (ZIKV), Semliki Forest virus (SFV), CHIKV, and Bunyamwera virus 
(BUNV). Together these clinically important arboviruses are responsible for 
endemic disease burdens in developing areas, and can cause large epidemic 
outbreaks of disease. Consequently, when Ae. aegypti comes into contact with 
humans there can be a massive health and economic burden (Figure 1.1, and 
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described further in Sections 1.3.1; Section 1.3.2; Section 1.3.3). The range of 
Ae. aegypti incorporates countries with very large populations including Brazil, 
India, Indonesia, and throughout South East Asia. Together, they threaten 
approximately half of the world’s population (Bhatt, Gething et al. 2013). Ae. 
aegypti is predominantly an urban vector which utilises the abundance of 
artificial containers that contain stagnant water as larval sites, and feeds almost 
entirely on humans (Kraemer, Sinka et al. 2015).  
 
As a vector species, Ae. aegypti is involved in a complex interplay between the 
human host and vector associated arboviruses. Consequently, multiple methods 
are currently being employed in an attempt to reduce the impact of arboviruses 
transmitted by Ae. aegypti to humans. These include the use of pesticides and 
habitat destruction to restrict Ae. aegypti population levels. The development of 
vaccines, such as the vaccine for yellow fever virus, 17D, and supportive 
treatments to alleviate symptoms are used to limit the disease burden in specific 
cases (Smith, Penna et al. 1938). Recently there has also been work to suppress 
arbovirus replication in the vector species. This can be achieved through the 
release of Wolbachia infected mosquitoes, or genetically engineering mosquitoes 
Figure 1.1 Predicted distribution of Ae. aegypti.  
A depiction of the predicted probability that Ae. aegypti is located in an area (from 
blue 0, to red 1) from (Kraemer, Sinka et al. 2015) 
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to be resistant to arboviruses (Flores and O'Neill 2018). Alternative methods 
include the release of insects carrying a dominant lethal genetic system (RIDL) 
(Alphey 2014) (Figure 1.2). In order to develop novel strategies to further 
restrict arbovirus infection, interactions between Ae. aegypti and the 
arboviruses they transmit need to be better studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arbovirus 
Vector 
Host 
e.g. bed nets 
/ pesticides / 
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e.g. vaccines 
/ supportive 
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Figure 1.2 Mechanisms used to suppress arbovirus infection  
Multiple mechanisms are utilised to prevent arboviral illness in humans (or other 
host species). Where vaccines are available, the arboviruses can be prevented from 
establishing an infection in the human host. For other arboviruses where no vaccines 
are available, supportive care may be used to alleviate symptoms. Various 
pesticides are used to suppress the population of mosquitoes in urban areas, and 
bed nets can also be used as a physical barrier preventing mosquitoes from biting 
and infecting people who live in areas where mosquitoes and arboviruses are 
endemic. Genetic engineering of mosquitoes, or infecting mosquitoes with strains of 
Wolbachia are recent techniques being utilised to suppress arbovirus replication in 
the mosquito, or to suppress the population of mosquitoes.  
Abbreviations: RIDL, release of insects carrying a dominant lethal genetic system. 
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1.2.1.1. Mosquito-arbovirus interactions 
Within the Ae. aegypti vector, arboviruses are well reported to be capable of 
establishing an infection in a range of cells and organs. Initially, arboviruses are 
taken up by Ae. aegypti in a blood meal from an infected vertebrate host. 
Consequently, the first site of infection is the midgut and the first barrier to 
arboviral infection is the midgut epithelium. Longitudinal and circular tracheal 
and muscle cells wrap around the midgut. Digestion products are absorbed and 
transported through the midgut into the haemolymph, which acts as the 
mosquito plasma (Okuda, de Souza Caroci et al. 2002). Arboviruses need to enter 
and successfully replicate in mosquito midgut epithelial cells, which has been 
shown to be a barrier to arboviral replication (Whitfield, Murphy et al. 1973, 
Scholle, Girard et al. 2004, Smith, Adams et al. 2008). After escaping the midgut 
into the haemocoel, the arbovirus needs to amplify, disseminating throughout 
the mosquito and infecting the salivary glands, before being transmitted 
horizontally to a new vertebrate host (Figure 1.3A). Many arboviruses can 
replicate in a range of insect tissues including the fat body, tracheal system, 
haemocytes, and nerve tissue. Very few arboviruses have been shown to be 
capable of replicating in muscle cells (Girard, Klingler et al. 2004, Salazar, 
Richardson et al. 2007, Dong, Kantor et al. 2016). Haemocytes are believed to 
form an important site of arboviral replication, as studies have shown over 90% 
of mosquito haemocytes can become infected within four days of infection 
(Parikh, Oliver et al. 2009, Carissimo, Pondeville et al. 2015). Arboviruses are 
also known to be capable of infecting mosquito ovaries. Infection of the ovaries 
can result in vertical transmission of the arbovirus, which can be an important 
mechanism for arboviral survival during unfavourable conditions (Lequime and 
Lambrechts 2014). Mosquito ovaries are comprised of multiple synchronous 
ovarioles. Ovarioles contain a germarium where follicles, or egg chambers, are 
initially formed. An egg chamber is capable of producing one egg, and is made 
up of one future oocyte and seven larger interconnected nurse cells. The egg 
chamber is surrounded by an epithelium of follicle cells covered by an ovarian 
sheath which contains muscle cells that function to slowly propel the egg 
chamber towards the oviduct (Snodgrass 1935, Hudson, Petrella et al. 2008) 
(Figure 1.3B). Primary follicles will develop after emergence to the 
previtellogenic stage, where follicle development is stopped until a blood meal. 
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After blood feeding, the follicle undergoes vitellogenesis. Eggs are laid two to 
three days after a blood meal, allowing the secondary follicles to develop into 
egg chambers (Nicholson 1921, Clements 1992). 
Once the arboviruses have been amplified and disseminated throughout the 
mosquito, salivary glands need to be infected to enable the arbovirus to be 
injected into a new host with the saliva. The salivary glands are a pair of organs 
which comprise of two lateral lobes, and one shorter median lobe connected to 
the salivary duct (Figure 1.3C). Different sections of the salivary glands secrete 
different proteins. For instance, proteins involved in interfering with the host 
immune response or host haemeostasis are produced in the distal lateral lobes 
(Phattanawiboon, Jariyapan et al. 2014, Pingen, Bryden et al. 2016, Jin, Guo et 
al. 2018). Arboviruses tend to establish an infection in the mosquito salivary 
glands at the distal or proximal lateral lobes (Salazar, Richardson et al. 2007, 
Raquin, Wannagat et al. 2012, Tchankouo-Nguetcheu, Bourguet et al. 2012). 
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Figure 1.3 Mosquito anatomy 
(A) A schematic of the mosquito showing the pathway arboviruses must follow to 
continue their life cycle. Arboviruses enter the mosquito midgut in a blood meal, 
replicate to escape, and disseminate throughout the mosquito until the salivary glands 
are infected. Arboviruses can then infect a new host. Adapted from Franz, Kantor et 
al. (2015). (B) The mosquito ovary and an individual ovariol. The ovariol is made up of 
the secondary follicle, germarium, and the primary vitellogenic follicle, containing 
nurse cells (sea green), the oocyte (grey) and follicular cells (red). Adapted from 
(Clements 1992) (C) A single adult female salivary glands comprising of two lateral 
lobes, separated into the proximal region (PL), and distal region (DL) and a median 
lobe (ML). Adapted from Jariyapan, Choochote et al. (2007)  
 
C 
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1.3. Arboviruses  
Arboviruses generally have four distinct types of genome: a single strand positive 
sense RNA genome (within the families Flaviviridae and Togaviridae), a genome 
composed of 9 to 12 segments of double stranded RNA (within the family 
Reoviridae), a genome composed of 1, 2, or 3 segments of negative sense RNA 
(within the families Peribunyaviridae, Orthomyxoviridae, Feraviridae, 
Fimoviridae, Jonviridae, Nairoviridae, Tospoviridae, Phasmaviridae, and 
Phenuiviridae), or a DNA genome (the only known DNA arbovirus is in the family 
Asfarviridae) (Hubalek, Rudolf et al. 2014, Adams, Lefkowitz et al. 2017).  
There are many clinically important arboviruses that infect humans, including 
West Nile virus (WNV), DENV, CHIKV, and JEV. Other economically important 
arboviruses of livestock include Venezuelan equine encephalomyelitis virus 
(VEEV), bluetongue virus, and Schmallenberg virus (Mellor 2000). These viruses 
are emerging into new areas due to climate change resulting in an extended 
transmission season and increased migration of vectors. The impact of increased 
globalisation through travel and trade is another cause of arbovirus introduction 
into new areas (Semenza and Menne 2009). This results in some arboviruses, 
such as DENV, increasing in incidence by 30 fold since the 1960s (World Health 
Organization. 2012). Other arboviruses, such as ZIKV, or Keystone virus, have 
been known for a long time but have only recently been associated with 
outbreaks and disease in humans (Duffy, Chen et al. 2009, Lednicky, White et al. 
2018). The life cycle of the arboviruses involves cycling between the 
invertebrate vector and vertebrate host (Lundstrom 1999, Mellor 2000, Hubalek, 
Rudolf et al. 2014). Arboviruses are transmitted from the reservoir host to a new 
uninfected host through a haematophagous arthropod such as a mosquito, tick, 
sand fly, or midge vector. These vectors may sometimes infect incidental hosts, 
which are animals that aren’t the usual feeding source for the vector, and are 
usually associated with more severe clinical consequences (Figure 1.4). All 
viruses, arboviruses included, need to manipulate the host cellular system in 
order to survive and replicate efficiently. 
Due to differences in the vertebrate host and arthropod vector, arboviruses have 
evolved very different replicative mechanisms for each. It has long been known 
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that arboviruses often establish a persistent infection in the arthropod vector, 
which may come with a ‘fitness cost’ to the vector. However, infection of 
mammalian cells usually results in a lytic infection, resulting in cell death (Peleg 
1968, Riedel and Brown 1979, Newton, Short et al. 1981, Sirisena, Kumar et al. 
2018).  
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Figure 1.4 A basic arbovirus transmission cycle 
The virus normally transmits between the reservoir host and the arthropod 
vector. Occasionally the vector infects an incident host, or the virus may be 
transmitted vertically to vector offspring. 
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There are two primary mechanisms of vertical transmission. Transovarial 
transmission, where the virus infects germinal cells, is generally more efficient 
that results in the majority of future eggs being infected (Rosen 1988). Trans-
egg infection is the second mechanism, where the virus infects the eggs during 
egg laying. Trans-egg infection process is generally regarded as less efficient 
(Rosen 1988, Lequime and Lambrechts 2014). It is estimated that less than 0.1% 
of mosquito-based infections are due to vertical transmission and that it is only 
believed to be important for arboviral survival during unfavourable conditions 
(Lequime and Lambrechts 2014).  
 
1.3.1. Alphaviruses 
Alphaviruses are a genus within the Togaviridae family. The other genus in the 
Togaviridae family is Rubiviridae, whose only species is the Rubella virus 
(Dominguez, Wang et al. 1990). Alphaviruses are 50-70 nm in diameter and have 
a single strand of positive sense RNA ((+)ssRNA) approximately 10 – 11 kb in 
length (Fuscaldo, Aaslestad et al. 1971, Arif and Faulkner 1972, Westaway, 
Brinton et al. 1985, Leung, Ng et al. 2011). The genome is initially transcribed 
into a polyprotein of non-structural proteins 1-4 (nsP1-4), which are 
subsequently cleaved into the constituent proteins. A second polyprotein of 
structural proteins is then transcribed, translated, and cleaved (Figure 1.5). 
Alphaviruses are spherical, possess T4 icosahedral symmetry, and a total of 240 
capsid protein monomers make up the capsid (Soderlund, Kaariainen et al. 
1975). The envelope contains approximately 80 spikes formed of trimers of 
E1/E2 heterodimers (Vogel, Provencher et al. 1986). Alphaviruses are split 
antigenically into eleven complexes. These are the Western equine encephalitis 
virus (WEEV), VEEV, Eastern equine encephalitis virus (EEEV), SFV, Middelburg 
virus (MIDV), Ndumu virus (NDUV), Barmah Forest virus (BFV), Trocara virus 
(TCV), salmon pancreas disease virus (SPDV), Southern elephant seal virus 
(SESV), and Eilat virus (EILV) (Kaslow, Stanberry et al. 2014). MIDV, NDUV, BFV, 
and SESV have no recognised clinical symptoms and EILV is incapable of infecting 
vertebrates (Kaslow, Stanberry et al. 2014). This section will detail diseases 
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commonly associated with alphaviruses, their epidemiology, and their 
replication.  
 
 
 
 
 
 
 
 
 
 
1.3.1.1. Alphavirus epidemiology 
Alphaviruses can be broadly split into two categories based on their geographical 
separation; Old World and New World. The Old World alphaviruses include CHIKV 
(primarily found in Africa, India, and South East Asia), SFV (Africa), and o’nyong-
nyong (ONNV) (Africa). New World alphaviruses include VEEV (Americas) and 
Mayaro virus (MAYV) (South America) (Schmaljohn and McClain 1996, Paredes, 
Weaver et al. 2005). The distribution of alphaviruses was believed to be due to 
at least 2 transoceanic migratory events (Powers, Brault et al. 2001). Although, 
more recent data suggests that the alphavirus genus originated in the southern 
oceans and spread equally into the Old World and New World (Forrester, Palacios 
et al. 2012). 
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Figure 1.5 The alphavirus genome 
The alphavirus genome (vRNA) is transcribed and translated into two 
polyproteins, the 5’ region of the genome encodes the non-structural 
polyprotein, which is subsequently cleaved into the constituent parts (nsP1-4), 
while the 3’ terminal of the genome encodes the structural polyprotein which 
is cleaved into the capsid (C), the assembly protein (E3), spike glycoprotein E1 
(E1), 6K protein (6K), and spike glycoprotein E2 (E2). The individual proteins 
are annotated within the polyproteins. 
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1.3.1.2. Alphavirus disease  
There are two broad disease phenotypes. Old World alphaviruses, such as CHIKV, 
are rarely fatal. Symptoms presented are generally fever, rash, and myalgia. 
CHIKV infection can also result in polyarthralgia in peripheral small joints, which 
can last weeks to months and is generally debilitating (Deller and Russell 1968, 
Adebajo 1996). The arthralgia can become chronic, likely due to the virus 
persisting in macrophages in the joints and results in an inflammatory immune 
response (Toivanen 2008). During the previous 60 years there have been sporadic 
epidemic outbreaks of CHIKV every 2-20 years, although due to the disease 
similarities with DENV, other small outbreaks may have been missed (Powers and 
Logue 2007). A large epidemic which lasted from 2004 – 2011 and was reported 
in over 40 countries resulted in 1.4 – 6.5 million cases (Suhrbier, Jaffar-Bandjee 
et al. 2012). These were predominantly located around the Indian Ocean, with 
La Reunion island being severely affected in 2005-2006, resulting in a total 
estimated economic burden of €43.9 million (at 2006 values) (Soumahoro, Boelle 
et al. 2011). This outbreak was later found to be driven by a single point 
mutation (A266V) in the E protein (Tsetsarkin, Vanlandingham et al. 2007). 
There were also localised outbreaks found in some European countries (Moro, 
Gagliotti et al. 2010, Frank, Schoneberg et al. 2011).   
New World alphaviruses, such as VEEV or EEEV, are generally associated with 
more severe disease phenotypes. This ranges from headaches and vomiting to 
encephalitis, respiratory symptoms, hematuria, seizures, and coma. Humans 
infected with EEEV can have a case fatality rate of between 50-70% (Zacks and 
Paessler 2010). VEEV results in encephalitis less frequently than EEEV, and 
infection generally results in flu-like symptoms. Case fatality rates in humans is 
low (<1%), although there are still neurological symptoms associated with 
infection including disorientation, mental depression, and convulsions in up to 
14% of infected people (Johnson and Martin 1974). The most recent major VEEV 
outbreak was in 1995 in Venezuela and Colombia, where estimated 75,000 - 
100,000 cases occurred (Rivas, Diaz et al. 1997).  
 
S Stokes, 2018  37 
1.3.1.3. Alphavirus replication 
Alphaviruses gain entry to the cell via the viral E glycoprotein. In mosquito 
salivary glands, the heparin sulfate proteoglycan is believed to mediate entry, 
although in human tissues the cellular receptor(s) remain unknown (Ciano, 
Saredy et al. 2014, Vancini, Hernandez et al. 2015). This binding is believed to 
mediate clathrin-dependent entry into the cell (Sourisseau, Schilte et al. 2007). 
Low pH triggers fusion of the endosomal membrane with the viral membrane, 
which then allows for viral RNA (vRNA) to be released into the cytoplasm (White 
and Helenius 1980, Vancini, Hernandez et al. 2015).  
The alphavirus genome is split into two main sections, the non-structural and 
structural sections (Figure 1.5). There is a opal ‘UGA’ termination codon 
between nsP3 and nsP4, which approximately 10% of the time is read-through. 
This read-through is due to the presence of the following cytosine nucleotide (as 
part of a ‘CUA’ codon). In mutational studies, the read through efficiency 
decreased from approximately 10% to less than 1% when the cytosine was 
mutated into a uracil, adenosine, or guanine (Li and Rice 1993). Isolates of SFV 
which have previously been found encoding an arginine amino acid instead of a 
stop codon expressed an increased proportion of the nsP1-4 polyprotein and 
were linked to increased neurovirulence (Tuittila, Santagati et al. 2000). 
After being translated, the non-structural polyprotein is cleaved into the 
constituent proteins through the protease action of nsP2. The nsP1-4 polyprotein 
is initially cleaved to produce nsP1-3 and nsP4. These form an unstable 
replication complex which can synthesise a negative strand of vRNA (de Groot, 
Hardy et al. 1990). nsP1 is then cleaved off the nsP1-3 polyprotein in trans, 
resulting in nsP1, and nsP2-3. These three proteins form another replication 
complex which is active on the negative strand to mediate genomic vRNA 
synthesis (De, Sawicki et al. 1996, Kujala, Ikaheimonen et al. 2001). Negative 
vRNA synthesis is prevented once the cleavage of nsP1-4 is complete, and the 
replication complex induces replication of the positive sense vRNA (Shirako and 
Strauss 1994). The structural polyprotein is translated under the control of the 
26S subgenomic promoter, the capsid auto-cleaves from the remainder of the 
polyprotein as it is being translated (Melancon and Garoff 1987). The capsid 
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protein is then available to associate with the region coding for nsP1 in the 
vRNA, ensuring full-length vRNA strands are packaged into nucleocapsid-like 
particles (Figure 1.6) (Weiss, Nitschko et al. 1989).  
The envelope glycoprotein E3 signals for the remainder of the polyprotein to be 
transferred to the endoplasmic reticulum, where host peptidases cleave it into 
the constituent proteins (Lobigs, Zhao et al. 1990). Another envelope 
glycoprotein, 6K, acts as a signalling mechanism for the processing of the 
downstream E1 glycoprotein (Sanz, Madan et al. 2003). The E1 and E2 precursor 
glycoproteins interact to form a heterodimer (Andersson, Barth et al. 1997). This 
heterodimer is transported to the Golgi complex from the endoplasmic reticulum 
and subsequently onto the cell surface where budding occurs (Fields and Kielian 
2013). During transport to the cell surface, host Furin proteases cleave the E2 
precursor glycoprotein into E2 and E3 (Zhang, Fugere et al. 2003, Fields and 
Kielian 2013). Upon release from the cells, an envelope is acquired from the host 
cell plasma membrane. This process has been shown to occur quickly, with SFV 
replication in chick embryo cells occuring at a rate of 200 plaque forming 
units/cell/hour (Acheson and Tamm 1967). 
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Figure 1.6 Alphavirus life cycle 
Alphaviruses are initially endocytosed into the cell through the viral E 
glycoprotein. The drop in pH results in fusion of the endosomal and viral 
membranes. Genomic RNA is released into the cytoplasm initially translating the 
non-structural polyprotein (nsPs). An unstable complex of nsP1-3 and nsP4 can 
synthesise a negative sense RNA ((-)RNA) genome which functions as a template 
for future positive strands of viral RNA ((+)RNA) to be produced. The structural 
proteins are translated under the control of an internal 26S subgenomic promoter. 
The (+)RNA and structural proteins migrate to the Golgi complex, followed by 
budding at the cell surface and release into a new envelope of host cell 
membrane. Adapted from Leung, Ng et al. (2011) 
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1.3.2. Flaviviruses 
Flaviviruses are a genus in the Flaviviridae family. Other members of the 
flaviviridae family include the genus pegivirus, pestivirus, and hepacivirus, 
which contain hepatitis C virus (HCV). This genus contains some of the most 
clinically important arboviruses, including DENV, JEV, WNV, and ZIKV. Most of 
the viruses in the flavivirus genus are transmitted by arthropods, and are 
approximately 40-65 nm in diameter (Smith, Brandt et al. 1970, Yang, Kim et al. 
2004). The genome of a flavivirus is a single strand of positive sense RNA which 
is approximately 11 kb in length (Yaegashi, Vakharia et al. 1986). The genome 
consists of one open reading frame which produces a poly-protein that is cleaved 
into a total of 11 proteins during and after translation and maturation (Figure 
1.7) (Cleaves 1985). DENV, one of the most well studied flaviviruses, comprises a 
capsid protein which forms a complex with the RNA genome. Approximately 180 
envelope (E) and 180 membrane proteins are found in the outer lipid envelope in 
a T=3 icosahedral symmetry (Zhang, Chipman et al. 2003, Strauss and Strauss 
2008, Byk and Gamarnik 2016). Flaviviruses are distributed over a large 
geographical range and rapidly spread into new ecological niches (Mutebi, 
Rijnbrand et al. 2004). Most flaviviruses use birds and small mammals as natural 
hosts. Humans can also be hosts, capable of amplifying the virus to titres high 
enough to establish a new infection in a naïve mosquito. Only a relatively small 
proportion of infections result in deadly diseases (Solomon and Mallewa 2001).  
Polyprotein 
5
’ 
vRNA 
Structural Non-structural 
 C pr M E NS1 NS2A NS3 NS4B NS5 
Figure 1.7 The flavivirus genome 
The flavivirus genome (vRNA) is transcribed and translated into one polyprotein. 
The 5’ region of the genome and polyprotein encodes the structural proteins 
(the capsid protein (C), peptide pr (pr), small envelope protein M (M), and 
envelope protein (E)). The 3’ region of the genome and polyprotein encodes the 
non-structural proteins (non-structural proteins 1-5 (NS1-5). The final cleaved 
proteins are indicated within the polyprotein. 
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1.3.2.1. Flavivirus epidemiology 
Flaviviruses which infect humans can be broadly split into three categories, 
those with no known vectors, those which use ticks as vectors, and those which 
use mosquitoes as vectors (Kuno, Chang et al. 1998, Gaunt, Sall et al. 2001). The 
mosquito borne flaviviruses can be further categorised into those which cause 
neurotropic diseases, such as JEV, and those which cause haemorrhagic diseases, 
such as DENV (Gaunt, Sall et al. 2001). Generally, flaviviruses which cause 
neurotropic diseases are transmitted by Culex species of mosquito, while 
flaviviruses associated with haemorrhagic diseases are more commonly 
transmitted by Aedes species of mosquito (Waddell and Taylor 1948, Haddow, 
Williams et al. 1964, Chamberlain, Gogel et al. 1966, Mattingly 1967, Nir, 
Goldwasser et al. 1968, Sucharit, Surathin et al. 1989). Flaviviruses are 
distributed throughout the world, with specific geographic spreads dependent on 
the vector. Generally, flaviviruses transmitted by mosquitoes are located around 
the tropics, such as India and South East Asia, and flaviviruses transmitted by 
ticks are more commonly located in the cooler climates, such as Russia or 
Northern Europe (Solomon and Mallewa 2001).  
Flaviviruses are believed to have originated from a common ancestor 
approximately 10,000 years ago in Africa (Billoir, de Chesse et al. 2000, Solomon 
and Mallewa 2001). It is believed that the tick-borne lineage diverged, prior to 
the mosquito-borne lineage (Gaunt, Sall et al. 2001, Mackenzie, Gubler et al. 
2004).  
 
1.3.2.2. Flavivirus disease 
There are three main disease phenotypes associated with flavivirus infection. 
These are neurological, viral haemorrhagic fever, and fever–arthralgia–rash 
symptoms (Solomon and Mallewa 2001).  Neurological symptoms, such as 
encephalitis, can be caused by TBEV, JEV, and St Louis encephalitis virus (SLEV). 
An example of a haemorrhagic virus is DENV, or YFV.  
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The neurotropic flavivirus, JEV, is regarded as the most important cause of 
mosquito-borne encephalitis in Asia and the Western Pacific (WHO 2015, Simon 
and Kruse 2018). Approximately 1 in 250 infections develop symptoms, which 
may include headache, fever, tremors, coma, and encephalitis. Up to 33% of 
symptomatic cases are fatal (NHS 2016). Each year there are between 60,000-
70,000 cases of JEV, which predominantly affects children, as infection results in 
lifelong immunity (WHO 2015).  
Haemorrhagic flaviviruses, which include DENV and YFV, are regarded as the 
most important arbovirus. This is due to their global distribution and significant 
clinical burden. It is estimated that half the world’s population is at risk of DENV 
infection, with approximately 390 million people being infected each year 
(Bhatt, Gething et al. 2013, WHO 2018). Of these, it is predicted that 96 million 
develop symptoms that include headache, muscle and joint pains, high fever 
(~105 ˚F / 40 ˚C), rash, vomiting, and swollen glands (Harris and Duval 1924, 
WHO 2018). Symptoms generally develop 3-15 days following the bite from an 
infected mosquito and may last between 2-7 days (WHO 2009). Haemorrhagic 
fever may develop as a consequence of plasma leaking from blood vessels which 
can result in severe bleeding, fluid accumulation, respiratory distress, or organ 
failure. There are five distinct DENV serotypes (DENV-1, DENV-2, DENV-3, DENV-
4, and DENV-5, although there is currently debate about whether DENV-5 exists) 
(Mustafa, Rasotgi et al. 2015). All serotypes appear to be able to circulate within 
the same population, although one serotype tends to dominate (Singh, Maitra et 
al. 1999, Dash, Parida et al. 2006, Shrivastava, Tiraki et al. 2018).  
ZIKV is another flavivirus closely related to DENV. ZIKV was identified in Zika 
forest in 1947, initially associated with only mild clinical symptoms in 
approximately 20% of cases until the 2015 outbreak in South and Central America 
(Dick, Kitchen et al. 1952). During this outbreak, ZIKV infection was found to 
correlate with an increase in the number of cases of Guillain-Barré Syndrome 
and foetal microcephaly (Oehler, Watrin et al. 2014, Rasmussen, Jamieson et al. 
2016, Styczynski, Malta et al. 2017, Wen, Song et al. 2017). This could be due to 
the effect of ZIKV NS4A and NS4B proteins, which disrupts the Akt-mTOR 
signalling pathway. The Akt-mTOR signalling pathway is known to have roles in 
cell development, proliferation, and inhibition of autophagy. Consequently, a 
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dysregulated Akt-mTOR pathway during neuronal development can lead to 
microcephaly (Liang, Luo et al. 2016).  
 
1.3.2.3. Flavivirus replication 
As arboviruses, the flaviviruses studied here replicate in both mammalian and 
insect cells. The replication strategy has been shown to be similar in the host 
and vector species. Generally, entry of flaviviruses into cells follows a similar 
mechanism to alphaviruses (Strauss and Strauss 2008). Flaviviruses bind the 
external viral E protein to a cellular receptor that trigger internalisation through 
specific cell-type dependent mechanisms (Ang, Wong et al. 2010, Piccini, 
Castilla et al. 2015). The cellular receptor varies depending on the flavivirus; 
DENV has been reported to bind to heparin sulfate, while ZIKV has been reported 
to bind to DC-SIGN, AXL, Tyro3, and TIM-1 in human skin cells (Chen, Maguire et 
al. 1997, Hamel, Dejarnac et al. 2015). Once the virus has been imported into 
endosomes, the fall in pH resulted in E-homodimers forming E-homotrimers 
(Zhang, Zhang et al. 2004, Huang, Butrapet et al. 2010). The E-homotrimers 
then reorientate so the fusion peptide is able to fuse the viral membrane with 
the host membrane. This results in the release of the viral genome into the 
cytoplasm. As flaviviruses possess a genome consisting of a single strand of 
positive sense RNA ((+)ssRNA), the genome is directly translated into a 
polyprotein which is cleaved into the individual constituent proteins by the auto-
catalytic NS3/NS2B enzymes and host cell proteases, including furin and signal 
peptidase (Bazan and Fletterick 1989, Falgout, Chanock et al. 1989, Markoff 
1989, Chambers, Grakoui et al. 1991, Stadler, Allison et al. 1997). NS5, the viral 
polymerase molecule is capable of synthesising a double strand RNA (dsRNA) 
viral genome (Chu and Westaway 1987, Guyatt, Westaway et al. 2001). The 
dsRNA genome is then transcribed into more viral (+)ssRNA, and translated into 
the polyprotein. This process occurs in cytoplasmic replication factories, prior to 
viral assembly occurring on the rough endoplasmic reticulum (Welsch, Miller et 
al. 2009, Cortese, Goellner et al. 2017). Progeny viruses are then transported to 
the Golgi apparatus and exocytosed at the cell surface (Hase, Summers et al. 
1987) (Figure 1.8). Interestingly, in mosquito cells, some flaviviruses, such as 
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DENV-2, appear to mature in nucleocapsid-like structures in the cytoplasm. 
Virions then bud at the plasma membrane or into cytoplasmic vacuoles (Hase, 
Summers et al. 1987). 
  
Figure 1.8 Flavivirus life cycle  
(1) A flavivirus E protein binds to a virus specific cellular receptor. (2) The 
virus enters the cell through receptor-mediated endocytosis. (3) Fall in pH 
causes a conformational change resulting in the viral RNA genome being 
released into the cytoplasm. (4) Genome is translated into a polyprotein 
which auto-cleaves. NS5 functions as a polymerase which is responsible 
for replication of viral genome. Viral assembly occurs on the rough 
endoplasmic reticulum (Rough ER). (5) Progeny viruses are transported to 
the Golgi for maturation and transport to the cell surface. (6) Virus is 
released from the cell surface. Adapted from Bartenschlager and Miller 
(2008). 
S Stokes, 2018  45 
1.3.3. Orthobunyaviruses  
Orthobunyaviruses are a genus of the Peribunyaviridae family, within the 
Bunyavirales order. There are over 170 viruses in the orthobunyavirus genus 
(Calisher 1996). The prototype species is BUNV. Most viruses in this genus are 
arboviruses, with a virion diameter of approximately 80-120 nm (Obijeski, Bishop 
et al. 1976, Talmon, Prasad et al. 1987). Heterodimers of envelope glycoproteins 
form on the surface of the virion. Orthobunyaviruses possess a genome made of 
three single strands of negative sense RNA ((-)ssRNA); termed the Small (S), 
Medium (M), and Large (L) segments (Figure 1.9). BUNV is reported to be 
pleomorphic in shape with locally-ordered lattices of glycoprotein spikes 
(Bowden, Bitto et al. 2013). Due to segmented structure of the genome, it has 
the potential to naturally re-assort genome segments between strains co-
infecting the same host cell.  
The viral genome comprises three single strands of negative sense RNA of 
approximately 1 kb, 4.5 kb, and 6.5 kb. The S segment transcribes two genes, 
the nucleocapsid protein (N), and a non-structural (NSs) protein (Elliott 1989). 
The M genome translates a polyprotein which is cleaved into a non-structural 
protein (NSm), and two glycoproteins (Gn, and Gc, corresponding to the location 
on the N- or C- terminal) (Lees, Pringle et al. 1986). The L genome translates a 
large protein which serves as the RNA-dependent RNA polymerase (RDRP) 
(Figure 1.9) (Elliott 1989).  
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Figure 1.9 The orthobunyaviridae genome  
Orthobunyaviridae have a genome comprising three single strands of negative 
sense RNA which is used to produce complementary RNA (cRNA) that is then 
transcribed and translated. The S segment encodes both the nucleocapsid 
protein (N) and an overlapping genomic region encodes the non-structural 
protein (NSs). The M segment encodes a polyprotein that is cleaved to produce 
Glycoproteins Gn and Gc, and a non-structural protein (NSm). Finally, the L 
segment encodes the RNA-dependent RNA polymerase.  
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1.3.3.1. Orthobunyavirus epidemiology 
Within the orthobunyavirus genus, there is the clinically important Bunyamwera 
serogroup that contains the prototype virus, BUNV. Other notable members of 
the Bunyamwera serogroup include Ngari virus (NRIV), Batai virus (BATV), and 
Cache Valley virus (CVV). BATV has been identified throughout Europe and Asia, 
while BUNV is predominantly distributed throughout Africa (Smithburn, Haddow 
et al. 1946, Kokernot, Smithburn et al. 1958, Bardos and Cupkova 1962, Liu, 
Shao et al. 2014). NRIV is a naturally occurring recombinant virus comprising of 
BATV M segment, and BUNV S and L segments (Section 1.3.3.3) (Yanase, Kato et 
al. 2006). As NRIV is a recombinant of BATV and BUNV. NIRV can be vectored by 
a wide range of mosquito species, including Aedes, Culex, and Anopheles. 
Consequently, it has a broad geographical spread throughout Europe, Central, 
and Eastern Asia (Bardos and Cupkova 1962, Singh and Pavri 1966, Yadav, Sudeep 
et al. 2012, Liu, Shao et al. 2014). To date, BATV has only been isolated in Africa 
once (Briese, Bird et al. 2006). However, due to the presence of vector species 
and the existence of NRIV, BATV distribution is believed to be severely 
underreported. Other viral members of this serogroup, such as CVV, are found 
distributed throughout North America, and can be spread by Ae. aegypti, 
although the evolutionary history of these viruses remains unknown (Holden and 
Hess 1959, Edwards, Higgs et al. 1998, Dutuze, Nzayirambaho et al. 2018). 
 
1.3.3.2. Orthobunyavirus disease 
There are a range of disease phenotypes experienced by people infected with 
orthobunyaviruses. Those infected with members of the California serogroup of 
orthobunyaviruses, such as La Crosse Virus (LACV), Californian encephalitis virus 
(CEV), or Jamestown Canyon virus (JCV), ranges from mild febrile disease to 
fatal encephalitis (CDC 2018). Most symptomatic cases experience sudden fever, 
followed by headache, fatigue, and vomiting, although symptoms usually end 
within 7 days. Up to half of cases may experience seizures, but fatalities are 
rare (<1%) (CDC 2018). 
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Within the bunyamwera serogroup, BUNV, BATV, and NRIV are known to cause 
disease in both humans and animals. BUNV infection generally results in mild 
symptoms, if any, which include fever, headache, joint pain, rash and occasional 
CNS symptoms (Southam and Moore 1951, Kokernot, Smithburn et al. 1958). 
BATV infection may result in flu-like symptoms in humans, although it has a 
more severe disease phenotype in ruminants, which includes abortions and 
premature births (Hubalek 2008). NRIV can result in more severe clinical 
symptoms, including haemorrhagic fever (Bowen, Trappier et al. 2001). NRIV has 
also been associated with a large outbreak in Sudan in 1988, although reported 
symptoms were less clinically severe (Nashed, Olson et al. 1993, Groseth, 
Weisend et al. 2012).  
 
1.3.3.3. Orthobunyavirus replication 
Generally, the viral Gn-Gc heterodimer binds to the cell receptor, enabling the 
virus to undergo endocytosis into the cell (Schmaljohn, Connie et al. 2007). The 
viral membrane fuses with the vesicle membrane after acidification of the 
vesicle, due to a conformational change in Gc, allowing the viral genome to be 
released (Gonzalez-Scarano, Janssen et al. 1985). Initially, viral cDNA of the S 
and L gene is transcribed through the action of virion-associated RDRP, the viral 
mRNA is then translated into the N, NSs, and RDRP proteins by free ribosomes. 
The M gene is translated by ribosomes bound to the endoplasmic reticulum, to 
produce Gc, Gn, and NSm. Gn and Gc are transported to the Golgi through Golgi 
targeting signals in Gn for viral assembly (Lappin, Nakitare et al. 1994, Shi, 
Lappin et al. 2004). 
A switch occurs from protein synthesis to viral replication, through a currently 
unknown mechanism. RDRP transcribes more viral genome in the cytoplasm. 
vRNA and complementary RNA (cRNA) are both encapsidated by the N protein, 
although with a higher affinity for vRNA (Severson, Partin et al. 1999, Kaukinen, 
Koistinen et al. 2001). This produces the ribonucleocapsid, which serves as an 
anti-termination signal enabling the entire genome to be synthesised (Eifan and 
Elliott 2009). Orthobunyaviruses usually mature by budding at smooth 
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membranes of the Golgi. A build-up of Gn and Gc proteins in the Golgi triggers 
viral assembly. The ribonucleocapsid carrying S, M, and L genes localizes to the 
Golgi, for some viruses in the bunyavirales order, including Seoul virus and 
Hantaan virus, this has been shown to be through interactions with the Human 
Small Ubiquitin-like Modifier-1 (SUMO1), the SUMO conjugating enzyme (Ubc9), 
and the Protein Inhibitor of Activated STAT (PIAS) 1, and PIAS2β (Lee, 
Yoshimatsu et al. 2003, Maeda, Lee et al. 2003). After budding at the Golgi, the 
virion is released from the cell by exocytosis due to signalling by the Gn 
cytoplasmic tail (Figure 1.10) (Överby, Pettersson et al. 2007). 
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Figure 1.10 Orthobunyavirus life cycle 
(1) The orthobunyavirus enters through pH mediated endocytosis. (2)  pH 
induced conformational change allows the release of viral RNA (vRNA) into the 
cytoplasm. (3) vRNA is transcribed into viral mRNA by virion associated RNA-
dependent RNA polymerase (L). (4) The viral mRNA is translated into the L, 
nucleocapsid and non-structural proteins (S) by cytoplasmic ribosomes. (5) The 
viral mRNA from the M genome is translated into a polyprotein by ribosomes 
attached to the endoplasmic reticulum, the polyprotein is then cleaved into the 
glycoproteins Gn, and Gc, and the non-structural NSm protein. (6) Gn-Gc 
heterodimers localize to the Golgi for virus assembly. (7, 8) Replication of vRNA 
is required to build-up sufficient quantities of genomic vRNA to be packaged into 
virions. (9) Ribonucleocapsids of S, M, and L segments are transported to the 
Golgi to be packaged with the Gn-Gc glycoproteins. (10, 11) The virus undergoes 
exocytosis into the extracellular space. From Szemiel (2011).  
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1.4. Post-translational modification  
The post-translational modification (PTM) of proteins plays an important role in 
the regulation of protein function within cells. PTMs can do this by providing a 
new charge or surface that influences protein-protein interactions, 
conformational structural changes, and catalytic or substrate binding properties 
of target proteins. Some well-characterised examples of PTMs include 
glycosylation, methylation, phosphorylation or acetylation. Along with these, the 
addition of small proteins or chains of proteins can be added onto acceptor sites 
of target proteins undergoing modification. Ubiquitin and related family 
members, including Small Ubiquitin-like MOdifier (SUMO) are key examples of 
such protein PTMs that influence target protein function or sub-cellular location. 
This section will focus on the ubiquitin family of PTMs, which is a group of nine 
members including ubiquitin, SUMO, Neural-precursor-cell-expressed 
developmentally down-regulated 8 (Nedd8), Interferon-Stimulated Gene 15 
(ISG15), Fau-ubiquitin like protein (FAT10), Autophagy-related protein 8 (ATG8), 
and Ubiquitin-fold modifier 1 (UFM1) (Pickart and Eddins 2004, Hochstrasser 
2009). These members all display similar structural homology but very divergent 
amino acid identity. For instance, there is only ~20% amino acid sequence 
identity between human ubiquitin and human SUMO1 (Bayer, Arndt et al. 1998). 
Another shared characteristic of all members of the ubiquitin-like family is the 
C-terminal diglycine motif, which is only exposed after proteolysis of the 
terminal region (Pickart and Eddins 2004). This terminal diglycine is responsible 
for enabling the mature ubiquitin family of proteins to modify the target protein 
through the formation of an isopeptide bond to lysine residues found within 
target substrate proteins. 
 
1.4.1. Ubiquitin 
Ubiquitin, the founding member of the family, was initially identified in 1975 as 
an inducer of differentiation of T-cells and B-cells. Ubiquitin was identified in 
animal cells, yeast, and higher plants using radioisotope studies (Goldstein, 
Scheid et al. 1975). Using this method ubiquitin was also identified in bacteria. 
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It was therefore believed to be found universally throughout life and given the 
name ubiquitin (Goldstein, Scheid et al. 1975). Later work showed that ubiquitin 
was only found in eukaryotic organisms (Rechsteiner 1988, Gottesman 1989). 
Bacteria have been shown to possess a ubiquitin-like pathway, called prokaryotic 
ubiquitin-like protein (Pup), which performs a similar biological function to 
ubiquitin (Pearce, Mintseris et al. 2008). 
The ubiquitination pathway involves a three step enzymatic cascade comprised 
of an activating enzyme (E1), conjugating enzyme (E2), and ligating enzymes 
(E3) (Scheffner, Nuber et al. 1995).  The enzymes exist in a hierarchical 
structure. There are two known activating enzymes in humans (Pickart 2001), 
and 35 E2 enzymes. The larger number of E2 enzymes is due to their selective 
interactions with the E3 ligating enzymes. There are hundreds of E3 ligating 
enzymes, which provide specialised substrate protein interactions and functions 
(Pickart 2001, van Wijk and Timmers 2010). One of the best-understood 
biological roles for ubiquitin is ATP dependent protein degradation through the 
26S proteasome. Poly-ubiquitin chains are covalently bound to the target 
protein, which then activate subunits of the proteasome that subsequently 
degrade the modified protein (Elsasser, Gali et al. 2002, Kerscher, Felberbaum 
et al. 2006).  
Various forms of PTM have been shown to influence arboviral replication. For 
instance, the E2 ubiquitin conjugating enzyme, UbcH10, is usually 
downregulated in cells following CHIKV infection. Studies which over expressed 
UbcH10 resulted in reduced cellular susceptibility to CHIKV infection indicating a 
role for ubiquitin conjugation in suppressing CHIKV replication, although no 
precise mechanism was identified (Treffers, Tas et al. 2015). Furthermore, nsP2 
from CHIKV and SFV have been shown to avoid the cellular transcriptional shut 
off by targeting RNA polymerase binding protein 1 (RPB1), a catalytic subunit of 
RNA Polymerase II, for ubiquitin mediated degradation (Akhrymuk, Kulemzin et 
al. 2012). Demonstrating that arboviruses hijack the ubiquitin pathway to 
benefit arboviral replication. Furthermore, a recently identified mosquito 
ubiquitin, named Ub3881, has been identified in mosquitoes to possess antiviral 
activity against DENV infection. DENV infection was found to downregulate 
expression of Ub3881, and overexpression studies indicate Ub3881 was required 
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to target DENV envelope protein for degradation, decreasing the number of 
infectious virions produced. Further depletion studies in mosquito cell culture 
and mosquitoes correlated with an increase in DENV replication, although it was 
not statistically significant (Troupin, Londono-Renteria et al. 2016).  
 
1.4.2. Overview of the Small Ubiquitin-like 
MOdifer (SUMO) protein 
This section aims to provide an overview of the SUMO modification pathway. 
PTM by SUMO can result in a range of altered biological roles, including protein 
localisation, protein-protein interactions, and regulation of gene expression 
through the modification of transcription factors (Geiss-Friedlander and Melchior 
2007, Cubenas-Potts and Matunis 2013). SUMO can also modify proteins through 
multiple mechanisms, including both covalent and non-covalent interactions. 
Various types of SUMO interactions include: covalent mono-SUMOylation bonds to 
SUMO conjugation sites on a target protein, covalent poly-SUMO chains on a 
target protein, or non-covalent interactions mediated by SUMO Interaction 
Motifs (SIMs) within target proteins. SUMO can also interact with the ubiquitin 
pathway through competitively binding to the same lysine residue on the 
substrate proteins thereby preventing protein degradation, or by acting as a 
signal for poly-ubiquitin chain formation mediated by SUMO targeted Ubiquitin 
ligases (STUbLs), such as RING finger protein 4 (RNF4), thereby promoting 
protein degradation (Pickart and Eddins 2004, Miteva, Keusekotten et al. 2010). 
SUMO modification has been shown to be involved in cellular immunity helping 
the cell overcome viral infection. This can occur through the actions of SUMO 
modification of RIG-I, enhancing its interaction with the downstream acceptor 
molecule Cardif, which increases the expression of IFN (Mi, Fu et al. 2010). 
Melanoma differentiation associated gene 5 (MDA5) has also been reported to be 
SUMOylated, resulting in an increase in IFN expression (Fu, Xiong et al. 2011). 
One member of the Tripartite Motif family (TRIM) of proteins, TRIM19, or 
promyelocytic leukaemia (PML) protein, contains three SIM sites, and four SUMO 
conjugation motif (SCM) sites, and has been shown to possess antiviral activity 
against a range of viruses including herpesviruses, papillomaviruses and 
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retroviruses (Maul, Ishov et al. 1996, Mossman, Saffran et al. 2000, Everett 2001, 
Shen, Lin et al. 2006). 
SUMO is known to have roles in cell cycle progression, and dysregulation of the 
SUMOylation pathway has well documented roles in cancer (Seeler and Dejean 
2017). SUMO also plays a role in the development of both mammals and 
Drosophila. Many signalling pathways with roles linked to embryonic 
development are known to be regulated by SUMO. For instance, SUMO negatively 
regulates JNK signalling that is responsible for dorsal closure in embryos, thorax 
closure in pupae, and stress induced apoptosis (Igaki 2009, Huang, Du et al. 
2011). Furthermore, Drosophila’s SUMO conjugating enzyme, Ubc9 (initially 
identified as Lesswright) has roles in anterior patterning, and is believed to be 
required for the nuclear localisation of Bicoid, a transcription factor (Epps and 
Tanda 1998). Currently, the only studies investigating the Ae. aegypti 
SUMOylation pathway have been based on bioinformatics, detailing the 
conservation of the pathway between Ae. aegypti and H. sapiens, demonstrating 
that the pathway is broadly conserved except the SUMO protein is lacking an 
internal SCM in insects (Choy, Severo et al. 2013, Urena, Pirone et al. 2016). 
 
1.4.2.1. SUMO proteins 
SUMO was initially identified in 1996 in mammalian cells (Matunis, Coutavas et 
al. 1996). There are 5 SUMO paralogues in humans; SUMO1, SUMO2, SUMO3, 
SUMO4, and SUMO5. mRNA for SUMO4 has been shown to be predominantly 
detected in the kidneys, while SUMO5 is more abundantly expressed in the testes 
and peripheral blood leukocytes (Bohren, Nadkarni et al. 2004, Liang, Lee et al. 
2016). All 5 paralogues are between 10.5-12 kDa in size (GenBank FJ042790.1 , 
Uniprot P55854 2014, Uniprot P61956 2014, Uniprot P63165 2014, Uniprot 
Q6EEV6 2014). Once SUMO mRNA has been transcribed, it is translated into an 
immature SUMO protein. The C-terminal of SUMO is cleaved by sentrin specific 
proteases (SENPs). This reveals the diglycine (GG) motif and produces a mature 
SUMO protein (Kamitani, Nguyen et al. 1997, Suzuki, Ichiyama et al. 1999). The 
structure of SUMO has previously been resolved and shown to be similar to the 
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tertiary structure of ubiquitin (Bayer, Arndt et al. 1998). Like ubiquitin, SUMO is 
known to covalently bind to the ε-amino group on an acceptor lysine residue 
located in the substrate protein. Studies have previously shown that SUMO and 
ubiquitin can compete for binding at the same lysine residue (Desterro, 
Rodriguez et al. 1998). The target lysine residue is commonly found in a SUMO 
Conjugation Motif (SCM; Ψ-Lys-X-[Asp/Glu]), where Ψ represents a branched 
amino acid and X represents any amino acid (Rodriguez, Dargemont et al. 2001). 
Analysis of various studies reveals that glutamic acid is preferentially bound over 
aspartic acid within the SCM (Wang and Dasso 2009, Wasik and Filipek 2014). 
SUMO has also been reported to be capable of binding inverted SCMs (Matic, 
Schimmel et al. 2010). Moreover, there are reports of SUMO modification that is 
dependent on phosphorylation, extended SUMO conjugation motifs, and SUMO 
that binds to negatively charged amino acids (Hietakangas, Anckar et al. 2006, 
Yang, Galanis et al. 2006). Approximately 25% of SUMO conjugation sites with 
target substrates occur at non-canonical SCMs (Matic, Schimmel et al. 2010).  
For an efficient transfer of SUMO from Ubc9 to the target acceptor lysine, the 
interaction needs to be stabilised. The SCM acts as a site with affinity for the 
amino acid residues in the Ubc9 near the active site. The four residues in the 
SCM interact with Ubc9. The first residue is hydrophobic which allows the side 
chains to form Van der Waals forces with four different Ubc9 residues (Pro128, 
Ala129, Gln130, and Ala131). The second residue is the conserved lysine that is the 
target for SUMO modification. Due to the interactions between the interfaces of 
Ubc9 and the target protein, the acceptor lysine can be observed to fit in a 
hydrophobic shallow groove. The orientation of the amino acid side chain of the 
third residue directs away from Ubc9. However, the amino acid space is required 
to saddle the consensus peptide through Van der Waals forces. The fourth 
residue, commonly Asp/Glu are believed to be preferred due to the longer side 
chain which enables hydrophobic Van der Waals forces to form (Bernier-
Villamor, Sampson et al. 2002). For SUMO modification of a target protein to 
occur more efficiently, an E3 ligase may help to stabilize the interaction 
between the target protein and Ubc9. Alternatively, extended versions of SCMs, 
or phosphorylation sites at the C-terminal have also been identified which 
enhance affinity for Ubc9 (Hietakangas, Anckar et al. 2006, Yang, Galanis et al. 
2006, Mohideen, Capili et al. 2009, Matic, Schimmel et al. 2010).  
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SUMO2 and SUMO3 proteins share 87% nucleotide sequence identity and 97% 
amino acid sequence identity (Saitoh and Hinchey 2000). Due to the high degree 
of homology at the amino acid level, these two proteins can’t be distinguished 
using antibodies, and therefore are often referred to as SUMO2/3. SUMO1 can be 
distinguished by antibodies as there is less amino acid identity, approximately 
47% (Saitoh and Hinchey 2000). SUMO2/3 also contains an internal SCM, which 
allows chains of SUMO2/3 to efficiently form (Muller, Hoege et al. 2001, Tatham, 
Jaffray et al. 2001). SUMO1, does not contain an SCM and consequently doesn’t 
efficiently form chains in vivo, but can be incorporated into the SUMO2/3 chains 
as a chain terminator (Tatham, Jaffray et al. 2001).  
In some eukaryotes including the fruit fly D. melanogaster, baker’s yeast 
Saccromyces cerevisiae and the nematode Caenorhabditis elegans, only one 
SUMO protein has been identified (Matunis, Coutavas et al. 1996, Lehembre, 
Badenhorst et al. 2000). This SUMO protein shares a high degree of sequence 
identity with human SUMO2/3 (Matunis, Coutavas et al. 1996, Saitoh and Hinchey 
2000). The D. melanogasters homologue is believed to function more like human 
SUMO1, due to the lack of internal SCM, and studies have suggested that 
uncontrolled SUMO chain formation can be lethal (Urena, Pirone et al. 2016). 
However, the SUMO homologue in S. cerevisiae has been found to be capable of 
forming poly-SUMO chains, due to the presence of three SCMs in its N-terminus 
(Bylebyl, Belichenko et al. 2003). The gene sequences of two SUMO proteins 
have been identified in the cockroach Blattella germanica, and in Ae. aegypti 
(Choy, Severo et al. 2013, Urena, Pirone et al. 2016). No biochemical studies 
have been performed thus far on an Ae. aegypti SUMO. 
Once SUMO is covalently bound to the substrate, non-covalent interactions can 
form that are mediated by SIMs in other proteins. This non-covalent interaction 
allows temporary protein-protein interactions to form. Multiple SIM motifs have 
been identified, the best characterized being the hydrophobic [Val/Ile]-X-
[Val/Ile]-[Val/Ile] (Minty, Dumont et al. 2000, Wang and Dasso 2009). 
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1.4.2.2. SUMO interaction motifs (SIMs) 
SIM sites are known to be important in regulating SUMO interactions. SIM sites 
function by binding onto the surface patch of the SUMO substrate between the 
α-helix and a β-sheet, extending the β-sheet by one strand. This interaction 
extends the β-strand in either a parallel or antiparallel orientation (Namanja, Li 
et al. 2012, Jardin, Horn et al. 2015). In S. cerevisiae, it has been found that in 
all SIM sites studied, antiparallel binding interactions are more stable when 
compared to parallel binding interactions (Jardin, Horn et al. 2015). SIM sites are 
frequently flanked by acidic residues or phosphorylated serine residues 
(Stehmeier and Muller 2009). In the mammalian system these can help 
determine SUMO2/3 specificity (Hecker, Rabiller et al. 2006).  
 
1.4.2.3. SUMO pathway 
The SUMOylation system is comprised of an analogous set of enzymes to the 
ubiquitin pathway as both contain E1, E2, and E3 enzymes. The ubiquitin 
pathway contains several E2 conjugation enzymes and many E3s (Rotin and 
Kumar 2009, Wasik and Filipek 2014). The SUMO pathway, however, only 
contains one E2 (Ubc9), and a limited number of E3s. Examples of E3 enzymes 
include the RING-finger-domain families, such as ‘SAP and Miz-finger domain-
containing protein 1 / Protein Inhibitor of Activated STAT’ (SIZ/PIAS), or RanBP2. 
E3 enzymes help increase the rate and specificity of SUMO ligation in vivo, 
although aren’t necessary in vitro if target proteins contain an SCM (Verger, 
Perdomo et al. 2003). The ubiquitin pathway also contains an E4 enzyme 
specifically responsible for efficient formation of poly-ubiquitin chains (Huang, 
Minaker et al. 2014). A potential SUMO E4-like enzyme, ZNF451, has also been 
identified as part of the vertebrate SUMOylation pathway (Eisenhardt, Chaugule 
et al. 2015). 
The mature SUMO protein binds E1 through the generated C-terminal glycine 
residue. E1 exists as a heterodimer comprising of the SUMO activating enzymes 
SAE1 and SAE2 (Desterro, Rodriguez et al. 1999). Using ATP and a magnesium 
ion, the E1 heterodimer activates SUMO, allowing it to form a thioester bond 
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with E1. Subsequently, SUMO forms a thioester bond with the E2 conjugating 
enzyme, Ubc9 (Schwarz, Matuschewski et al. 1998, Desterro, Rodriguez et al. 
1999). E3 enzymes are known to play important regulatory roles in SUMOylation, 
as they increase SUMOylation efficiency (Johnson and Gupta 2001). SENPs, 
initially utilised to mature SUMO, are also required to deSUMOylate target 
proteins, releasing SUMO into a pool of unconjugated SUMO. The SUMOylation 
pathway can be seen depicted in Figure 1.11.   
Figure 1.11 H. sapiens SUMOylation pathway.  
SUMO is activated by the SAE1/SAE2 activating heterodimer in an ATP dependent 
manner. SAE1/2 (grey) forms a thioester bond with the terminal glycine of SUMO 
(yellow) and then passes SUMO to Ubc9 (blue), forming a second thioester bond. 
Ubc9 can directly SUMOylate a substrate protein at a SCM, but in vivo this process 
is often assisted by the presence on an E3 ligase (PIAS; pink). Modification of 
substrate proteins occurs via an isopeptide linkage at a target lysine residue. SENPs 
can deSUMOylate proteins contributing to a pool of unconjugated SUMO.  
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1.4.2.3.1. Activating enzyme 
The mature SUMO protein is activated by the SUMO activating enzyme (SAE) 1 - 
SAE2 heterodimer. There is only one SUMO E1 activating heterodimer which 
activates SUMO in two steps. ATP and magnesium are utilised to prime the 
terminal glycine of SUMO, and a conserved catalytic cysteine residue located 
within SAE1/2. The subsequent binding of the terminal glycine of SUMO to the 
cysteine residue of SAE1/2 results in a thioester bond forming (Desterro, 
Rodriguez et al. 1999). Some viruses, such as adenovirus has been shown to 
target the SAE1 protein of the heterodimer for degradation. This occurs through 
the action of the Gam1 protein, which forms a complex with ubiquitin in order 
to degrade the protein. As there is no longer an activating enzyme, cellular 
SUMOylation is prevented (Boggio, Passafaro et al. 2007). A combination of the 
activating enzyme and the C-terminal of the ubiquitin-like modifier which 
interacts with the E1 have been shown to be responsible for E1-ubiquitin-like 
modifier specificity. For instance, the E1 for NEDD8 would not activate ubiquitin 
without specific mutations (Walden, Podgorski et al. 2003, Souphron, Waddell et 
al. 2008, Ronau, Beckmann et al. 2016). Furthermore, SAE1/2 has been shown to 
be a substrate for SUMO modification, altering its cellular localisation, and 
decreasing the interaction between SAE1/2 and Ubc9 (Truong, Lee et al. 2012, 
Truong, Lee et al. 2012). SAE1/2 has also previously been reported to be able to 
autoSUMOylate during in vitro studies (Truong, Lee et al. 2012). 
 
1.4.2.3.2. Conjugating enzyme 
The E2 conjugating enzyme is responsible for covalently binding SUMO onto the 
substrate protein. The SUMO system only has one known E2 enzyme, Ubc9 (Gong, 
Kamitani et al. 1997, Schwarz, Matuschewski et al. 1998). The surface of Ubc9 is 
known to possess a positive charge, while the corresponding surface in SUMO-1 
possesses a negative charge resulting in an attraction between the proteins 
(Tong, Hateboer et al. 1997, Liu, Jin et al. 1999). Ubc9 initially forms a thioester 
bond with SUMO through the terminal glycine with the Cys93 in the Ubc9 
catalytic triad (Schwarz, Matuschewski et al. 1998, Tatham, Kim et al. 2003). 
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The cysteine residue orientates itself in order to form a new thioester bond 
requiring another ATP (Gong, Kamitani et al. 1997, Olsen, Capili et al. 2010). 
The surface of Ubc9 opposing the catalytic site is known to possess a distinct 
charge, which may assist with conjugating SUMO instead of ubiquitin or other 
ubiquitin-like modifiers (Giraud, Desterro et al. 1998). Mammalian SUMO1, 
SUMO2, and SUMO3 can all also bind the N-terminal of Ubc9 with similar affinity, 
SUMOylating Ubc9 (Tatham, Kim et al. 2003). Interestingly, the formation of a 
thioester bond has been shown to be initially slowed by the presence of the 
amino acids Asp100 and Lys101, the subsequent rate of transfer to the target 
protein is then enhanced by the presence of these amino acids (Tatham, Chen et 
al. 2003). 
 
1.4.2.3.3. Ligating enzyme 
The E3 ligating enzymes are responsible for increasing the rate of SUMO 
conjugation to substrate proteins. This is usually accomplished through two 
mechanisms. The E3 can enhance the rate of transfer by ‘priming’ the 
Ubc9~SUMO thioester and can also form a complex of the substrate protein with 
Ubc9~SUMO thioester. Consequently, the E3 enzymes are believed to be 
responsible for substrate specificity. However, relatively few E3 enzymes have 
been identified for the SUMO pathway (Cubenas-Potts and Matunis 2013, Jiang, 
Saavedra et al. 2014, Cappadocia and Lima 2018). Examples include RanBP2, Pc2 
polycomb protein, ZNF451, and the PIAS family (Takahashi, Toh-e et al. 2001, 
Pichler, Gast et al. 2002, Merrill, Melhuish et al. 2010, Eisenhardt, Chaugule et 
al. 2015). The PIAS family have been studied in more detail and consequently, 
will be the focus of this section.  
The PIAS proteins were initially identified due to their role in suppressing STAT 
and therefore suppressing the innate immune response, this was later found to 
be through PIAS activity as an E3 SUMO ligase (Chung, Liao et al. 1997, Liu, Liao 
et al. 1998, Takahashi, Toh-e et al. 2001, Kotaja, Karvonen et al. 2002, Rogers, 
Horvath et al. 2003). PIAS proteins are split into multiple functional domains 
including the SAP, PINIT, SP-RING, SIM, and S/T domains (Figure 1.12). The N-
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terminal Scaffold Associating region/Acinus/PIAS (SAP) domain is responsible for 
binding to different biological factors, including DNA, transcription factors, and 
nuclear receptors (Liu, Gross et al. 2001, Tan, Hall et al. 2002). The PINIT 
domain is responsible for regulating the localisation of PIAS within the cell 
(Duval, Duval et al. 2003). The SP-RING domain functions in protein-protein 
interactions, and is the catalytically active site of the proteins SUMO ligase 
activity (Hochstrasser 2001). The C-terminal S/T domain has been shown to be 
highly variable, with several roles including binding to nuclear coactivators 
(Jiménez-Lara, Heine et al. 2002). Finally, between the S/T domain and the SP-
RING domain there is one, or more, SIM site(s) which are believed to help 
facilitate SUMO interactions (Minty, Dumont et al. 2000, Kaur, Park et al. 2017). 
PIAS proteins have been found to be substrates of SUMO modification, recent 
studies have found that SUMO modification of PIAS1 inhibits its function as an 
inhibitor of activated STAT (Alagu, Itahana et al. 2018). 
 
 
Figure 1.12 Schematic of PIAS1 domains 
Domain structures, function, and PTM of HsPIAS1 is indicated. P is 
phosphorylation site, M is methylation site, numbers indicate the number 
of amino acids. Adapted from (Rytinki, Kaikkonen et al. 2009).  
Abbreviations: Scaffold Associating region/Acinus/PIAS (SAP), Siz PIAS-
Really Interesting New Gene (SP-RING), SUMO Interaction Motif (SIM), 
Serine/threonine-rich C-terminal (S/T). 
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1.4.2.3.4. Sentrin specific proteases 
(SENPs) 
SENPs are deSUMOylating enzymes which have two roles in the cell. They mature 
the SUMO protein by cleaving off the C-terminal, revealing a diglycine motif, and 
they deSUMOylate modified proteins (Li and Hochstrasser 1999, Gong, Millas et 
al. 2000, Mossessova and Lima 2000). This results in a constant cellular supply of 
unconjugated SUMO which can subsequently be used in other modifications. This 
is a tightly regulated process, as uncontrolled deSUMOylation is highly toxic to 
mammalian cells (Johnson 2004). Humans possess 6 reported SENPs (1-3, 5-7) 
which fall into two branches based on their genetic similarity. SENP6 and SENP7 
are closely related to each other and share homology with the yeast homologue 
Ulp2, but more distant from SENP1-3, SENP5, and the yeast homologue Ulp1 (Li 
and Hochstrasser 2000, Nayak and Muller 2014). In humans, SENP-3, -5, -6, and -
7 have all been shown to preferentially target poly-SUMO2/3 chains, likely by 
trimming the external SUMO proteins off one at a time (Di Bacco, Ouyang et al. 
2006, Eckhoff and Dohmen 2015).  
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1.5. Interactions between the viruses and the 
immune responses regulated by SUMO 
1.5.1. Vertebrate innate immune response 
Vertebrates possess a complex immune system ranging from an initial intrinsic 
immune response within cells at the site of infection, to a complex extracellular 
immune system. As the focus of this study is on the cellular mechanisms that 
influence arbovirus replication, only the mechanisms associated with cell based 
immunity will be presented. Cellular innate immunity is provided by biological 
factors which are upregulated in response to infection. Cellular intrinsic 
immunity is provided by biological factors that are constitutively expressed in 
the cell. Both the intrinsic and innate cellular immune response is tightly 
regulated in order to efficiently respond to infection, but not be constantly 
active. SUMO modification is well reported to regulate a plethora of components 
in the host innate immune response ensuring the immune response is only active 
in response to infection (Adorisio, Fierabracci et al. 2017). As a consequence of 
host cell intrinsic and innate immune factors, viruses have evolved a range of 
mechanisms to interfere with regulators of the immune response in order to 
replicate more efficiently.  
When a cell becomes infected, pattern recognition receptors (PRR), such as the 
family of Toll-like receptors (TLR), or  the cytoplasmic Retinoic acid inducible 
gene I (RIG-I) receptor, detects the pathogen associated molecular patterns 
(PAMPS) and initiate expression of antimicrobial genes to prime neighbouring 
cells. The most effective immune strategy to prime neighbouring cells that all 
mammalian cells possess is the interferon (IFN) system. There are three types of 
IFN, named type I, type II, and type III, which are released from an infected cell 
to signal neighbouring cells to enter an antiviral state. Cells possess IFN 
receptors which can recognise the different types of IFN. Type I IFN, comprising 
IFNα, IFNβ, IFNε, IFNκ, and IFNω are recognised by IFN alpha receptors 1 and 2 
(IFNAR1/2), type II IFN, comprising IFNγ, is recognised by IFN gamma receptors 
(IFNGR), and type III IFN comprises IFNλ1, IFNλ2, and IFNλ3, and is recognised by 
IL-28 receptor α, and IL-10 receptor β (Kotenko, Gallagher et al. 2003). The 
focus of this section will be on IFN types I and II.  
S Stokes, 2018  64 
Upon activation, IFN receptors activate the Janus kinase – signal transducer and 
activator of transcription (JAK-STAT) pathway. Briefly, activation of the IFN 
receptors by IFN results in the activation of members of the Janus kinase family. 
Janus Kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) are activated in response to 
type I IFN, while JAK1 and JAK2 are activated in response to type II IFN. 
Following activation of JAK1/TYK2 STAT proteins form homo- or hetero-dimers 
of STAT1/STAT2, or STAT2/STAT2. When IFNγ activates the JAK1/JAK2 proteins, 
STAT1 form homodimers. These STAT dimers translocate to the nucleus and 
function as a transcription factor, activating antiviral genes, including the MxA 
protein, protein kinase R (PKR), and TLRs (Figure 1.13) (Shuai, Stark et al. 1993, 
Silvennoinen, Ihle et al. 1993, Watling, Guschin et al. 1993).  
SUMO is reported to regulate the signalling pathways that result in translation of 
types I and II IFN, and components of the JAK-STAT pathway. For instance, ssRNA 
is a PAMP detected by TLR7 and TLR8, which activate the myeloid differentiation 
primary response 88 (MyD88) signalling pathway. The MyD88 signalling cascade 
activates many important cellular proteins, including the transcription factors 
interferon regulatory factor 7 (IRF7) and IRF8. IRF7 and IRF8 then translocate to 
the nucleus to trigger the transcription of IFN (Kawai, Sato et al. 2004). SUMO 
modification of IRF7 and IRF8 has been shown to prevent the activation of these 
proteins, thereby suppressing the IFN response. Furthermore, removal of SUMO 
by SENP1 allows IRF8 to be activated (Kubota, Matsuoka et al. 2008, Chang, Xu 
et al. 2012). Other IRF family members, including IRF1 and IRF3 have also been 
reported to be targets of PIAS mediated SUMO modification, which suppresses 
this transcriptional activity (Nakagawa and Yokosawa 2002, Han, Jiang et al. 
2008). Within the JAK-STAT pathway of neighbouring cells, SUMO has a well 
reported role of modifying STAT1 in a PIAS dependent manner. This effectively 
inhibits the type II IFN response, although the type I response can still occur 
through the formation of STAT2 homo-dimers (Rogers, Horvath et al. 2003). 
Another important PRR is the RIG-I protein. This cytoplasmic protein detects 
viral RNA triggering a signalling cascade which activates IRF3 and NF-κB. IRF3 
triggers the transcription of IFN, while the NF-κB pathway triggers the 
production of a myriad of gene products, including antiviral proteins such as pro-
inflammatory cytokines, interleukins, or Mx1 (Liu, McEachin et al. 2003, 
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Gérardin, Baise et al. 2004, Gao, Hannan et al. 2006). RIG-I is known to be a 
target for SUMO modification which enhances modification of RIG-I by ubiquitin, 
and therefore promotes interactions with downstream proteins, and upregulates 
the antiviral response (Mi, Fu et al. 2010). There are also components of the NF-
kB pathway which are also targets for modification by SUMO. NF-κB essential 
modulator (NEMO), a subunit of the IκB kinase complex which activates NF-κB, is 
SUMO modified in a PIAS dependent manner. SUMO modification results in the 
nuclear localisation of NEMO, and allows the ubiquitylation of NEMO to activate 
downstream signalling proteins in the cytoplasm (Huang, Wuerzberger-Davis et 
al. 2003, Mabb, Wuerzberger-Davis et al. 2006). SENP2, a SUMO protease is 
upregulated by NF-κB activation and functions to deSUMOylate modified NEMO, 
resulting in a negative feedback loop, which restricts the activation of the NF-κB 
pathway (Lee, Mabb et al. 2011). SUMO modification is also capable of 
negatively regulating the NF-κB pathway. IκBα is an inhibitor of the NF-κB 
pathway which is usually degraded through the proteasome. However, SUMO 
modification of IκBα protects the inhibitor from degradation, resulting in 
SUMOylation maintaining the repression of the NF-κB pathway (Desterro, 
Rodriguez et al. 1998). 
One important antiviral cellular mechanism is the phosphorylation of eukaryotic 
translation initiation factor 2α (eIF2α) by the dsRNA dependent protein kinase R 
(PKR). PKR is an ISG, induced by type I IFN, which is required to be SUMOylated 
in order to phosphorylate and activate eIF2α. The phosphorylation of eIF2α 
serves to prevent the initiation of translation of both cellular and viral proteins, 
and can result in cellular apoptosis indicating another antiviral role for SUMO 
modification (Harding, Novoa et al. 2000, Wek, Jiang et al. 2006, Muaddi, 
Majumder et al. 2010, de la Cruz-Herrera, Campagna et al. 2014).  
When under stress, cells can also form nuclear stress granules formed of 
multiple strands of mRNA stalled in translation. They form through interactions 
between mRNA binding proteins through conventional protein-protein 
interactions, and intrinsically disordered regions. One mechanism by which 
stress granule formation is initiated is through the inhibition of eIF4A (Dang, 
Kedersha et al. 2006). eIF4A has been shown to be modified by SUMO1 and 
SUMO2 in vivo, where SUMO modification is required for the formation of eIF4A 
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induced stress granules (Jongjitwimol, Baldock et al. 2016). Stress granules 
recruit antiviral proteins including RIG-I and PKR that stimulates their activation 
(Onomoto, Jogi et al. 2012, Reineke, Kedersha et al. 2015, Reineke and Lloyd 
2015).  
SUMO has been shown to regulate multiple aspects of the cellular innate immune 
response, yet currently very few studies have been published investigating 
interactions between arboviruses and host SUMOylation (Section 1.5.4). Section 
Figure 1.13 Overview of the antiviral interferon response 
Left hand side: In an infected cell, viral pathogen associated molecular patterns 
(PAMPS) are detected by pattern recognition receptors (PRRs), such as the family of 
Toll-like receptors (TLR) or Retinoic acid inducible gene-I (RIG-I). Activation of these 
proteins triggers signalling pathways which induces expression of antiviral 
compounds, including interferon (IFN). Right hand side: extracellular IFN activates 
IFN receptors, which activates the Janus kinase – signal transducer and activator of 
transcription (JAK-STAT) signalling pathway. JAK phosphorylates STAT, STAT forms a 
hetero- or homo-dimer, and translocates to the nucleus to trigger expression of IFN 
stimulated genes (ISG), putting the cell into an antiviral state.  
Abbreviations: phosphate (P); protein kinase R (PKR); tyrosine kinase (TYK2) 
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1.5.1.1, Section 1.5.1.2, Section 1.5.1.3 describe mechanisms that arboviruses 
from three distinct families employ to evade the mammalian innate immune 
response. Multiple components of these immune pathways described have been 
shown to be targets of SUMO mediated regulation. However, the role of host 
SUMOylation in response to arbovirus infection with respect to these immune 
pathways has yet to be investigated. 
 
1.5.1.1. Alphaviruses and innate immune 
evasion 
Members of the alphavirus family have been shown to suppress the host cell 
immune response by multiple mechanisms. Alphaviruses are capable of both, 
host-cell transcription and translation shut-off. Transcriptional shut-off is 
conducted through the activity of the viral nsP2 protein of Old World 
alphaviruses. nsP2 translocates to the nucleus  where it targets the catalytic 
subunit of RNA polymerase II, RPB1, for ubiquitin mediated degradation 
(Peranen, Rikkonen et al. 1990, Akhrymuk, Kulemzin et al. 2012). New World 
alphaviruses use the capsid protein to mediate host-cell transcriptional shut-off, 
by forming a complex with nuclear import and export factors, thereby blocking 
nuclear import mediated by different karyopherins (Garmashova, Gorchakov et 
al. 2007, Atasheva, Fish et al. 2010). 
During alphavirus infection, PKR becomes highly activated to the point where 
the cell experiences nearly complete eIF2α phosphorylation, resulting in 
translational shut-off (Ventoso, Sanz et al. 2006). Old World alphaviruses avoid 
this shut-off due to the presence of a highly stable hairpin loop in the RNA which 
provides resistance to eIF2α phosphorylation, by stalling the ribosome at the 
correct AUG, enabling viral RNA to be translated (Ventoso, Sanz et al. 2006, 
Toribio, Diaz-Lopez et al. 2016). Interestingly, New World alphaviruses enhance 
the shut-off of host cell translation by promoting phosphorylation of eIF2α then 
utilising the stable hairpin loop to continue translation of viral proteins, 
restricting the amount of host cell antiviral proteins that are translated (Aguilar, 
Weaver et al. 2007). 
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Alphaviruses have also developed mechanisms to interfere with the IFN pathway. 
CHIKV nsP2 has been identified as the protein responsible for inhibiting the 
nuclear localisation of STAT dimers, thereby reducing ISG expression. This 
appears to be independent of the function of nsP2 in host-cell shut-off, but the 
function is ablated if the nuclear localisation signals on nsP2 are mutated. This 
indicates that the nuclear localisation of nsP2 is required for it to inhibit STAT 
nuclear localisation (Fros, Liu et al. 2010, Fros, van der Maten et al. 2013). 
Together, these strategies ensure that alphaviruses are able to suppress the 
cellular immune response and are consequently able to replicate efficiently 
(Figure 1.14).  
Like many other viruses, SFV is capable of disrupting the formation of cellular 
stress granules, preventing their antiviral activity. The c-terminal domain of 
nsP3 from SFV has been shown to sequester Ras-GAP SH3-domain-binding-protein 
(G3BP), a protein consistently found in all types of stress granule, and therefore 
inhibit stress granule formation (McInerney, Kedersha et al. 2005, Beckham and 
Parker 2008, Lloyd 2012, Panas, Varjak et al. 2012).  
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Figure 1.14 Innate immune evasion strategies employed by alphaviruses 
Alphaviruses utilise different strategies to avoid the mammalian immune 
response. The viral RNA possesses a stable hairpin loop at the 5’ end, 
resulting in successful translation initiation. This occurs following protein 
kinase R (PKR) phosphorylation of eukaryotic translation initiation factor 2α 
(eIF2α) which results in shut-off of host cell translation. The viral 
nonstructural protein 2 (nsP2) also translocates to the nucleus to degrade the 
RNA Polymerase II (RNA Pol II) subunit, RPB1, preventing host cell 
transcription. nsP2 is also capable of preventing the nuclear localisation of 
signal transducers and activators of transcription (STAT) dimers, both 
mechanisms reduce expression of interferon (IFN) stimulated genes (ISGs).  
Abbreviations: tyrosine kinase (TYK2), Janus kinase (JAK), phosphate (P). 
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1.5.1.2. Flaviviruses and innate immune 
evasion 
At least four PRRs are utilised by the cell to detect flaviviruses, these are the 
Retinoic acid-inducible gene I (RIG-I)-like receptors, TLR3, 7, and 8, nucleotide-
binding oligomerization domain (NOD)-like receptors, and the cyclic GMP-AMP 
synthesase–stimulator of interferon genes (cGAS-STING) - dependent pathway 
(reviewed by Takeuchi and Akira (2010)). Consequently, many flaviviruses have 
developed mechanism to evade this host cell response. For instance, WNV, 
DENV, JEV, and TBEV have all been shown to delay the onset of IFN signalling by 
forming intracellular membranes to hide the viral dsRNA. dsRNA is a key PAMP 
that initiates an interferon response through the activation of a variety of PRRs 
including TLR3 and RIG-I (Fredericksen and Gale 2006, Welsch, Miller et al. 2009, 
Överby, Popov et al. 2010, Espada-Murao and Morita 2011, Junjhon, Pennington 
et al. 2014).  
Many flaviviruses have also been shown to block the IFN response. For instance, 
NS2A of Kunjin virus (a strain of WNV; WNVKUN) has been identified as an 
inhibitor to IFN-β transcription (Liu, Chen et al. 2004). DENV NS2A, NS4A and 
NS4B can prevent JAK-STAT signalling by reducing the phosphorylation and 
transport of STAT1 into the nucleus (Muñoz-Jordán, Sánchez-Burgos et al. 2003). 
Upon activation by interferon, the STAT family of proteins usually form 
homodimers or heterodimers which induce expression of ISGs, reviewed in 
Harrison (2012). DENV and ZIKV NS5 proteins have been shown to block STAT2 
signalling. DENV blocks STAT2 through promoting proteasome mediated 
degradation of STAT2, following targeting by the E3 ubiquitin ligase UBR4 
(Mazzon, Jones et al. 2009, Morrison, Laurent-Rolle et al. 2013). ZIKV blocks 
STAT2 signalling through the same pathway, but independent of the E3 ubiquitin 
ligase (Grant, Ponia et al. 2016). Both mechanisms prevent the cellular 
interferon-dependent innate immune response from restricting viral replication. 
Recent studies with ZIKV have also found that the NS5 protein blocks IFN 
induction and signalling, this was achieved by reducing levels of STAT2, and 
blocking phosphorylation of STAT1 (Hertzog, Dias Junior et al. 2018). 
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Other anti-antiviral mechanisms employed by flaviviruses include the NS3 
protein of DENV, which has been reported to bind to a protein called 14-3-3ε, 
which functions to translocate RIG-I within the cell. NS3 binding to 14-3-3ε 
prevented translocation of RIG-I, and thereby blocked the RIG-I mediated 
antiviral response (Chan and Gack 2016).  
DENV has also been shown to form a stable complex of NS2B-NS3 which is 
capable of inhibiting IFN signalling by proteolytically cleaving the STING protein, 
a component of the cGAS pathway. This has also been shown to be species 
specific, as the mouse STING was not cleaved by DENV NS2B-NS3 (Falgout, Pethel 
et al. 1991, Aguirre, Maestre et al. 2012). NS2B-NS3 has also been shown to 
block the induction of RIG-I through masking the kinase domain of IκB kinase ε, 
thereby preventing the phosphorylation and nuclear translocation of IFN 
regulatory factor 3 (IRF3) (Anglero-Rodriguez, Pantoja et al. 2014). NS4B from 
DENV has been implicated in suppressing the RNA interference (RNAi) response in 
the human liver Huh7 cell line (Kakumani, Ponia et al. 2013). Although as the 
RNAi response is not the most potent antiviral mechanism in mammals, this may 
have a more prominent role in the vector species.  
Subgenomic flavivirus RNA (sfRNA), a non-coding RNA derived from the 3’ 
untranslated region (reviewed by Clarke, Roby et al. (2015)), has also been 
implicated in being an antagonist of IFN production. This has been found to 
occur through multiple mechanisms, including inhibiting the activation of RIG-I, 
through blocking nuclear translocation of IRF3, and sfRNAs from ZIKV may also 
antagonise MDA5 activation (Schuessler, Funk et al. 2012, Chang, Hsu et al. 
2013, Manokaran, Finol et al. 2015, Donald, Brennan et al. 2016). Furthermore, 
sfRNAs are resistant to Dicer or exoribonuclease 1 (XRN1) mediated degradation 
of the viral genome, due to the presence of pseudoknots and stem loops 
restricting the RNA interference response (Schnettler, Sterken et al. 2012).   
Flaviviruses are capable of targeting individual ISGs in order to prevent antiviral 
mechanisms utilised by the cell. For instance, one family of ISGs, MxA, has been 
shown to have antiviral activity against various RNA viruses (Landis, Simon-
Jodicke et al. 1998, Chieux, Chehadeh et al. 2001). WNVKUN is believed to hide 
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from MxA through the induction of membranous structures (Hoenen, Liu et al. 
2007).  
Finally, it’s also reported that various flaviviruses are capable of promoting 
suppressors of cytokine signalling (SOCS)-1 and SOCS3 expression through binding 
to the Tyro3/Axl/Mer (TAM) receptor on certain cell types, such as dendritic 
cells. This has the function of suppressing JAK-STAT signalling (Mansfield, 
Johnson et al. 2010, Bhattacharyya, Zagorska et al. 2013). Together, these 
demonstrate a wide range of strategies flaviviruses employ to evade antiviral 
responses in the cell (Figure 1.15).  
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Figure 1.15 Innate immune evasion strategies employed by flaviviruses 
Flaviviruses utilise various strategies to avoid the mammalian innate immune 
response. DENV and ZIKV non-structural protein 5 (NS5) have both been shown 
to degrade the signal transducer and activator of transcription 2 (STAT2). 
DENV non-structural protein 2A (NS2A), 2B (NS2B), 4B (NS4B), and ZIKV NS5 
have also been shown to inhibit the phosphorylation of STAT1, which results 
in fewer STAT1/2 heterodimers forming. DENV NS3 also has roles in binding to 
14-3-3ε, preventing 14-3-3ε from shuttling retinoic acid-inducible gene I (RIG-
I) into the nucleus. Furthermore, subgenomic flaviviral RNA (sfRNA) can 
inhibit activation of RIG-I.  DENV NS2B-NS3 also serves to proteolytically 
cleave stimulator of interferon genes (STING), a component of the cyclic GMP-
AMP synthesase (cGAS) signalling pathway. DENV can also bind to 
Tyro3/Axl/Mer (TAM) receptors on specific cell types, which induces 
expression of suppressors of cytokine signalling (SOCS)-1 and -3, which 
suppress the janus kinase - signal transducers and activators of transcription 
(JAK-STAT) pathway.  
Abbreviations: interferon (IFN), interferon stimulated genes (ISG), double 
stranded RNA (dsRNA), tyrosine kinase (TYK2), phosphate (P). 
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1.5.1.3. Orthobunyaviruses and innate 
immune evasion 
Orthobunyaviruses have not been studied to the same extent as alphaviruses and 
flaviviruses. The majority the immune evasion mechanisms that are adopted by 
orthobunyaviruses utilise the non-structural NSs protein (Section 1.3.3.3). The 
NSs protein has been shown to act as an IFN antagonist. BUNV NSs inhibits the 
phosphorylation of the RNA polymerase II, which decreases the amount of host 
mRNA synthesis (Thomas, Blakqori et al. 2004). The C-terminal of BUNV NSs 
interacts with the protein Mediator of RNA polymerase II transcription subunit 8 
(MED8), part of the mediator complex which regulates RNA polymerase II 
transcription, preventing transcription initiation (Léonard , Kohl et al. 2006). 
LACV NSs also targets the RNA polymerase II to block the IFN response, but this is 
achieved through degradation of the RNA pol II protein (Verbruggen, Ruf et al. 
2011). Both of these mechanisms have the effect of restricting the cells antiviral 
response, while not restricting the viruses’ transcription, due to the function of 
the viral RDRP. Finally, NSs has also been reported to delay cellular apoptosis 
through suppressing the interferon regulatory factor-3 signalling pathway (Kohl, 
Clayton et al. 2003). This extends the length of time which orthobunyaviruses 
are able to replicate for within the cell (Figure 1.16). 
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Figure 1.16 Innate immune strategies utilised by orthobunyaviruses 
Innate immune evasion strategies employed by Orthobunyaviruses have only 
been reported to utilise the non-structural protein produced by the S gene 
(NSs). BUNV NSs serves to inhibit phosphorylation of RNA polymerase II (RNA 
Pol II), while LACV NSs degrades RNA Pol II. BUNV NSs can also interact with 
Mediator of RNA Pol II transcription subunit 8 (MED8), preventing MED8 from 
interacting with RNA Pol II, thereby reducing host cell gene expression. NSs 
can also suppress the interferon response factor 3 signalling pathway (IRF3), 
reducing the induction of interferon stimulated genes (ISG) and delaying 
apoptosis.  
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1.5.2. Invertebrate innate immune response 
As the SUMOylation pathway in mosquitoes has yet to be fully deciphered, this 
section will broadly describe the vector innate immune response.  
Mosquito cell culture is well known to develop a persistent infections which 
rarely result in cell death (Peleg 1968). This is believed to be due to the antiviral 
mechanisms of the vector cell restricting arboviral replication. Invertebrates do 
not have an adaptive immune response, or a directly equivalent IFN based 
antiviral response. Consequently, invertebrates predominantly rely on cellular 
based innate immune response, although they do possess haemocytes which act 
as circulating immune cells. Classically, most work on invertebrate immune 
responses was conducted on Drosophila melanogaster (D. melanogaster), 
although much of this work has now also been studied in more relevant species 
such as Ae. aegypti. Consequently, much of what is described here will focus on 
D. melanogaster. Important invertebrate innate antiviral pathways include the 
Toll, immune deficiency (IMD), JAK-STAT, and RNAi pathways as summarised in 
Figure 1.17, all of the following pathways have been shown to be antiviral in 
mosquitoes (for review see Sim, Jupatanakul et al. (2014)).  
The Toll and IMD pathways are functionally similar to the mammalian nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. The Toll 
pathway was initially identified as an antiviral pathway in D. melanogaster 
(Zambon, Nandakumar et al. 2005). Briefly, extracellular PAMPs are detected by 
PRRs which stimulates the secretion of a cytokine, Spätzle (DeLotto and DeLotto 
1998). Spätzle activates the transmembrane Toll receptor, which signals through 
associated adaptor proteins to phosphorylate Cactus, a homologue of the IκB 
protein in humans (Nicolas, Reichhart et al. 1998). Cactus phosphorylation leads 
to proteasomal degradation, which allows Dorsal (named Rel1 in mosquitoes), to 
translocate to the nucleus and transcribe Toll-regulated antimicrobial genes 
(Lemaitre, Nicolas et al. 1996, Sim, Jupatanakul et al. 2014).  
The IMD pathway is also activated through the detection of extracellular PAMPs 
by PRRs, resulting in the activation of the IMD protein. In D. melanogaster the 
Peptidoglycan Recognition Proteins (PGRP) are the PRRs which activate the IMD 
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pathway (Choe, Lee et al. 2005). The IMD pathway then splits into two branches; 
one activates the transcription factor AP-1 through the JNK signalling, the other 
branch results in the activation and translocation of the NF-κB like transcription 
factor, Relish (Rel2 in mosquitoes) (Davis 1994, Sluss, Han et al. 1996, Stöven, 
Ando et al. 2000, Sanders, Foy et al. 2005, Fragkoudis, Chi et al. 2008, Costa, 
Jan et al. 2009) (Figure 1.17). 
The JAK-STAT pathway is widely known in mammals for its role in the IFN 
response. In D. melanogaster, the pathway is activated either by initial binding 
of the ligand Unpaired (Upd) to the extracellular region of the Domeless (Dome) 
receptor or through the action of the cytokine Vago, independent of Dome 
(Harrison, McCoon et al. 1998, Brown, Hu et al. 2001, Hombría, Brown et al. 
2005, Paradkar, Trinidad et al. 2012). D. melanogaster is only reported to 
possess one Janus kinase (Hopscotch, or Hop in mosquitoes), and one STAT 
transcription factor (Binari and Perrimon 1994, Hou, Melnick et al. 1996, Yan, 
Small et al. 1996). Similar to mammals, receptor activation results in a 
conformational change and dimerization of Dome. This leads to self-
phosphorylation of the receptor associated Hop, which recruit the STAT proteins 
to be phosphorylated by the Dome/Hop complex. STAT proteins are dimerized 
and translocate to the nucleus to induce gene expression (Arbouzova and Zeidler 
2006) (Figure 1.17). 
The most potent mechanism invertebrates have for restricting arbovirus 
replication is from the RNA interference (RNAi) pathway. There are three RNAi 
pathways, the small interfering RNA (siRNA) pathway, the micro RNA (miRNA) 
and Piwi-interacting RNA (piRNA) pathways (for review, see Blair and Olson 
(2015), Olson and Blair (2015)). miRNA genes are commonly utilised by the cell 
as a form of post-transcriptional gene regulation, affecting approximately 15% of 
the Drosophila genome (Grün, Wang et al. 2005). The function of the piRNA 
pathway is still largely unresolved. Generally they are thought to regulate 
transposons in germline cells. The piRNA pathway is distinct from miRNA and 
siRNA as the biogenesis is independent of Dicer (Vagin, Sigova et al. 2006). The 
siRNA pathway is the best studied of the RNAi pathways and has a widely known 
role in cellular antiviral defence. Upon arboviral replication in the host cell, the 
siRNA pathway is initiated by long strands of dsRNA located in the cytoplasm. 
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The dsRNA is cleaved by Dicer 2 into siRNA stretches of 21 nucleotides. The 
siRNA-Dicer 2 complex, in association with the dsRNA binding protein R2D2, 
enables the 21 nucleotide stretch of dsRNA to bind and load onto the RNA-
induced silencing complex (RISC), which assembles  differently in humans and 
invertebrates (Yoda, Kawamata et al. 2010). Argonaute 2 (Ago2) is the effector 
protein of the RISC complex, which unwinds the double stranded siRNA into a 
single guide strand of siRNA. If the guide siRNA forms a base paired duplex with 
the complementary viral RNA strand, Ago2 then cleaves the complementary RNA 
strand at the centre of the base paired duplex (Bernstein, Denli et al. 2001, 
Martinez, Patkaniowska et al. 2002, Pham, Pellino et al. 2004, Matranga, Tomari 
et al. 2005, Rand, Petersen et al. 2005). 
There is also a degree of crosstalk between the immune pathways which likely 
evolved to ensure a comprehensive immune response. For instance, Dicer 2, 
along with its function in the RNAi pathway, also activates TNF receptor-
associated factor (TRAF). TRAF cleaves and activates Rel2, the NF-κB like 
transcription factor utilised in the IMD pathway. This allows Rel2 to promote the 
transcription of Vago, which is secreted and activates the JAK-STAT pathway, in 
a similar manner to the IFN response in mammals (Deddouche, Matt et al. 2008, 
Paradkar, Trinidad et al. 2012, Paradkar, Duchemin et al. 2014) (Figure 1.17). 
Many arboviruses have co-evolved with their vector species with the aim to 
minimise adverse effects on vector survival. Consequently the majority of the 
evidence of viruses possessing strategies to suppress the vector immune 
responses is recent and not fully uncovered. Section 1.5.2.1, Section 1.5.2.2, 
Section 1.5.2.3 will describe what is currently known about mechanisms the 
arboviruses employ to evade the vector immune response.  
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Figure 1.17 Mosquito immune response  
In Toll pathway signalling, extracellular viral pathogen associated molecular 
patterns (PAMPS) are detected by pattern recognition receptors (PRR) which 
then cleave Spätzle. Spätzle binds and activates the Toll receptor which 
triggers the phosphorylation (P) and degradation of Cactus. Cactus degradation 
enables the transcription factor RelI to localise to the nucleus and induce 
expression of toll-regulated genes. The IMD pathway is also activated by viral 
PAMPS triggering PRR (probably the peptidoglycan recognition protein (PGRP)), 
resulting in IMD activation and a functional split in the pathway. One branch 
triggers the c-Jun N-terminal kinase (JNK) signalling pathway which activates 
the transcription factor activator protein I (AP-I). The other branch 
phosphorylates and cleaves the transcription factor Rel2, which activates it 
allowing Rel2 to translocate to the nucleus and induce IMD regulated gene 
expression. The JAK-STAT pathway is activated by unpaired (Upd) binding to 
the receptor, Dome. Binding activates the receptor associated Hop janus 
kinase, which then recruits and phosphorylates the transcription factor, STAT.  
 
Continued on next page 
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1.5.2.1. Alphaviruses and Ae. aegypti 
immune response 
The primary mechanism of suppressing alphavirus replication in Ae. aegypti is 
through the action of the RNAi pathway. Old World alphaviruses have previously 
been reported to suppress the Toll, IMD, and JAK-STAT pathway immune 
responses in Ae. aegypti cell lines. Prior stimulation of the antiviral pathways 
has been shown to reduce SFV and CHIKV replication in invertebrate cell culture, 
this was achieved through non-specific and incomplete host cell transcriptional 
shut-off (Fragkoudis, Chi et al. 2008, McFarlane, Arias-Goeta et al. 2014). 
Although the specific viral protein was not identified, it is likely to be the 
function of nsP2 in the Old World alphaviruses, as this is the protein identified as 
being responsible for host cell shut-off in vertebrate cells, as described (Section 
1.5.1.1) (Garmashova, Gorchakov et al. 2006, Breakwell, Dosenovic et al. 2007). 
CHIKV has also been shown to influence the RNAi pathway through altering 
miRNA expression within Ae. albopictus cells (a mosquito vector closely related 
to Ae. aegypti). For instance, CHIKV infection upregulated the miRNA named 
miR-2944b-5p, which is predicted to target four cellular pathways including 
STAT dimerises and translocates to the nucleus triggering JAK-STAT regulated 
genes. The JAK-STAT pathway can be inhibited by the suppressors of cytokine 
signalling (SOCS), preventing Hop from phosphorylating STAT, or protein 
inhibitor of activated STAT (PIAS) preventing dimerised STAT from inducing gene 
expression. The RNA interference (RNAi) pathway is activated by activation of 
Dicer 2 (Dcr2) by viral double stranded RNA (viral dsRNA). Dcr2 cleaves the viral 
dsRNA into 21 bp lengths called siRNA which are then loaded onto RNA induced 
silencing complex (RISC), which degrades one strand of siRNA and utilises the 
other for targeted degradation of viral RNA. Dcr2 activation also activates TRAF 
which results in Rel2 cleavage, transcription of Vago, and further activation of 
the JAK-STAT pathway. Adapted from Sim, Jupatanakul et al. (2014) 
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protein processing in the ER, citrate cycle, ribosome, and ubiquitin mediated 
proteolysis (Shrinet, Jain et al. 2014). SFV, however, contains viral siRNA ‘hot 
spots’ in its genome, which produce more abundant siRNAs with poor antiviral 
activity that act to suppress this arm of invertebrate immunity (Siu, Fragkoudis 
et al. 2011). 
Interestingly, when mosquitoes are infected with SINV, the viral siRNA produced 
is crucial for vector survival. If the accumulation of this viral siRNA is 
suppressed, the virus replicates to higher titres but at the cost of vector 
survival, indicating an evolutionary trade-off for the virus (Myles, Wiley et al. 
2008).  
 
1.5.2.2. Flaviviruses and Ae. aegypti 
immune response  
DENV infection of adult Ae. aegypti has been reported to down regulate several 
antimicrobial peptides that are promoted by the Toll signalling pathway 
(Ramirez and Dimopoulos 2010). The transcriptome of DENV infected mosquitoes 
and mosquitoes with an over-activated Toll pathway had overlapped intensity of 
up- and down-regulated transcripts. This indicates that the Toll pathway is a 
regulator of DENV infection in mosquitoes (Xi, Ramirez et al. 2008). 
Furthermore, similar studies in Ae. aegypti cell culture has also been shown to 
down-regulate the transcription of many antimicrobial compounds stimulated 
from both the IMD and Toll pathways (Sim and Dimopoulos 2010). JEV has also 
been reported to block the phosphorylation of the STAT protein of the JAK-STAT 
pathway in RNAi deficient Ae. albopictus cells (Lin, Chou et al. 2004). Together, 
this indicates that flaviviruses utilise a wide range of mechanisms to suppress 
the Ae. aegypti Toll, JAK-STAT, and IMD immune pathways.  
As the RNAi pathway is the primary method of antiviral action in invertebrates, 
flaviviruses have reportedly evolved multiple mechanisms to suppress the RNAi 
response. DENV NS4B has been reported to suppress the RNAi response in both 
mammals and in the invertebrate fall armyworm Spodopetra frugiperda, possibly 
through interfering with Dicer 2 activity (Kakumani, Ponia et al. 2013), although 
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this has not yet been studied in Ae. aegypti vector.  YFV capsid protein has also 
been implicated as a viral suppressor of RNA silencing, through interfering with 
Dicer 2, and with a conserved function in other flaviviruses (Samuel, Wiley et al. 
2016). sfRNA also possesses a functional role in the Ae. aegypti vector, along 
with the H. sapiens host. sfRNAs have been shown to inhibit the processing of 
dsRNA by Dcr2 and Ago2 in vitro and vector mosquitos (Schnettler, Sterken et al. 
2012, Moon, Dodd et al. 2015). Other studies investigating the role of sfRNAs in 
mosquitoes have suggested a tissue specific role for sfRNAs, as relatively larger 
quantities of sfRNA, and corresponding higher viral titres were produced in the 
salivary glands compared to the midgut or carcass (Pompon, Manuel et al. 2017). 
DENV infection can also lead to altered expression of cellular miRNA. The 
miRNAs altered included those involved in protein transport, transcriptional 
regulation, mitochondria, chromatin modification, and signal transduction 
processes in order to promote viral replication (Campbell, Harrison et al. 2014). 
WNVKUN has also been shown to encode its own miRNA strand which targeted and 
increased accumulation of Ae. aegypti GATA4 transcripts. When GATA4 mRNA 
was silenced, WNVKUN replication was significantly reduced, indicating that the 
arbovirus is able to manipulate expression of cellular proteins to benefit the 
virus in Ae. aegypti (Hussain, Torres et al. 2012). 
 
1.5.2.3. Orthobunyaviruses and Ae. aegypti 
immune response 
The NSs proteins from BUNV and LACV have been reported as viral suppressors of 
RNAi. Studies that deleted sections of NSs and assessed the replication in Dcr2 
deficient mosquito cell lines found BUNVΔNSs to be less infectious in Ae. aegypti 
mosquitoes. This indicates that NSs has a role in suppressing the function of Dcr2 
in the vector, although a mechanism has not been identified (Soldan, Plassmeyer 
et al. 2005, Szemiel, Failloux et al. 2012). 
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1.5.3. SUMOylation pathway interactions with 
viruses 
PTM by SUMO is known to be an essential form of cellular modification. 
SUMOylation has previously been shown to either positively or negatively 
influence viral replication for a range of DNA and RNA viruses in mammalian cells 
(Wilson 2012, Wimmer and Schreiner 2015, Wilson 2017). SUMOylation is also 
known to help host cells enter an antiviral state, due to alterations of host cell 
signalling pathways (Hannoun, Maarifi et al. 2016). As a consequence, many 
viruses may need to alter cellular SUMOylation in order to propagate efficiently. 
This section will focus on interactions between the SUMOylation machinery and 
viral proteins. 
Many aspects of viral replication are known to be regulated by SUMOylation of 
viral proteins. For instance, the N protein from severe acute respiratory 
syndrome (SARS) coronavirus is SUMO modified, promoting oligomerization (Li, 
Xiao et al. 2005). Furthermore, SUMO modification of the M1 matrix protein of 
influenza A virus promotes viral assembly and maturation (Wu, Jeng et al. 2011). 
Other studies have found components of the SUMOylation pathway to be 
targeted by viruses in order to promote viral replication. Human Papillomavirus 
has been found to decrease the cellular concentration of Ubc9 through the 
action of the E6 oncoprotein, decreasing overall cellular SUMOylation in order to 
promote viral propagation (Heaton, Deyrieux et al. 2011). Furthermore, the 
latent membrane protein 1 from Epstein Barr virus (EBV) has been found to 
possess a C-terminal activating region, which interacts with Ubc9 in order to 
increase cellular SUMOylation (Bentz, Whitehurst et al. 2011). RNAi studies have 
implicated SAE1/2 and Ubc9 in restricting adeno-associated virus replication by 
targeting entry of the capsids (Hölscher, Sonntag et al. 2015). Members of the 
PIAS family of proteins, which are classically regarded as suppressors of innate 
immunity, have also been reported to localise to nuclear domains during Herpes 
Simplex Virus-1 (HSV-1) infection to suppress replication as part of an intrinsic 
immune response (Brown, Conn et al. 2016, Conn, Wasson et al. 2016). In 
contrast, HCV infected cells upregulated the expression of SUMO1, with 
depletion of SUMO1 resulting in reduced viral replication, indicating that SUMO1 
has a pro-viral effect on HCV replication (Akil, Wedeh et al. 2016). 
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1.5.4. SUMO and arboviruses 
To date, there are three studies looking at the interaction between arboviruses 
and the SUMO pathway with contradictory outcomes (Chiu, Shih et al. 2007, Su, 
Tseng et al. 2016, Feng, Deng et al. 2018). Chiu, Shih et al. (2007) demonstrated 
that Ubc9 in human cells could interact with DENV E protein, possibly through 
SUMO modification of Lysines 51 and 241. Ubc9 could also restrict DENV 
replication following ectopic expression. This is supported by recent studies by 
Feng, Deng et al. (2018) who utilised siRNA to deplete expression of Ubc9 and 
found an increase in DENV RNA, although they did not investigate a phenotype. 
In contrast to this, Su, Tseng et al. (2016) demonstrated that the NS5 protein is a 
target for SUMO modification which prevents ubiquitin-mediated degradation 
and consequently helps to stabilize the viral protein, furthermore shRNA 
transduction to deplete expression of Ubc9 was found to suppress DENV 
replication (Su, Tseng et al. 2016). Together, these demonstrate that there is a 
role for the SUMOylation pathway in the regulation of arboviruses. However, 
currently the role of SUMOylation on arbovirus replication in H. sapiens is 
contradictory, and no work has yet been conducted in the mosquito vector 
species. 
Studies have been conducted in D. melanogaster investigating changes in the 
SUMO proteome in response to bacterial lipopolysaccharide (LPS) activation of 
host immune responses. A total of 710 proteins were confidently identified as 
being SUMO modified, of which 4.8% were known to be in a functional group 
involved in an immune response. Proteins which were found to be SUMO 
modified include: STAT92E (transcription factor in JAK-STAT pathway), Basket 
(JNK signalling), 14-3-3ε (signalling and protein transport), Casp (negative 
regulator of  IMD/NF-κB pathway), or Imd (signal transducer in IMD/NF-κB 
pathway) (Gronholm, Ungureanu et al. 2010, Handu, Kaduskar et al. 2015). This 
indicates a prominent role for SUMO modification during the regulation of 
invertebrate immunity.  
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1.6.  Premise and primary objectives of the 
project 
Arboviruses are a major pathogen of both humans and livestock. Understanding 
the molecular basis for how they replicate in both the host and vector species 
may be key to identifying novel strategies for controlling arbovirus replication.  
The SUMO pathway is well known to both positively and negatively influence the 
replication of a wide range of RNA and DNA viruses in a virus dependent manner. 
However, to date, there are only two studies which focus on the influence of the 
SUMO pathway on arboviruses. Both focus on DENV, and both studies are 
conducted in H. sapiens cells. Consequently, there is a lack of understanding 
about the influence of this pathway on arboviruses in the vector species, and 
with a range of arboviruses from different viral families.  
The primary objectives of the work presented here aims to: 
• Investigate the homology between the H. sapiens and uninvestigated Ae. 
aegypti  SUMOylation pathways  
• Characterise the biochemical properties of the Ae. aegypti SUMOylation 
pathway with respect to the H. sapiens SUMOylation pathway 
• Investigate the physiological effect of the Ae. aegypti SUMOylation 
pathway on arbovirus replication (SFV, BUNV, and ZIKV). 
• Investigate the physiological effect of components of the H. sapiens 
SUMOylation pathway on SFV, BUNV, and ZIKV replication.  
In doing so, the aim is to improve our understanding of the influence of 
invertebrate and vertebrate SUMOylation on arbovirus replication.  
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2.1. Materials 
2.1.1. Cells and cell culture reagents 
2.1.1.1. Cell lines utilised 
 
Name Type 
Growth and 
maintenance 
media 
Growth and 
maintenance 
conditions 
A20 
Larval Ae. aegypti cell line 
originally cultured by Varma and 
Pudney (1969). 
L15 
supplemented 
with 10% FBS  
28˚C 
Aag2 
Larval Ae. aegypti cell line 
originally cultured by Peleg (1968). 
Have been validated to show they 
possess an immune response 
comparable to Ae. aegypti 
mosquitoes (Barletta, Silva et al. 
2012). 
AF5 
Single cell clone of Ae. aegypti 
cells originally derived from Aag2s 
and found to have a similar 
immune response to Aag2s (Varjak, 
Maringer et al. 2017). 
HFt 
Human Foetal Foreskin Fibroblast 
cells immortalized by stable 
expression of human telomerase, 
as described by Smith, Goddard et 
al. (2013). HFt cells were gifted 
from Steven McFarlane (MRC-
University of Glasgow Centre for 
DMEM 
supplemented 
with 10% FBS 
and 5 µg/ml 
Hygromycin 
 
 
37˚C, 5% CO2 
 
Table 2-1 Summary table of cell lines used in this study 
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Virus Research).  
 
 
 
 
 
 
 
37˚C, 5% CO2 
A549-Npro 
Human alveolar carcinoma cells, 
modified to contain an NPro which 
renders the cells IRF3 deficient 
and prevents them from producing 
an interferon response, as 
previously described (Hilton, 
Moganeradj et al. 2006, Perez-
Cidoncha, Killip et al. 2014). 
Gifted from Dr Claire Donald (MRC- 
University of Glasgow Centre for 
Virus Research). 
DMEM 
supplemented 
with 10% FBS, 
and 0.5 µg/ml 
Puromycin 
HEK-293T 
Human embryonic kidney cells that 
express a mutant version of the 
SV40 large T antigen (DuBridge, 
Tang et al. 1987). 
DMEM 
supplemented 
with 10% FBS 
Vero-E6 
African green monkey kidney 
epithelial cells (Yasumura and 
Kawakita 1963). 
DMEM 
supplemented 
with 10% FBS 
BHK 
Baby Hamster kidney cells 
originally cultured by Macpherson 
and Stoker (1962). 
GMEM 
supplemented 
with 10% FBS 
and 10% TPB 
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2.1.1.2. Cell culture reagents utilised 
 
Name Source Catalogue number 
2.5% Trypsin (10X) Gibco 15090-046 
Avicel RC dispersible 
microcrystalline cellulose 
(Avicel) 
FMC BioPolymer RC-591NF 
Dharmacon DhermaFECT 2 GE Healthcare T-2002-02 
Dimethyl sulphoxide (DMSO) Sigma D2660 
Dulbecco’s Modified Eagle 
Medium (DMEM) 
Gibco 41966-029 
Fetal Bovine Serum (FBS) Gibco 10270-106 
Glasgow’s Minimum 
Essential Medium (GMEM) 
Gibco 21710-025 
Hexadimethrine bromide 
(Polybrene) 
Sigma-Aldrich H9268 
Leibovitz’s-L15 Gibco 31415-029 
Lipofectamine2000 Invitrogen 11668027 
Lipofectamine LTX with PLUS 
reagent 
Invitrogen 10964021 
Poly-D-Lysine Hydrobromide Sigma-Aldrich P7405 
Puromycin Sigma-Aldrich P8833 
Sodium Bicarbonate Gibco 25080-060 
Tryptose Phosphate Broth 
(TPB) 
Gibco 18050-039 
Versene in PBS E&O laboratories BM0400 
Table 2-2 List of cell culture reagents used in this study 
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2.1.1.3. Viruses 
 
Virus Description 
SFV-eGFP Semliki Forest virus modified to encode an eGFP within 
the nsP3 protein, as described by Tamberg, Lulla et al. 
(2007). The plasmid was kindly gifted by Dr Esther 
Schnettler (Bernhard Nocht Institute for Tropical 
Medicine). 
SFV-Ffluc Semliki Forest virus modified to encode a Firefly 
luciferase (Ffluc) reporter protein within the nsP3 
protein, as previously described (Tamberg, Lulla et al. 
2007). The plasmid was kindly gifted by Dr Esther 
Schnettler (Bernhard Nocht Institute for Tropical 
Medicine). 
ZIKV PE243 A clinical strain of ZIKV originally isolated from a 
patient in Recife (Brazil) from the 2016 outbreak, as 
described Donald, Brennan et al. (2016). The virus was 
grown and gifted by Dr Claire Donald (MRC-University of 
Glasgow). 
ZIKV-nl A clinical strain of ZIKV containing a NanoLuciferase 
reporter protein. The modified polyprotein contains a 
duplicated copy of the capsid protein flanked by a foot-
and-mouth-disease virus 2A autoprotease, as previously 
described   Mutso, Saul et al. (2017), Royle, Donald et 
al. (2017). The virus was produced and gifted by Jamie 
Royle (MRC-University of Glasgow Centre for Virus 
Research) subsequent stocks were grown by the author. 
Table 2-3 Viruses used in this study 
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BUNV A wild type strain of Bunyamwera virus, as described by 
Bridgen and Elliott (1996), gifted by Dr Xiaohong Shi 
(MRC – University of Glasgow Centre for Virus Research) 
BUNV-nl A strain of Bunyamwera virus modified to contain a 
NanoLuciferase (nl) reporter protein within the 
cytoplasmic domain of NSm, producing a fusion NSm-nl 
protein. As described by Dietrich, Shi et al. (2017), 
gifted by Dr Xiaohong Shi (MRC – University of Glasgow 
Centre for Virus Research). 
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2.1.2. Antibodies 
 
Target Origin Source Primary 
or 
secondary 
Dilution  
used 
SUMO1 Rabbit Abcam – AB32058 Primary 1:1000 
SUMO2/3 Mouse Abcam – AB81371 Primary 1:1000 
Ubc9 Goat Abcam – AB21193 Primary 1:1000 
Actin Rabbit Sigma Aldrich –A5060 Primary 1:1000 
SAE2 Rabbit Bethyl – A302-925A Primary 1:1000 
PIAS1 Rabbit LSBio – LS-B9173 Primary 1:1000 
PIAS2α Rabbit Millipore – ABS447 Primary 1:1000 
GFP Rabbit Abcam – AB290 Primary 1:1000 
ZIKV NS3 Rabbit A kind gift from Andres 
Merits (University of 
Tartu, Estonia) (Mutso, 
Saul et al. 2017) 
Primary 1:1000 
BUN N Rabbit A kind gift from Dr 
Xiaohong Shi (MRC – 
University of Glasgow 
Centre for Virus 
Research) (Weber, Dunn 
et al. 2001) 
Primary 1:5000 
Mouse 
primary 
Goat with 
fluorophore 
Thermo Scientific - 
SA535521 
Secondary 1:10000 
Table 2-4 Antibodies used in this study 
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antibodies conjugate 
Rabbit 
primary 
antibodies 
Goat with 
fluorophore 
conjugate 
Thermo Scientific – 
SA535571 
Secondary 1:10000 
Goat 
primary 
antibodies 
Donkey 
with 
fluorophore 
conjugate 
Li-Cor – 926-32214 Secondary 1:10000 
Rabbit 
primary 
antibodies 
Goat with 
peroxidase 
conjugate 
Sigma Aldrich – A0545 Secondary 1:5000 
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2.1.3. Plasmids 
 
Name Description Source 
pACYC-AaSAE2/1 Bacterial dual expression vector 
containing the Ae. aegypti 
SAE1/2 activating heterodimer. 
This study 
pET28a-HsSUMO1 Bacterial expression vector 
containing the sequence for 
HsSUMO1 
cDNA obtained from 
Professor Ron Hay, 
plasmids were a kind 
gift from Dr Chris 
Boutell 
pET28a-HsSUMO2 Bacterial expression vector 
containing the sequence for 
HsSUMO2 
cDNA obtained from 
Professor Ron Hay, 
plasmids were a kind 
gift from Dr Chris 
Boutell 
pET28a-HsSUMO3 Bacterial expression vector 
containing the sequence for 
HsSUMO3 
cDNA obtained from 
Professor Ron Hay, 
plasmids were a kind 
gift from Dr Chris 
Boutell 
pET28a-HsUbc9 Bacterial expression vector 
containing the sequence for 
HsUbc9 
cDNA obtained from 
Professor Ron Hay, 
plasmids were a kind 
gift from Dr Chris 
Boutell 
pET28a-AaSUMO Bacterial expression vector 
containing the sequence for 
AaSUMO 
Dr Sue Jacobs, 
unpublished data 
Table 2-5 Plasmids used in this study 
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pET28a-SUMO 
chimaera 
Bacterial expression vector 
containing the sequence for 
SUMO chimaera 
Synthesised by 
GENEWIZ, cloned in 
this study 
pET28a-SUMO 
chimaera K11R 
Bacterial expression vector 
containing the sequence for 
SUMO chimaera with a mutated 
lysine -> arginine at position 11 
Synthesised by 
GENEWIZ, cloned in 
this study 
pET45b-AaUbc9 Bacterial expression vector 
containing the sequence for 
AaUbc9 
This study 
pET45b-AaPIAS Bacterial expression vector 
containing the sequence for 
AaPIAS 
Synthesised by 
GENEWIZ, cloned in 
this study  
pET45b-AaPIAS 
C371A 
Bacterial expression vector 
containing the sequence for 
AaPIAS with a cysteine –> 
alanine mutation at position 371 
Synthesised by 
GENEWIZ, cloned in 
this study 
pET45b-AaUbc9 
C93S 
Bacterial expression vector 
containing the sequence for 
AaUbc9 with a mutated cysteine 
–> serine at position 93 
This study 
pGEX-HsSAE1/2 Bacterial expression vector 
containing the sequence for 
HsSAE1/2 as described in 
(Tatham, Jaffray et al. 2001) 
cDNA obtained from 
Professor Ron Hay, 
plasmids were a kind 
gift from Dr Chris 
Boutell  
pCMV.DR.8.91 Lentivirus helper vector that 
expresses the reverse 
transcriptase polymerase, 
capsid protein (gag), and 
regulatory proteins (Rev and 
A kind gift from 
Professor Rodger 
Everett (MRC – 
University of 
Glasgow Centre for 
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Tat) as described in (Everett, 
Rechter et al. 2006) 
Virus Research) 
pCMV-SFV4.eGFP Plasmid encoding Semliki Forest 
Virus containing an internal 
eGFP reporter protein as 
described in (Tamberg, Lulla et 
al. 2007) 
A kind gift from Dr 
Esther Schnettler 
(Bernhard Nocht 
Institute for Tropical 
Medicine) 
pCMV-SFV4.Ffluc Plasmid encoding Semliki Forest 
Virus containing an internal 
Firefly luciferase reporter 
protein as described in 
(Tamberg, Lulla et al. 2007) 
A kind gift from Dr 
Esther Schnettler 
(Bernhard Nocht 
Institute for Tropical 
Medicine) 
pVSV-G Lentivirus helper vector that 
expresses the VSV envelope 
protein, used in the production 
of lentivirus vectors as 
described in (Everett, Rechter 
et al. 2006) 
A kind gift from 
Professor Rodger 
Everett (MRC – 
University of 
Glasgow Centre for 
Virus Research) 
shCtrl Plasmids encoding a short 
hairpin RNA against a non-
targeted control sequence (5’-
TTATCGCGCATATCACGCG-3’) 
A kind gift from Dr 
Chris Boutell 
(Everett, Rechter et 
al. 2006). 
pLKO-shSUMO1 Plasmids encoding a short 
hairpin RNA against SUMO1 
A kind gift from Dr 
Kristen Conn, 
unpublished data, 
from MISSION shRNA 
lentivirus vector 
collection (Sigma-
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Aldrich) 
pLKO-shSUMO2/3 Plasmids encoding a short 
hairpin RNA against SUMO2/3 
A kind gift from Dr 
Kristen Conn, 
unpublished data, 
from MISSION shRNA 
lentivirus vector 
collection (Sigma-
Aldrich) 
pLKO-shPIAS1 Plasmids encoding a short 
hairpin RNA against PIAS1 (5’-
TTGTAAGTCGTAAGGCATGGG-3’) 
as described in Brown, Conn et 
al. (2016) 
A kind gift from Dr 
Kristen Conn 
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2.1.4. Primer sequences 
 
Primer Use Sequence (5’-3’) 
pET-Ubc9 F Cloning CCGGACCGGTTCCGGAATTGCGATCGC 
pET-Ubc9 R Cloning CGCGCTCGAGCTACTCCGTGGCAGCCATGG 
Ubc9 C93S Int 
F1 
Site directed 
mutation 
AACCGTCTCTCTGTCGC 
Ubc9 C93S Int 
R1 
Site directed 
mutation 
GCGACAGAGAGACGGTT 
AaSAE2 F Cloning GCACTGCAGGAAACAATAGC 
AaSAE2 R Cloning CTCAGCTCCCGCTTCCGGATCC 
AaSAE2 F1 Cloning TCTCCGGATACTGCGGATCC 
AaSAE2 R1 Cloning GAATGATGTTTCCCGCCATGG 
AaSAE2 F2 Cloning GCTTTGAAGTCAAATCCATGG 
AaSAE2 R2 Cloning CAATGTGTACTCTTACC 
AaSAE1 F Cloning ACCGCAGACGCCGCCTTG 
AaSAE1 R Cloning GATATTAAAGTATATACG 
AaSAE1 F1 Cloning GAACGAACCGTGCGGAAGCTTC 
AaSAE1 R1 Cloning CTGAGCCCGAGACAAAGAAGCTTC 
AaPIAS F for 
pET45b 
Cloning CCGGACCGGTATGAGAAAAACGCGG 
AaPIAS R for 
pET45b 
Cloning CGCGGCGGCCGCTCATATCTTGG 
pET28- 
AaSUMO F 
Cloning GGCGCATATGTCTGAAGAAAAAAAGG 
pET28-AaSUMO 
R 
Cloning TATCCTCGAGTTATCCGCCTGTCTG  
Table 2-6 Oligonucleotide sequences used in this study 
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pET28-SUMO 
chimera F 
Cloning ATTGCATATGTCCGAGGAGAAGCC 
Q_AaSUMO_F Q-PCR CGCCAATTTTCAGCACAC 
Q_AaSUMO_R Q-PCR CGGATCCCTTCGAGTCC 
Q_AaUbc9_F Q-PCR CGGCGAGGAGCGAAAAG 
Q_AaUbc9_R Q-PCR TTCTTTCCTGGAATAG 
Q_AaPIAS_F2 Q-PCR GACAATCTTGTTATCGATGGCT 
Q_AaPIAS_R Q-PCR GCGCTTCAATGGGAGATC 
Q_LacZ_F Q-PCR CCGGCTGTGCCGAAAT 
Q_LacZ_R Q-PCR GCGGCTGATGTTGAACTGG 
Q_Ago2_F Q-PCR GAGCAAACAAATATCCCA 
Q_Ago2_R Q-PCR TGGTGTCGCTTTTGGAC 
Q_AeS7_F Q-PCR CCAGGCTATCCTGGAGTTG 
Q_AeS7_R Q-PCR GACGTGCTTGCCGGAGAAC 
Q_BUNV_Lprt_
F_cRNA strand 
Q-PCR GACACCCCTGAGCTAGAGGAGC 
Q_BUNV_Lprt_
R_cRNA strand 
Q-PCR CCACCTCTGTCTCTGCTCTGGC 
Q_SFV_Stru_F Q-PCR GCCGAAAACGCAGCCCAAG 
Q_SFV_Stru_R Q-PCR GGCGTACCCAGTGACCTTTCCTT 
Q_ZIKV_NS3_F Q-PCR ATCTGTATGGAGGTGGGTGC 
Q_ZIKV_NS3_R Q-PCR CTCTCCCTCAATGGCTGCTA 
T7-AaSUMO F dsRNA 
synthesis 
taatacgactcactatagggTCCGAATCGGAGCACATT
AA 
T7-AaSUMO R dsRNA 
synthesis 
taatacgactcactatagggCATGTTCCATGGCTTGTA
CG 
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T7-AaUbc9 F dsRNA 
synthesis 
taatacgactcactatagggATGTCCGGAATTGCGATC
GC 
T7-AaUbc9 R dsRNA 
synthesis 
taatacgactcactatagggGGATCCTTGATGTTCGGT
TCGT 
T7_AaPIAS_F_3 dsRNA 
synthesis 
taatacgactcactatagggAAcAGGAGGATTACTTCC
CACC 
T7_AaPIAS_R_3 dsRNA 
synthesis 
taatacgactcactatagggGCAGACGGGACAGTTCCA
AG 
Ago2 T7 F dsRNA 
synthesis 
taatacgactcactatagggGCCCTCAACAAGAAACAC
C 
Ago2 T7 R dsRNA 
synthesis 
taatacgactcactatagggGGCGTTGATCTTGAGCCA 
βGal T7 F dsRNA 
synthesis 
taatacgactcactatagggGTCGCCAGCGGCACCGCG
CCTTTC 
βGal T7 R dsRNA 
synthesis 
taatacgactcactatagggCCGGTAGCCAGCGCGGAT
CATCGG 
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2.1.5. Reagents, chemicals, buffers, and kits 
2.1.5.1. Commercial kits 
 
  
Name Source Catalogue 
number 
EndoFree Plasmid Maxi Kit Qiagen 12362 
Fast SYBR Green Master mix 
Applied Biosystems 4385612 
Firefly Luciferase kit Promega E1500 
MEGAScript RNAikit Ambion AM1626 
Micro BCATM Protein Assay 
Kit 
Thermo Scientific 23235 
NanoLuciferase kit Promega N1110 
PureLink HiPure Plasmid 
Filter Maxiprep Kit 
Invitrogen K210017 
QIAEX II® Gel Extraction Kit Qiagen 20021 
QIAprep Spin Miniprep Kit Qiagen 27106 
QIAquick PCR Purification 
Kit 
Qiagen 28106 
Rneasy Plus Mini Kit Qiagen 74136 
TaqMan Reverse 
Transcription reagents 
Applied Biosystems N8080234 
Table 2-7 Commercial kits used in this study 
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2.1.5.2. Buffers made in house 
 
   
Name Component 
3x BM 30% SGB (v/v), 30% Glycerol (v/v), 8 M urea, 
6.5% SDS (w/v), 100 mM DTT 
3xBM -DTT 30% SGB (v/v), 30% Glycerol (v/v), 8 M urea, 
6.5% SDS (w/v) 
Blocking buffer (FBS) 5% filtered FBS in PBS 
Blocking buffer (milk) 5% Skimmed Milk Powder in PBST 
Coomassie Brilliant Blue Stain 0.12% Coomassie Brilliant Blue powder, 50% 
Methanol, 10% Acetic acid in water 
Coomassie destain Solution 5% Methanol, 7% Acetic acid in water 
Coomassie fix solution 50% Methanol, 10% Acetic acid in water 
DNA loading buffer 65% Sucrose (w/v), 10 mM Tris, 10 mM EDTA 
Fixing buffer 1.8% Formaldehyde, 0.1% NP40 in PBS 
PBST 0.05% Tween-20 in PBS 
Stacking Gel Buffer (SGB) 0.5 M Tris, 0.4% SDS (w/v), pH6.8 
TAE Buffer (50x) 40 mM Tris, 1 mM EDTA, 5 mM sodium 
acetate (pH7.6) 
Trypsin-versene 2.5% trypsin (v/v) in versene 
Table 2-8 List of buffers made in house and used throughout the study 
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2.1.5.3. Reagents used  
 
Name Source 
Catalogue / CAS 
number 
100bp DNA ladder Promega G571A 
1kb DNA ladder Promega G210A 
2-Propanol Sigma-Aldrich 24137 
2-Mercaptoethanol MERCK 8.05740.0250 
Acetic Acid VWR Chemicals 20104.334 
Amersham Protran 0.2 µm NC 
blotting membrane 
GE Healthcare 10600001 
Agar E&O laboratories BM5280 
Agarose Sigma-Aldrich A9539 
Ampicillin Melford A0104 
Bovine Serum Albumin (BSA) BioRad 500-0207 
CellLyse Sigma-Aldrich C2978 
Chloramphenicol Sigma-Aldrich C0378 
Coomassie Brilliant Blue BioRad 161-0400 
d-Desthiobiotin Sigma-Aldrich D1411 
Deoxynucleotides 
(dATP/dGTP/dCTP/dTTP) 
Sigma-Aldrich DNTPCA10 
DL-Dithiothreitol (DTT) Sigma-Aldrich 43819 
Ethylenediaminetetraacetic acid 
(EDTA) 
VWR 
International 
60-00-4 
Ethanol Fisher Chemicals 64-17-5 
Ethidium Bromide Sigma-Aldrich E1510 
Formaldehyde solution (36.5-38%) Sigma-Aldrich F8775 
Glycerol Fisher Chemicals 56-81-5 
Gurr Giemsa VWR Chemicals 350864X 
His-select® Nickel Affinity Gel Sigma-Aldrich P6611 
Imidazole 99+% (titration) Sigma-Aldrich 10250 
Isopropyl-thio-β-D-galactoside GibcoRBL 15529-019 
Table 2-9 Reagents used in the study 
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(IPTG) 
Hygromycin B Invitrogen 10687010 
Kanamycin Sigma-Aldrich 60615 
KPL True Blue Peroxidase 
Developing Solution 
Sera Care 5510-0030 
Luria-Bertani (LB) Broth E&O laboratories BM5300 
Methanol Fisher Chemicals 67-56-1 
PageRulerTM Prestain NIR Protein 
Ladder 
Thermo Scientific 26635 
Phosphate Buffered Saline (PBS) Sigma-Aldrich D1408 
Protease inhibitor cocktail 
tablets, EDTA Free 
Roche 11 873 580 001 
Magnesium Chloride (MgCl2) VWR Chemicals 25108.260 
Nonidet P-40 (NP40) Substitute Sigma-Aldrich 9016-45-9 
NuPAGETM MES SDS running buffer 
(20X) 
Invitrogen NP0002 
NuPAGETM Sample Reducing Agent 
(10X) 
Invitrogen NP0004 
NuPAGETM Transfer Buffer Invitrogen NP0006-1 
NuPAGETM 4-12% Bis-Tris Gel 
10x12 well 
Invitrogen NP0322BOX 
NuPAGETM 4-12% Bis-Tris Gel 
10x15 well 
Invitrogen NP0323BOX 
Skimmed Milk Powder Marvel  
Slide-A-Lyzer® MINI Dialysis Unit 
MWCO 3500 
Thermo Scientific 69552 
S.O.C. Media Invitrogen 15544-034 
Sodium Chloride VWR Chemicals 27810.295 
Sodium dodecyl sulfate solution 
(SDS) 
Sigma-Aldrich 05030 
Strep.Tactin SuperflowTM Agarose Novagen 71592 
Tris Roche 10 708 976 001 
Triton-X-100 Promega H5142 
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Tween 20 Millipore 655204 
Urea Sigma-Aldrich U0631 
 
 
2.1.6. Enzymes 
All restriction enzymes and corresponding buffers were obtained from NEB. 
Phusion High-fidelity DNA polymerase and T4 DNA Ligase were obtained from 
NEB. 
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2.1.7. Reagents used for prokaryotic work 
2.1.7.1. Bacterial strains and culture media 
Two strains of chemically competent Escherichia coli (E. coli) were used in this 
study. DH5α (Invitrogen) were used in plasmid DNA amplification and cloning. 
The strain BL21(DE3) (New England Biolabs) was used in protein expression. All 
bacterial cultures were grown in a Luria-Bertani (LB) medium overnight, and 
spread onto agar plates containing the relevant antibiotic selection for the 
plasmid. Concentrations were: Ampicillin 100 µg/ml, Kanamycin 50 µg/ml, 
Chlormphenicol 50 µg/ml 
 
 
2.1.6.2. Buffers for protein purification from 
bacterial extracts 
The reagents used for protein purification can be found in Table 2-9. 
6xHis epitope tag purification buffer: 
Used for AaSUMO, AaUbc9, AaUbc9 C93S, AaPIAS, AaPIAS C371A, HsSUMO1, 
HsSUMO2, HsSUMO3, HsUbc9, HsSAE1/2, SUMO chimaera, and SUMO chimaera 
K11R; 
50 mM Tris (pH 7.0), 250 mM NaCl, 5% Glycerol, 2.5 mM MgCl2, 10 mM 2-
Mercaptoethanol, 30 mM Imidazole, 0.1% Triton-x-100, Protease Inhibitor 
Cocktail Tablet. Final pH 7.5. 
 
6xHis tag elution buffer:  
50 mM Tris (pH 7.0), 250 mM NaCl, 5% Glycerol, 2.5 mM MgCl2, 10 mM 2-
Mercaptoethanol, 350 mM Imidazole, 0.1% Triton-x-100, Protease Inhibitor 
Cocktail Tablet. Final pH 7.5. 
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6xHis tag dialysis buffer: 
50 mM Tris (pH7.0), 150 mM NaCl,  5% Glycerol, 2 mM MgCl2, 1 mM DTT 
 
Strep.II tag purification buffer: 
Used for AaSAE1/2; 
50 mM Tris (pH 7.0), 50 mM NaCl, 1 mM MgCl2 
 
Strep.II tag elution buffer: 
50 mM Tris (pH 7.0), 50 mM NaCl, 1 mM MgCl2, 2.5 mM d-Desthiobiotin (pH 8.5) 
 
Strep.II tag dialysis buffer: 
50 mM Tris (pH7.0), 150 mM NaCl,  5% Glycerol, 2 mM MgCl2, 1 mM DTT 
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2.2. Methods 
 
2.2.1. Cloning and DNA manipulation 
2.2.1.1. DNA quantitation 
The Nanodrop 2000 spectrophotometer (Thermo Scientific), was used to quantify 
DNA or RNA when necessary measuring absorbance at 260 and 280 nm. 
 
2.2.1.2. Polymerase Chain Reaction (PCR) 
amplification 
PCR was utilised for the amplification of nucleic acids. A total of 50 µl volume 
was used for each reaction, and occurred in a PCR Thermal Cycler (Techne TC-
312). Each reaction contained 10 µl 5x Phusion® HF buffer (1x), 1 µl Phusion® 
DNA polymerase (1 U), 0.5 µl dNTPs (5 µM), 10 µM forward primer, 10 µM reverse 
primer, and approximately 50-100 ng template DNA or cDNA, made up with 
nuclease free water. Reactions were prepared on ice. Standard reactions were 
cycled as noted (Table 2-10). For dsRNA synthesis, the oligonucleotides 
contained an additional T7 sequence (5’-taatacgactcactataggg-3’), consequently 
the reaction cycle was modified (Table 2-11). Furthermore, for the production 
of T7-SUMO for dsRNA production, the concentration of oligonucleotides was 
decreased to 500 nM forward or reverse primer. 
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Stage Temperature 
(˚C) 
Duration 
Initial denaturation 98 3 minutes 
Denaturation 98 30 seconds 
Oligo annealing TM -10 45 seconds 
Extension 72 30 seconds 
Denaturation 98 30 seconds 
Oligo annealing TM -5 45 seconds 
Extension 72 30 seconds 
Final extension 72 5 minutes 
Stage Temperature 
(˚C) 
Duration 
Initial denaturation 98 3 minutes 
Denaturation 98 30 seconds 
Oligo annealing TM -5 45 seconds 
Extension 72 30 seconds -> 1 
minute 
Final extension 72 5 minutes 
Cycle 35 
times 
Cycle 6 
times 
Cycle 35 
times 
Table 2-10 Standard PCR cycle 
Table 2-11 T7 PCR cycle 
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2.2.1.3. Restriction endonuclease digestion  
A total volume of 20 µl of reaction mixture was made up for each digestion, 
containing 1 µl restriction enzyme (1 U/µl), 2 µl 10x required buffer, and 
plasmid DNA (up to 1 µg), made up in DNase-free water. The restriction enzymes 
and required buffers were purchased from New England Biosciences (NEB). 
Reactions were incubated for 1-2 hours at 37 ˚C prior to being analysed by 
agarose gel electrophoresis and extracted for further use (Section 2.2.1.4). 
 
2.2.1.4. Agarose gel electrophoresis  
All DNA products, and dsRNA products, were analysed by agarose gel 
electrophoresis in 1% agarose gels prepared with 1x TAE buffer containing 
ethidium bromide at 0.5 µg/ml. Samples were mixed with DNA loading dye at a 
1:5 ratio, and the gels were resolved at 60 V for between 30 minutes – 2 hours, 
depending on the size of the product and distance required between bands. DNA 
ladder markers were used alongside samples to provide reference about the 
concentration and fragment size. After resolution, samples were visualised by an 
ultraviolet (UV) transilluminator. Short wave UV was used for imaging and long 
wave UV was used for gel extraction. Fragments were isolated with a scalpel and 
DNA isolated with the QIAEX II® Gel Extraction Kit (Section 2.1.5.1), following 
manufacturers guidance. 
 
2.2.1.5. DNA Ligation 
Digested fragments of the vector backbone and insert were examined on a 1% 
agarose gel and quantified by Nanodrop spectrophotometer to confirm expected 
size and assess concentration (Section 2.2.1.1; Section 2.2.1.4). The products 
were ligated together at a ratio of 7:1 insert fragment to vector backbone. 
Ligation reactions occurred in 10 µl volumes with 1 µl T4 DNA ligase and 1 µl DNA 
ligase buffer (Section 2.1.6). Samples were incubated overnight at 15 ˚C. 
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2.2.1.6. Transforming competent bacteria 
E. coli DH5α’s, used for DNA isolation and amplification, were transformed in 50 
µl aliquots. Either 10 µl of ligated product (Section 2.2.1.5) or 100 ng plasmid 
DNA was gently mixed with the competent bacteria and left to incubate on ice 
for 30 minutes. The competent bacteria were then heat shocked at 42 ˚C for 45 
seconds, and cooled briefly on ice. The bacteria were subsequently grown in 300 
µl S.O.C medium for 45 minutes without any antibiotic present at 37 ˚C, and 
plated onto antibiotic selective plates. Bacterial plates were incubated 
overnight at 37 ˚C.  
E. coli BL21 (DE3)’s, used for protein isolation, were transformed in 20 µl 
aliquots. Approximately 100 ng plasmid DNA was mixed with the competent 
bacteria and left to incubate on ice for 30 minutes. The competent bacteria 
were subsequently heat shocked at 42 ˚C for 30 seconds, and briefly cooled on 
ice. The bacteria were then grown in 300 µl S.O.C. Medium for 45 minutes 
without any antibiotic, and plated onto antibiotic selective plates overnight at 
37 ˚C. 
 
2.2.1.7. Growing bacterial cultures of E. coli 
DH5α 
After competent DH5α were transformed with a plasmid of interest (Section 
2.2.1.6), individual colonies were selected to be grown in LB Broth (Table 2-9). 
For small scale plasmid isolation colonies were grown o/n in 5 ml LB aliquots 
containing the relevant antibiotic with constant shaking. For large scale plasmid 
isolation, individual colonies were grown for 3 hours in 5 ml aliquots before 
being transferred to pre-warmed 350 ml batches of LB broth, containing the 
relevant antibiotic and allowed to grow o/n at 37 ˚C with constant shaking. 
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2.2.1.8. Isolation and amplification of DNA 
using kits 
Small scale isolation  
Colonies of DH5α were grown as specified (Section 2.2.1.7). To isolate the 
plasmid DNA, 3 ml of culture was centrifuged in an Eppendorf tube at 13,000 
rpm for 3 minutes (Eppendorf benchtop centrifuge). The supernatant was 
removed and plasmid DNA was extracted using the QIAprep® Spin Miniprep Kit 
(Table 2-7) following manufacturers protocol. Following isolation, plasmid DNA 
was analysed by restriction digest and agarose gel electrophoresis, to confirm 
correct insert, and sequenced to confirm the gene sequence was correct. 
Large scale isolation 
Colonies of DH5α were grown as specified (Section 2.2.1.7). To isolate plasmid 
DNA, colonies were centrifuged at 3500 rpm for 30 minutes (Megafuge 16R, 
Thermoscientific). The supernatant was subsequently removed, and DNA was 
extracted using the EndoFree® Plasmid Maxi Kit, if the samples were to be used 
for mammalian transfection (Table 2-7). Samples that were intended to be used 
for further cloning, or bacterial transfection, were isolated using the PureLink 
HiPure Plasmid Filter Maxiprep Kit (Table 2-7). 
 
2.2.1.9. Sequencing by commercial 
companies 
DNA samples to be sequenced were sent to Source Bioscience for processing by 
Sanger sequencing. Samples were sequenced with primers provided by the 
company and data was subsequently analysed with VectorNTI® software (Life 
Technologies). 
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2.2.1.10. Site directed mutagenesis of 
plasmid DNA by PCR 
The gene of interest (AaUbc9) was amplified using two pairs of forward and 
reverse primers, one pair at the 5’ and 3’ ends of the gene, and a 
complementary pair of internal primers which contained the Guanosine-Cytidine 
base pair mutation at position 278 to change the codon from 5’-TGT-3’ 
(Cysteine) in to a 5’-TCT-3’ (Serine). Two PCR reactions were initially needed 
which amplified the 5’ and 3’ halves of the gene. The next step involved 
combining the 5’ and 3’ halves and conducting a third PCR using the external 5’ 
and 3’ primers again, as described in (Heckman and Pease 2007) (Table 2-10).  
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Figure 2.1 Schematic of site directed mutagenesis protocol for AaUbc9 
The gene of interest was amplified using forward and reverse primers (1 and 4). 
Mutants are produced from two internal primers (2 and 3) which contain the 
genetic changes encoding the amino acid change Cysteine – Serine at position 93. 
In the first set of PCR reactions, primers 1 and 3 are used together, and primers 2 
and 4 are used as a separate PCR reaction. Equal concentrations of the products 
are then combined to produce a template for the third PCR, which were 
undertaken using primers 1 and 4. Primers 1 and 4 also contained restriction 
endonuclease sites for future cloning into plasmid vectors. 
 
Primer 1 
Primer 4 
Specific 
mutation in 
primers 2 and 3 
Primer 1 
Primer 2 
Primer 3 
Primer 4 
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2.2.1.11. dsRNA synthesis for cell culture 
Total RNA was extracted from Ae. aegypti A20 cell culture, using RNAeasy Plus 
Kit, following the manufacturer’s instructions (Table 2-7; Section 2.2.6.4), and 
cDNA was synthesised with random hexamer primers to use as a template for the 
PCR reaction (Section 2.2.6.5; Section 2.2.1.2). As the kit uses T7 DNA-
dependent RNA polymerase, all the genes of interested used required the 
addition of a T7 gene sequence (5’-taatacgactcactataggg-3’) which was included 
in the primer sequences (Table 2-6). Between 700 ng – 1 µg of purified T7-PCR 
product was used to produce dsRNA using the MEGAScript RNAi Kit (Table 2-7). 
The dsRNA synthesis occurred following the manufacturers guidance. The 
optional step of pre-heating the elution solution to 95 ˚C was undertaken in 
order to increase yields. Concentration of dsRNA was measured as described 
(Section 2.2.1.1), and purity of product was checked by agarose gel 
electrophoresis (Section 2.2.1.4). 
 
2.2.1.12. dsRNA synthesis for adult Ae. 
aegypti 
Total RNA was extracted from Ae. aegypti A20 cell culture, using RNeasy 
Plus Kit, following manufacturer’s guidance (Table 2-7; Section 2.2.6.4). cDNA 
was synthesised with random hexamer primers to use as a template for the PCR 
reaction (Section 2.2.6.5; Section 2.2.1.2). As the kit uses T7 DNA-dependent 
RNA polymerase, all the genes of interested used required the addition of a T7 
gene sequence (5’-taatacgactcactataggg-3’) which was included in the primer 
sequences (Table 2-6). Between 10 - 15 µg of purified T7-PCR product was used 
to produce dsRNA using reagents from a MEGAScript RNAi Kit (Table 2-7). The 
initial reaction to synthesise dsRNA was set up as shown in Table 2-12, and the 
reaction was allowed to continue o/n at 37 ˚C. The following day RNA was 
annealed together for 5 minutes at 75 – 80 ˚C and left to cool at room 
temperature (RT). To remove DNA and any single stranded RNA which did not 
anneal, the sample was subjected to nuclease digestion; the reaction was set up 
as shown in Table 2-13. The reaction occurred at 37 ˚C for 1 hour. The dsRNA 
was subsequently purified by suspending the dsRNA in a binding buffer, as 
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described in Table 2-14 binding the dsRNA to a column and centrifuging at 
12400 rpm for 1 minute at 4 ˚C (Eppendorf benchtop centrifuge). Elution 
solution was pre-heated to 95 ˚C to maximise yields. dsRNA was then 
centrifuged at 4 °C at 12,400 rpm for 5 minutes and transferred to another 
RNase free Eppendorf tube in order to remove the salt pellet. The concentration 
and purity was checked to ensure there would be enough dsRNA in the final 
volume to treat mosquitoes with 2 µg dsRNA / mosquito (Section 2.2.1.1; 
Section 2.2.1.4). The dsRNA was vortexed with 1/10 volumes Sodium Acetate 
and 3 volumes 100% ethanol, the mixture was incubated at -80 °C for 2 hours. 
The sample was centrifuged again (30 minutes, 4 °C, 13,000 rpm) supernatant 
was discarded and the pellet was washed with 1 ml 70% ethanol, followed by 
another 10 minute centrifuge at 4 °C (13,000 rpm). The wash was removed and 
the pellet was allowed to air dry for 2 minutes before resuspension in nuclease 
free H2O at 60 °C. The dsRNA was checked again by making a 1/50 dilution, 
quantifying on the nanodrop and resolving on an agarose gel (Section 2.2.1.1; 
Section 2.2.1.4). 
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Component Total for nuclease digestion 
dsRNA solution 300 µl 
Nuclease free H2O To total volume of 750 µl 
10X Digestion buffer 75 µl 
DNase I 30 µl 
RNase 30 µl 
Component Total for dsRNA synthesis for 
mosquito depletion 
DNA template 10-15 µg 
Nuclease free H2O To total volume of 300 µl 
10x T7 reaction 30 µl 
ATP solution (75mM) 30 µl 
GTP solution (75mM) 30 µl 
CTP solution (75mM) 30 µl 
UTP solution (75mM) 30 µl 
T7 enzyme mix 30 µl 
Table 2-12 Components in a nuclease digestion for mosquito 
depletion 
Table 2-13 dsRNA synthesis reaction for mosquito depletion 
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Component Total for dsRNA purification 
dsRNA solution 750 µl 
Nuclease free H2O 2.25 ml 
10X binding buffer 750 µl 
100% Ethanol 3.75 ml 
 
  
 Table 2-14 dsRNA binding solution for mosquito depletion 
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2.2.2. Purification of recombinant proteins  
2.2.2.1. Expression in recombinant BL21 
(DE3) 
After competent E. coli BL21 (DE3) cells were transformed with a bacterial 
expression plasmid of interest (Section 2.2.1.6), 5 independent colonies were 
selected to be grown together o/n in LB broth with the relevant antibiotic at 37 
˚C with constant shaking as starter cultures. The starter cultures were used to 
set up larger pre-warmed cultures of 200-250 ml supplemented with the relevant 
antibiotic. The larger cultures were grown for 2 hours at 37 ˚C with constant 
shaking, and then transferred to a shaking 30 ˚C incubator, and protein 
expression was induced with the addition of 0.1 mM IPTG for 4-5 hours (Table 2-
9). 
 
2.2.2.2. Purification of 6xHis tagged proteins  
BL21 (DE3) cells were initially transformed, and grown to express the protein of 
interest (Section 2.2.1.6; Section 2.2.2.1). Bacterial pellets containing 
bacterial expression plasmids which encode HsSUMO1, HsSUMO2, HsSUMO3, 
HsUbc9, HsSAE1/2, AaSUMO, AaUbc9, AaUbc9 C93S, AaPIAS, AaPIAS C371A, 
SUMO chimaera, or SUMO chimaera K11R, were re-suspended in 25 ml 6xHis 
purification buffer (Section 2.1.6.2). The bacteria were lysed by probe-
sonication (45 pulses, 30 Amps), and cell debris was centrifuged at 13000 xg for 
10 minutes (Thermo Scientific Evolution RC) and filtered through a 0.45 µm filter 
(Sartorius). His-select Nickel Affinity Gel (Ni-NTA beads) (Table 2-9) were spin 
washed twice in 1ml 6xHis purification buffer by centrifugation at 6000 rpm for 
30 seconds, and re-suspended in 300 µl 50% (w/v) purification buffer. The 
samples were tumbled end-over-end for 90 minutes at RT, washed twice in 10 ml 
6xHis purification buffer, centrifuged at 1500 xg for 5 minutes (Eppendorf 
benchtop centrifuge), and washed a further three times in 1 ml 6xHis 
purification buffer. Proteins were eluted in 750 µl 6xHis elution buffer in three 
fractions (Section 2.1.6.2). Dialysis of protein samples occurred with slide-a-
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lyser MINI dialysis units (Thermo Scientific), in 6xHis dialysis buffer for four hours 
(Section 2.1.6.2). 
 
2.2.2.3. Purification of Strep.II tagged 
proteins 
Bacterial pellets containing bacterial expression plasmids which encode 
AaSAE1/2 were re-suspended in 2 ml Strep.II tag purification buffer (Section 
2.1.6.2). Samples were then lysed by digital sonicator (7 repeats, 50% intensity, 
30 seconds, 4 ˚C, Branson Digital Sonifier) and cell debris was centrifuged at 
14000 xg for 10 minutes at 4 ˚C (Thermo Scientific Evolution RC). The samples 
were then filtered with a 0.45 µm filter, tumbled end-over-end for 90 minutes at 
RT, and washed three times with 1 ml Strep.II tag purification buffer. Samples 
were then eluted in three fractions of 600 µl Strep.II tag elution buffer, and 
dialysed o/n at 4 ˚C in Strep.II tag dialysis buffer (Section 2.1.6.2).   
 
2.2.2.4. Quantification of proteins by BSA 
titration 
Samples were resolved on a NuPAGETM 4-12% Bis-Tris Gel alongside a prediluted 
BSA titration and coomassie stained, protein concentration was determined on 
the Li-Cor Odyssey Imaging System (Table 2-9; Section 2.2.6.1; Section 
2.2.6.2; Li-Cor Odyssey CLx).  
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2.2.3. In vitro assays of recombinant proteins 
2.2.3.1. SUMOylation assays 
SUMOylation assays were carried out in 50 mM Tris (pH7.0), 50 mM NaCl, and 5 
mM ATP. The reactions analysed by Western blot consisted of 50 ng SUMO, 50 ng 
Ubc9, and 50 ng SAE1/2 and 10 ng PIAS, where applicable, and occurred at 
either 28 ˚C or 37 ˚C, as indicated. Reactions analysed by Coomassie stain 
consisted of 300 ng SUMO, 100 ng Ubc9, 100 ng SAE1/2, and 20 ng PIAS where 
applicable. Reactions were allowed to continue for the desired length of time 
until the reaction was terminated by the addition of 3XBM (Table 2-8). 
Thioester-formation assays were terminated with 3XBM –DTT (Table 2-8). 
Samples were boiled at 95 ˚C for 10 minutes and resolved by SDS-PAGE before 
being transferred to a nitrocellulose membrane for analysis by Western blot 
(Section 2.2.6.1; Section 2.2.6.3). 
Assays conducted for Mass Spectrum analysis by collaborators were conducted 
using 5 µg SUMO, 500 ng Ubc9, 500 ng SAE1/2, and 50 ng PIAS when required. 
Reactions were conducted at 28 ˚C for 1 hour and terminated with NuPAGETM 
Sample Reducing Agent (Table 2-9). Samples were subsequently boiled for 10 
minutes at 95 ˚C prior to being shipped to collaborators (Dr Michael Tatham, and 
Professor Ron Hay, University of Dundee) on dry ice. 
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2.2.4. Cell culture methods  
2.2.4.1. Maintenance, growth, and passaging 
of cells 
Mammalian cell cultures were sustained in T75 tissue culture flasks, unless 
otherwise stated (Nunc Fisher Scientific UK Ltd). Cells were maintained in 
appropriate media (Table 2-1) at 37 ˚C with 5% CO2. When cells were 
approximately 90% confluent they were washed 2 - 3 times with 5 ml versene, 
and incubated with 2 ml trypsin-versene until the cells detached (Table 2-8). An 
aliquot of detached cells were re-suspended in 5 ml of the appropriate media 
before being seeded in a new flask or counted prior to seeding (Section 
2.2.4.2). 
Ae. aegypti cell cultures were sustained in T25 tissue culture flasks (Nunclon 
Delta surface Thermo scientific). Cells were maintained in L15 media at 28 ˚C 
with no CO2 (Table 2-1), when cells were approximately 90% confluent they 
were knocked off into 2 ml of media using a Cell Scraper (Corning incorporated 
costar). An aliquot of cells were either re-suspended in 5 ml media in a new 
flask or counted and seeded for future experiments (Section 2.2.4.2). 
 
2.2.4.2. Seeding of cells 
The number of cells was determined using a Neubauer haemocytometer counting 
chamber using a light microscope. Mammalian cells were seeded in 6-, 12-, or 
24-well plates. HFt cells were seeded at 1.5 x 105 cells / well in a 24-well plate, 
A549-Npros were seeded in 12 well plates at 3 x 105 cells / well, and BHK cells 
were seeded in 6 well plates at 5 x 105 cells / well.  
Ae. aegypti cell culture were seeded in 24-well plates at 5 x 105 cells / well, 
after the wells had been treated with Poly-D-Lysine Hydrobromide. Briefly, Poly-
D-Lysine Hydrobromide was diluted in sterilised PBS, the wells were incubated 
with 500 µl Poly-D-Lysine at room temperature for 30 minutes before the Poly-D-
Lysine was aspirated off.   
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All cells in 24-well plates were covered with 1 ml of appropriate media, 12-well 
plates were covered in 1.5 ml media and cells in 6-well plates were covered with 
a total volume of 3 ml media. Cells were incubated in the required conditions 
overnight prior to future experiments.  
 
2.2.4.3. Transfection of mammalian cells 
Two different mammalian cell lines were transfected with plasmids: 
BHK 
3 x 105 BHK cells were seeded per well of a 6 well plate, each well was 
transfected with 2 µg pCMV-SFV4.eGFP or pCMV-SFV4.Ffluc using 
Lipofectamine2000 following manufacturers guidance (Section 2.2.4.2; Section 
2.2.4.3; Table 2-2; Table 2-5). Conditioned media was added to transfection 
media after 4 hours and at the end of the day the transfection media was 
removed and fresh media was added. Cells were then incubated at 37 ˚C during 
propagation of virus stocks (Section 2.2.5.1). 
 
HEK-293T  
HEK-293T cells were seeded at a concentration of 2 X 106 cells in a 60 mm dish. 
Cells were incubated o/n at 37 ˚C in 5% CO2 in 5 ml media, 3 µg of pLKO plasmid 
expressing a non-target control, SUMO1-targeting, SUMO2/3-targeting, or PIAS1-
targeting short hairpin RNA (called shCtrl, shSUMO1, shSUMO2/3, or shPIAS1, 
respectively), along with the helper plasmids pVSV-G (3 µg) and pCMV-DR8.91 (3 
µg) (Table 2-5) were combined with 250 µl of serum-free DMEM. PLUS reagent (8 
µl) was added to the plasmid mixture and incubated for 15 minutes at room 
temperature. Simultaneously, 12 µl of Lipofectamine was also mixed with 250 µl 
serum-free DMEM, and left to incubate at room temperature for 15 minutes. 
After the incubation was completed, the serum-free DMEM with PLUS reagent, 
and serum-free DMEM with Lipofectamine were mixed together and allowed to 
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incubate together for a further 15 minutes at room temperature. Conditioned 
media was removed, and HEK-293T cells were incubated with the transfection 
media for 4 hours at 37 ˚C. A 50:50 mix of fresh and conditioned media was then 
replaced and incubated o/n at 37 ˚C. When CPE was observed (approximately 2 
days post transfection), cell supernatant containing released lentiviral particles 
were harvested, and filtered through a 0.45 µm filter. Samples were then 
immediately used (Section 2.2.4.4). 
 
2.2.4.4. Lentivirus transduction of cells 
60 mm dishes of HFt cells at 4 x 105 cells / dish were seeded (Section 2.2.4.2). 
Filtered lentivirus (3.5 ml) was mixed with polybrene (3.5 µl) for each target 
(Table 2-2). The filtered lentivirus with polybrene was subsequently added to 
each dish, the cells were allowed to incubate o/n at 37 ˚C. The following day, 
the media was removed and fresh media supplemented with 1 µg/ml Puromycin, 
and 50 µg/ml of Hygromycin was applied to select for successfully transduced 
cells. The cells were passaged under continuous selection pressure, (5 µg/ml of 
Hygromycin, and 0.5 µg/ml of Puromycin). mRNA and protein expression was 
assessed by q-PCR and Western blotting (Section 2.2.6.3; Section 2.2.6.6). 
 
2.2.4.5. dsRNA transfection of mosquito cells 
AF5 cells were seeded in 24 well plates at 2.5 x 105 cells / well, and left to 
incubate o/n at 28 ˚C. Target dsRNA (300 ng) was transfected with 2 µl 
DharmaFECT2 (Table 2-2) per well following manufacturer’s instructions. Cells 
were incubated at 28 ˚C for 72 hours prior to infection (Section 2.2.5.5).   
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2.2.5. Virology 
2.2.5.1. Propagation of SFV 
BHK cells were transfected with either the plasmid pCMV-SFV4.Ffluc, or pCMV-
SFV4.eGFP (as described in Section 2.2.4.3), and incubated at 37 ˚C until CPE 
was observed, at which point the supernatant containing SFV was collected and 
centrifuged at 3000 rpm at 4 ˚C for 10 minutes, 1 ml of this p0 stock was used to 
infect a T175 flask of BHKs. The flask was incubated at 37 ˚C for 2-4 days until 
CPE was observed. Supernatant was then collected, centrifuged again at 3000 
rpm at 4 ˚C for 10 minutes; virus was then aliquoted and stored at -80 ˚C for 
titration and future experiments. 
 
2.2.5.2. Propagation of BUNV 
An aliquot of both wild type BUNV and BUNV possessing a NanoLuciferase 
reporter protein was provided by Dr Xiaohong Shi (MRC – University of Glasgow 
Centre for Virus Research), this was used to infect a monolayer of 80-90% 
confluent BHK cells at a low MOI (0.01 - 0.001) (Table 2-1; Table 2-3). Upon 
observation of CPE (approximately 4 - 5 days post infection), supernatant was 
harvested and centrifuged at 3000 rpm at 4 ˚C for 10 minutes. Virus was 
aliquoted and stored at -80 ˚C for titration and future experiments. 
 
2.2.5.3. Propagation of ZIKV 
An aliquot of a clinical strain of ZIKV (PE243) and ZIKV possessing a 
NanoLuciferase reporter protein was provided by Dr Claire Donald (MRC – 
University of Glasgow Centre for Virus Research) and Jamie Royle (MRC – 
University of Glasgow Centre for Virus Research), respectively (Table 2-3). This 
virus was used to infect a roller bottle containing 60-70% confluent Vero cells at 
a low MOI (0.01 – 0.001) (Table 2-1). Media pH was maintained during this time 
by the addition of Sodium Bicarbonate (Table 2-2). Upon observation of CPE, 
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approximately 7 – 12 days post infection, virus was harvested and supplemented 
with an additional 10% FBS, aliquoted and stored at -80 ˚C for titration and 
future experiments.  
 
2.2.5.4. Determining viral titre  
Viral titre was determined by either lytic plaque formation or 
Immunocytochemistry (ICC) plaque staining. For the three viruses used; SFV and 
BUNV were titrated by lytic plaques, ZIKV was titrated by ICC. All titration 
involved 10-fold serial dilutions of the virus from stock concentrations. Titrations 
were calculated by determining the number of plaque forming units per ml 
(pfu/ml) of virus supernatant using the following formula: 
𝑝𝑓𝑢 /𝑚𝑙 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
 
Lytic plaques 
BHK cells were seeded in 12 well plates at 2.5 x 105 cells / well and left to 
incubate o/n at 37 ˚C (Table 2-1). SFV or BUNV were serially diluted in serum-
free GMEM and used to infect the cultured cells (Section 2.2.5.5). Infected cells 
were overlaid with an Avicel overlay (Table 2-2), and incubated for 48 hours 
(SFV) or 96 hours (BUNV). Overlay was removed by gently washing 2 - 3 times 
with 1 ml room temperature 1x PBS until all the Avicel had been removed. The 
cells were simultaneously fixed and stained with Giemsa (Table 2-9), and the 
number of lytic plaques counted under a plate microscope.  
 
ICC plaque assay 
A549-NPro cells were seeded in 12 well plates at 3 x 105 cells / well and left to 
incubate o/n at 37 ˚C. ZIKV was serially diluted in serum-free DMEM and used to 
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infect cultured cells (Section 2.2.5.5). Cells were then overlaid with an Avicel 
overlay and incubated for 72 hours at 37 ˚C (Table 2-2). Overlay was removed 
by gently washing 2 – 3 times with 1 ml room temperature 1xPBS until the Avicel 
had been removed. The cells then underwent an Immunocytochemistry (ICC) -
staining (Section 2.2.6.7) and the number of plaques counted under a plate 
microscope.  
 
2.2.5.5. Infection of cultured cells 
Media was aspirated and an appropriate volume of virus stock was then diluted 
in 100 – 500 µl of serum-free media, depending on the size of the well. Virus was 
absorbed by incubating the cells under the relevant conditions for 1 hour (Table 
2-1). The plates were rocked and rotated every 10 - 15 minutes to ensure even 
distribution of the virus across the cell monolayer. Finally, the cells either had 
the media replaced if a luciferase assay was being conducted (Section 2.2.7), or 
an Avicel overlay made up to 0.6% if a plaque assay was being conducted (Table 
2-2). 
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2.2.6. Analytical techniques 
2.2.6.1. Sodium dodecyl sulfate – 
Polyacrylamide gel electrophoresis 
If cells were being used for SDS-PAGE and Western blotting, cells were washed 
twice with PBS before whole lysates were harvested in 3x BM diluted in water to 
1.5x BM (Table 2-8). Samples from protein assays were terminated in 3x BM and 
therefore could instantly be resolved by SDS-PAGE. All samples were boiled for 
10 minutes at 95 ˚C prior to loading. Wells were loaded with 10-15 µl of sample, 
and a PageRuler pre-stained NIR protein ladder was used as a reference marker 
for molecular mass. Proteins were resolved on Novex 4-12% Bis-Tris gels using 
NuPAGE MES (1x) running buffer (Table 2-9). Gels were resolved at 210 volts 
until the dye front reached the bottom of the gel. Resolved SDS-PAGE gels were 
then Coomassie stained (Section 2.2.6.2) or transferred to a nitrocellulose 
membrane for Western blotting (Section 2.2.6.3). 
 
2.2.6.2. Coomassie staining of SDS-PAGE gels 
Gels required for Coomassie staining analysis were fixed with Coomassie fix 
solution for 5 minutes (Table 2-8). The Coomassie fix solution was washed off 
with distilled water, and Coomassie Brilliant Blue Stain was added to the gel 
(Table 2-8). This was incubated together for 3 minutes before being washed off 
with distilled water again. The gel was then briefly rinsed in 100% Methanol, and 
left in Coomassie destain solution at room temperature with constant shaking 
until bands were visible (Table 2-8).  
 
2.2.6.3. Western blotting 
Resolved SDS-PAGE gels were transferred to an Amersham protran 0.2 µm 
nitrocellulose blotting membrane in 1x NuPage transfer buffer and 10% Methanol 
at 30 V for 60 mins.  The membranes were blocked in blocking buffer (5% FBS) at 
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RT for 1 hour (Table 2-8). The required primary antibody was diluted in blocking 
buffer (5% FBS), and incubated on the blotting membrane at room temperature 
for 1 hour or o/n at 4 °C with constant shaking (Table 2-4; Table 2-8). The 
membrane was washed 3 times for 5 minutes each in PBST at room temperature. 
Secondary antibody was incubated with the membrane at room temperature for 
1 hour (Table 2-4). The membrane was then washed 3 times for 5 minutes each 
with PBST, 2 times with PBS, and rinsed 4 times with distilled water. Western 
blots were imaged and quantified using a LiCor Odyssey Imaging System. 
 
2.2.6.4. RNA extraction  
Cells were seeded at 2 x 105 cells / well and left to incubate overnight in the 
required conditions (Table 2-1; Section 2.2.4.2). RNA extraction occurred 
following the RNeasy Plus Mini Kit (Qiagen) following manufacturers guidance 
(Table 2-7). Cells were harvested in 350 µl Buffer RLT Plus, and stored at -20 ˚C 
until processing.  
 
2.2.6.5. Complementary DNA (cDNA) 
synthesis  
Extracted RNA was used as a template for cDNA synthesis by reverse 
transcription of mRNA using the TaqManTM Reverse Transcription Reagents kit 
and the provided random hexamer primers (Table 2-7). Purified RNA underwent 
reverse transcription in a final volume of 20 µl of reaction mix, consisting of a 
final concentration of 1x RT buffer, 1.75 mM MgCl2, 0.5 mM each dNTP, 1 U / µl 
RNase Inhibitor, 2.5 U / ml MultiScribeTM RT, 2.5 µM Random Hexamers, and 1 µl 
template RNA (under 1 µg / reaction). The solution was made up to 20 µl in 
nuclease-free water. The RNA template was incubated at 25 ˚C for 10 minutes, 
to anneal primers, 37 ˚C for 60 minutes for extension, and 95 ˚C for 5 minutes 
to inactivate the reverse transcriptase. 
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2.2.6.6. Quantitative polymerase chain 
reaction (q-PCR) 
SYBR Green 
Ae. aegypti mRNA expression was analysed in triplicate using a SYBR Green 
Master mix with gene specific primers (Table 2-6). Each reaction occurred in a 
20 µl volume, consisting of 10 µl SYBR Green, 1 µl each Forward and Reverse 
primer, and 0.3 µl cDNA template, made up with nuclease-free water. Samples 
were initially denatured at 95 ˚C for 20 seconds, prior to 40 cycles of 3 second 
denaturation at 95 ˚C, and 30 second anneal / extend stage at 60 ˚C. Previously 
validated ribosomal S7 was used as an endogenous control (Table 2-6) 
(McFarlane, Arias-Goeta et al. 2014). q-PCR was conducted on an Applied 
Biosystems 7500 Fast-Real Time PCR system using MicroAmp plates and Optical 
Adhesive covers (Applied Biosystems). Results were subsequently analysed using 
Applied Biosystems 7500 Software v2.0.5. 
 
Primer-probes 
Primer probe analysis was conducted on mammalian cells with targeted gene 
expression being depleted (Section 2.2.4.4). Here, the reactions occurred 
comprising of 1 µl gene specific primer-probe mix, 10 µl Taqman Fast universal 
mix, 2 µl cDNA, to a total volume of 20 µl with nuclease-free water (Table 2-7). 
Samples were initially denatured at 95 ˚C for 20 seconds, prior to 40 cycles of 3 
second denaturation at 95 ˚C, and 30 second anneal / extend stage at 60 ˚C. 
Commercial GAPDH (4333764F) was used as an endogenous control; commercial 
primer probes to SUMO1 (4331182 (Hs02339312_g1)), SUMO2/3 (4331182 
(Hs02743873_g1)), and PIAS1 (4331182 (Hs00184008_m1)) were all obtained from 
Thermo Fisher Scientific. Q-PCR was conducted on an Applied Biosystems 7500 
Fast-Real Time PCR system using MicroAmp plates and Optical Adhesive covers 
(Applied Biosystems). Results were subsequently analysed using Applied 
Biosystems 7500 Software v2.0.5. 
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2.2.6.7. ICC-staining plaque assay 
Cells undergoing an ICC-staining plaque assay had the Avicel overlay washed off 
2 – 3 times in 1x PBS. Cells were then simultaneously fixed and permeabilized in 
Fixing buffer (Table 2-8). Cells were washed twice in PBST and blocked in 
blocking buffer (5% milk) for 30 minutes at room temperature with constant 
shaking (Table 2-8). Cells were incubated for 60 minutes at room temperature 
with the primary antibody of interest diluted in blocking buffer (5% milk) (Table 
2-8). Cells were washed twice for 5 minutes each in PBST, and incubated for 2 
hours with a relevant IgG-peroxidase secondary antibody. Three 5 minute washes 
with PBST were performed following the secondary antibody and True Blue 
Peroxidase stain was added and incubated until the colour was developed (Table 
2-9). Plates were washed three times with PBST, once with PBS and once with 
distilled H2O. Plates were allowed to dry prior to plaques being counted under a 
light microscope. 
 
2.2.6.8. In Cell Western Blot (ICWB) 
Throughout ICWB experiments, all reagents were filter sterilised with a 0.45 µm 
filter. All incubation steps occurred in the dark, and at no point were the plates 
allowed to come into contact with blue roll. 
Experiments which required an ICWB were seeded on glass bottom 24 well plates 
(Greiner Bio-one) at 1 x 105 cells / well. Cells were infected, and incubated with 
an Avicel overlay for the duration of the experiment (Section 2.2.5.5). The 
Avicel overlay was washed off 3-4 times in 1x PBS, filtered with a 0.45 µm filter 
(Table 2-2). Cells were then simultaneously fixed and permeabilized in filtered 
Fixing buffer (Table 2-8). Cells were washed twice in filtered 1x PBST, and 
blocked in filtered blocking buffer (5% FBS) for 1 hour at room temperature with 
constant shaking (Table 2-8). Cells were subsequently incubated for 1 hour at 
room temperature with the primary antibody of interest diluted in blocking 
buffer (5% FBS) and filtered. Cells were washed 4 times for 15 minutes each in 
500 µl filtered PBST, and incubated for 2 hours with the relevant Celltag 700 
(1:5000)- IgG fluorophore secondary antibody made up in filtered blocking buffer 
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(5% FBS) (Table 2-4). Wells were washed 5 times for 15 minutes in 1ml filtered 
PBST, followed by 3 washes of 15 minutes in 1ml filtered PBS, and 2 times for 30 
minutes in 1ml filtered H2O. Plates were allowed to dry prior to being scanned 
on the LiCor, with scanning offset to 4 µm. Staining area was assessed by LiCor 
Image Studio Lite.  
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2.2.7. Reporter assays 
2.2.7.1. Firefly-luciferase reporter assay  
Upon completion of experiments using SFV4-Ffluc, media was aspirated off. 
When HFt cells were infected they were washed twice with PBS and lysed with 
50 µl of 1x Cell Culture Lysis Reagent (CCLR) (Promega). When AF5 cells were 
used, 50 µl of 1x CCLR was immediately added to the cells. Following 
manufacturer’s instructions, samples were vortexed, for 15 seconds and 
transferred to a fresh Eppendorf tube. Luciferase Assay Reagent (50 µl) was then 
mixed with 10 µl sample and the samples were tested using a Glomax 
luminometer (Promega) following manufacturer’s instructions (Table 2-7). 
Readings were produced in relative light units and were recorded (Section 
2.2.8.3). 
 
2.2.7.2. NanoLuciferase reporter assay 
Upon completion of experiments using ZIKV-Nl or BUNV-NL, media was aspirated 
off. When HFt cells were infected they were also washed twice with PBS. 
Samples were incubated directly with 50 µl Nano-Glo® Luciferase Assay Substrate 
+ Buffer mix (Promega) (Table 2-7). Samples were transferred to an Eppendorf 
tube, and incubated at room temperature for 3 minutes prior to being tested in 
a GloMax luminometer (Promega) following manufacturer’s guidance. Readings 
were produced in relative light units and were recorded (Section 2.2.8.3). 
During mosquito analysis, samples were provided by collaborators of mosquitoes 
which had been treated with dsRNA to LacZ as a non-target control, or dsRNA to 
SUMO and subsequently fed blood containing ZIKV-NL at 1x107 pfu/ml, 
supplemented with 2 mM ATP. Samples had already been lysed with glass beads 
by the collaborators (Floriane Almire, and Dr Emilie Pondeville, University of 
Glasgow), so 10 µl sample was mixed with 50 µl Nano-Glo® Luciferase Assay 
Substrate + Buffer (Table 2-7). 
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2.2.7.3. Protein quantification assay  
Samples that needed to be quantified prior to mass spectrometry were 
harvested in CellLyse lysis buffer (Table 2-9). Samples were then sonicated using 
a digital sonicator (7 repeats, 50% intensity, 30 seconds, 4 ˚C, Branson Digital 
Sonifier), and a Micro BCA Protein Assay Kit (Table 2-7) was utilised to quantify 
the concentration of protein against a standard curve of known BSA 
concentrations, following manufacturer’s instructions. Samples were diluted 1:5, 
1:10, and 1:20 and quantified using a Nanodrop 2000 spectrophotometer 
(Thermo Scientific) measuring absorbance at 562 nm.  
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2.2.8. Bioinformatics 
2.2.8.1. Joined Advanced SUMOylation site 
and SIM Analyser (JASSA) 
Annotated amino acid sequences were obtained from UniProt for the proteins of 
interest. These amino acid sequences were then analysed through JASSA which is 
an online tool (http://www.jassa.fr/) that predicts sites likely to be SUMO 
modified (Beauclair, Bridier-Nahmias et al. 2015). The results were then 
annotated and presented using Illustrator for Biological Sequences (Ren, Wen et 
al. 2009, Liu, Xie et al. 2015). Some sites were also modelled to demonstrate 
location of the potential site of SUMO modification (Section 2.2.8.2). 
 
2.2.8.2. Modelling software 
Annotated amino acid sequences were obtained from UniProt for the proteins of 
interest. Viral proteins which had already been analysed with JASSA (Section 
2.2.8.1), and the resolved structures available were then downloaded and 
analysed by the modelling programme Chimera 1.10.1 (Pettersen, Goddard et al. 
2004). 
Models of Ae. aegypti SUMOylation pathway proteins were conducted by 
obtaining the sequence of the proteins from UniProt, and predicting the tertiary 
structure with either Phyre2 or Chimera 1.10.1 (Pettersen, Goddard et al. 2004, 
Kelley and Sternberg 2009). The models predicted with Chimera were then 
plotted against the resolved structure of the H. sapiens SUMOylation proteins 
(Pettersen, Goddard et al. 2004).  
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2.2.8.3. Amino acid alignment 
Amino acid alignment was conducted using the online software T-COFFEE 
(http://tcoffee.crg.cat/) (Notredame, Higgins et al. 2000). These results were 
then plotted and exported with BOXSHADE 
(http://sourceforge.net/projects/boxshade/).  
 
2.2.8.4. Statistical analysis   
Statistical analysis and graphs were produced with GraphPad 7.02. 2-Way 
ANOVAs, or Mann-Whitney U-tests were used to determine statistical significance 
(indicated in figures). 
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2.2.9. Cloning strategies used in this study 
All cloning conducted used procedures detailed in Section 2.2.1 using 
oligonucleotides detailed in Table 2-6. Specific approaches to cloning 
components of the Ae. aegypti SUMOylation pathway into vectors are described 
in this section. The correct construction was confirmed by restriction 
endonuclease digestion (Section 2.2.1.3) and sequencing (Section 2.2.1.9). 
Unless stated otherwise, genes were cloned from cDNA originally extracted from 
A20 cells by Dr Sue Jacobs (Table 2-1). 
 
2.2.9.1. Cloning of pACYC-AaSAE1/2 
The pACYCDuet-1 vector is a bacterial expression vector that allows dual 
expression of two proteins following induction with IPTG. The vector is designed 
with chloramphenicol resistance, and a 6xHis tag in the N-terminal of one 
protein, and an S-tag on the C-terminal of the second protein (Figure 2.3). cDNA 
from A20 cells was used as a template with the primers AaSAE2 F, AaSAE2 R, 
AaSAE2 F1, AaSAE2 R1, AaSAE2 F2, AaSAE2 R2 (Table 2-6). AaSAE2 is a large 
gene (approximately 2000 bp), consequently AaSAE2 was cloned in three sections 
of approximately 650 bp, 450 bp, and 800 bp, and further PCRs were conducted 
to ensure the template was complete. Primers were designed to bind to the 
gene as depicted (Figure 2.2). The restriction endonuclease sites EcoRI and NotI 
were used to ligate the insert into the vector backbone.  
AaSAE1 was cloned with the primers AaSAE1 F, AaSAE1 R, AaSAE1 F1, and 
AaSAE1 R1 (Table 2-6). AaSAE1 is also a large gene (approximately 1000 bp); 
consequently the gene was cloned in two parts of approximately 250 bp and 750 
bp. An additional stop codon was inserted at the C-terminal to prevent the S-tag 
from being translated. AaSAE1 was ligated into MCS2 on NdeI and XhoI. 
A Strep.II tag was synthesised (Dundee Cell Products) of the sequence 5’-
TGGAGCCACCCGCAGTTCGAAAAG-3’ which was ligated to replace the 6xHis tab 
between the NcoI and EcoRI sites on the N-terminal of AaSAE2. 
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AaSAE2 F AaSAE2 F1 AaSAE2 F2 
AaSAE2 R2 AaSAE2 R1 AaSAE2 R 
Figure 2.3 AaSAE2 primer binding sites 
Image depicts the primer binding sites for cloning of AaSAE2  
Figure 2.2 pACYCDuet-1 expression plasmid map 
The plasmid map of pACYADuet-1, with cloning sites and other regions of interest 
shown. The plasmid expresses resistance to chloramphenicol. Image from Novagen. 
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2.2.9.2. Cloning of pET28a-SUMO chimaera 
and pET28a-SUMO chimaera K11R 
The SUMO chimaera and SUMO chimaera K11R mutant were synthesised 
(GENEWIZ), and digested and ligated into the pET28 bacterial expression vector 
on the sites NdeI and XhoI, using the primers pET28-AaSUMO R and pET28-SUMO 
chimaera F (Section 2.1.6; Section 2.2.1.3; Section 2.2.1.5; Table 2-6; Figure 
2.4).  
  
Figure 2.4 pET28a vector map 
The plasmid map of pET-28a, with cloning sites and other regions of 
interest shown. The plasmid expresses resistance to kanamycin. The image 
is from Novagen. 
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2.2.9.3. Cloning of pET45b-AaUbc9 and 
pET45b-AaUbc9 C93S 
AaUbc9 was cloned from A20 cDNA extracted by Dr Sue Jacobs (Unpublished 
data), using the primer sequences pET-Ubc9 F and pET-Ubc9 R (Table 2-6). This 
was cloned into the pET45b bacterial expression vector which contains an 
ampicillin resistance gene (Figure 2.5) on the AgeI and XhoI restriction sites. 
AaUbc9 C93S was produced using site directed mutagenesis by PCR described 
(Section 2.2.1.10) using the Ubc9 C93S Int F1 and Ubc9 C93S Int R1 primers 
(Table 2-6). AaUbc9 C93S was subsequently amplified with pET-Ubc9 F and pET 
Ubc9 R primers and cloned into the pET45b vector on the AgeI and XhoI 
restriction sites. Sequencing confirmed the mutation was present (Section 
2.2.1.9). 
 
  
Figure 2.5 pET45b vector map 
The plasmid map of pET-45b, with cloning sites and other regions of interest 
shown. The plasmid expresses resistance to ampicillin. The image is from 
Novagen. 
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2.2.9.4. Cloning of pET45b-AaPIAS and 
pET45-AaPIAS C371A 
AaPIAS and AaPIAS C371A were synthesised (GENEWIZ) and amplified by PCR with 
the primers AaPIAS F for pET45b and AaPIAS R for pET45b (Table 2-6). The 
primers contained AgeI and NotI restriction sites for cloning into the pET45b 
vector (Figure 2.5). 
 
2.2.9.5. Cloning of pET28a-AaSUMO  
Using pET28 vector (Figure 2.4), AaSUMO was cloned from a plasmid of pET45-
AaSUMO (produced by Dr Sue Jacobs, unpublished data) using the primer 
sequences pET28-AaSUMO F and pET28-AaSUMO R (Table 2-6). PCR products 
were digested in NdeI and XhoI for ligation into the pET28 vector. 
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3. Conservation of the 
SUMOylation pathway 
between Ae. aegypti 
and H. sapiens  
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3.1. Overview 
A limited amount of research has been conducted on the AaSUMOylation 
pathway. Two previous studies have utilised a bioinformatics approach to 
compare the conservation of SUMO orthologues between invertebrate and 
vertebrate species. Choy et al., (2013) compared the amino acid sequence of 
ubiquitin and ubiquitin-like proteins between four vector species. They found 
Ae. aegypti and Anopheles gambiae (An. gambiae) to both possess two SUMO 
orthologues, whereas Culex quinquefasciatus (C. quinquefasciatus) and Ixodes 
scapularis (I. scapularis) only possess one each (Choy, Severo et al. 2013). Urena 
et al., (2015) compared the SUMO amino acid sequence from a range of insect 
species to mammalian SUMO homologues, including that of H. sapiens. They 
were able to determine that all insect SUMO proteins appear to lack a SUMO 
Conjugation Motifs (SCM) important for poly-SUMO chain formation (Urena, 
Pirone et al. 2016). However, neither study determined if constituent proteins of 
the SUMO pathway were expressed, or investigated their respective biochemical 
properties to orthologous proteins. Consequently, the biological activity of these 
proteins within insect vectors remains to be characterised.  
Arboviruses are required to replicate efficiently in the vertebrate and 
invertebrate cells. Consequently, any divergence in biological activity of the 
SUMOylation pathways of Ae. aegypti and H. sapiens could result in different 
physiological consequences between species. It was hypothesised that if there is 
a high degree of conservation between the SUMOylation pathways, then any 
interaction between arboviruses and the SUMOylation pathway will likely be 
conserved between the two species.  
A limited amount of research has currently been conducted on the interactions 
between arboviruses and the SUMOylation pathway in either H. sapiens or Ae. 
aegypti. Consequently, a bioinformatics approach was initially undertaken to 
determine if arboviral proteins contained sites amenable to SUMO modification. 
It was hypothesised that if SUMO modification was crucial for viral replication, 
SCM (ψ-K-x-[E/D]) sites would likely be conserved between closely related viral 
strains, and potentially between different virus family members. This strategy 
potentially increases the risk of false positives as it does not take protein folding 
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into account, or may miss genuine targets that require SUMO E3 ligases for 
modification independently of SCMs. However, this methodology serves as an 
initial indication of how likely viral proteins were to be targets of SUMO 
modification, and consequently, how likely the SUMOylation pathway is to affect 
arboviral replication. 
In this chapter, the degree of conservation of the SUMOylation pathway between 
Ae. aegypti and H. sapiens were compared, and the antibody binding for the 
constituent parts of the SUMOylation pathways investigated. Furthermore, for 
each component of the SUMOylation pathway, mass spectrometry analysis was 
conducted to provide experimental evidence of protein expression. The arboviral 
proteins which could represent targets of SUMO modification for BUNV, SFV, and 
ZIKV have been determined.  
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3.2. Conservation of the SUMOylation pathway  
3.2.1. Conservation of SUMO 
The annotated Ae. aegypti genome sequence revealed the presence of two 
SUMO homologues, which we named Aedes aegypti SUMOa (AaSUMOa; Q16EQ3) 
and Aedes aegypti SUMOb (AaSUMOb; Q16I57). These were compared to the 
sequence of Homo sapiens SUMO 1-3 (HsSUMO1-3; P63165; P61956; P55854). The 
highest degree of amino acid identity was found with either AaSUMOa or 
AaSUMOb with HsSUMO3 (Figure 3.1A). Interestingly, however, neither AaSUMOa 
nor AaSUMOb contained an internal SCM like HsSUMO3. This indicates that 
AaSUMOa and AaSUMOb are unlikely to efficiently form poly-SUMO chains in 
contrast to its closest HsSUMO orthologue. 
In order to determine any substantial differences in the tertiary structure of the 
SUMO homologues, the structure of AaSUMOa was modelled using Phyre2 (Figure 
3.1B) (Kelley and Sternberg 2009). The structural alignment with the resolved 
structure of HsSUMO3 was additionally compared with the programme Chimera 
1.10.1 (Pettersen, Goddard et al. 2004, Xu, Plechanovova et al. 2014). As 
demonstrated in Figure 3.1C, there was a high degree of structural similarity 
observed between AaSUMOa and HsSUMO3, with the only difference observed in 
the highly flexible N-terminal region. Together, Figure 3.1B and Figure 3.1C 
demonstrate that multiple programmes predict a highly conserved tertiary 
structure. Antibody binding was also tested, this demonstrated that the antibody 
raised to HsSUMO2/3 could be utilised as a tool to detect AaSUMO conjugated 
HMW proteins (Figure 3.1D). Unfortunately, unconjugated SUMO was not 
detected in this assay (data not shown) and therefore we cannot confirm the 
predicted molecular weight of the protein (~15 kDa). As the amino acid 
sequence identity between AaSUMOa and AaSUMOb is high, it was predicted that 
any biochemical differences would be conserved between the two homologous 
proteins. Furthermore, as there was no direct evidence to specifically support 
AaSUMOb expression (Table 3-1); the focus of the rest of the study was on 
AaSUMOa.  
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AaSUMOa    1 MSEEKKD-SKGSES-EH-----INLKVLGQDNAVVQFKIKKHTPLRKLMNAYCDRAGLSM 
AaSUMOb    1 MSTDKKDQPKAAES-EH-----INLKVLGQDNAVVQFKIKKHTPLKKLMNAYCDRSGLSM 
HsSUMO3    1 MSEEKPKEGVKTEN-DH-----INLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSM 
HsSUMO2    1 MADEKPKEGVKTENNDH-----INLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSM 
HsSUMO1    1 MSDQEAKPSTEDLG-DKKEGEYIKLKVIGQDSSEIHFKVKMTTHLKKLKESYCQRQGVPM 
 
AaSUMOa   54 QVVRFRFDGQPINENDTPTTLEMEEGDTIEVYQQQTGG 
AaSUMOb   55 QVVRFRFDGQPITENDSPTTLEMEEGDTIEVYQQQTGG 
HsSUMO3   55 RQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGG 
HsSUMO2   56 RQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGG 
HsSUMO1   60 NSLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGG 
 
B 
C 
A
Continued on next page 
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Figure 3.1 Conservation of SUMO between Ae. aegypti and H. sapiens. 
(A) The annotated amino acid sequence of the two SUMO proteins in Ae. 
aegypti was compared to the sequence of H. sapiens SUMO3, HsSUMO1 and 
HsSUMO2 was included for comparison. Dashed box indicates the conjugation 
motif on HsSUMO2/3. (B) Modelling the predicted structure of AaSUMOa with 
Phyre2, (C) and comparing the resolved structure of HsSUMO3 (PDB ID: 2MP2) 
to the predicted structure of AaSUMOa modelled with Chimera, demonstrated 
structural conservation between the orthologous proteins. (D) 2.5 x 105 Ae. 
aegypti cells (A20, Aag2, AF5) or 1 x 105 H. sapiens cells (HFt; positive control) 
were seeded and incubated overnight. Cells were lysed into 100 µl and 10 µl 
cell lysate was resolved by SDS-PAGE and a Western blot was conducted with 
antibodies to HsSUMO2/3 (upper blot). A Western blot probing for the 
expression of Actin was also conducted (lower blot) as a loading control. 
Molecular weight markers indicated. 
A20    Aag2    AF5       HFt 
D 
kDa 
250 
130 
95 
70 
40 
Actin 
HMW SUMO 
conjugates 
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3.2.2. Conservation of Ubc9 
The annotated genome sequence of AaUbc9 was compared to the published 
sequence of HsUbc9. This demonstrated a high degree of amino acid identity, at 
85%. Including the conservation of C93 (indicated with a ‘#’), which is important 
for the function of Ubc9 as a conjugation enzyme in H. sapiens. Furthermore, 
the ‘PAQA’ sequence is conserved (indicated by a bar) between HsUbc9 and 
AaUbc9, which has been shown to be the residues responsible for efficient 
recognition of SCM sites (Bernier-Villamor, Sampson et al. 2002). Interestingly, 
however, the D100 is not conserved between HsUbc9 and AaUbc9. This amino 
acid, along with K101 has been shown to slow the rate of thioester bond 
formation, which indicates that AaUbc9 may form thioester bonds at a greater 
rate than HsUbc9 (Figure 3.2A) (Tatham, Chen et al. 2003). The predicted 
tertiary structure of AaUbc9 was produced using multiple programmes, and a 
comparison of the structure of AaUbc9 against the resolved structure of HsUbc9 
was conducted (Figure 3.2B; Figure 3.2C) (Giraud, Desterro et al. 1998). Once 
again, multiple programmes confirmed the conservation of secondary (α-helix 
and β-sheets) and tertiary structure of the protein. Antibody binding was 
assessed, and one antibody was found which cross reacted between species 
which resolved at the expected molecular weight of ~20 kDa (Figure 3.2D).  
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HsUbc9    1 MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGKKGTPWEGGLFKL 
AaUbc9    1 MSGIAIARLGEERKAWRKDHPFGFVARPVKNADGTLNLMTWECAIPGKKGTPWEGGLYKL 
 
HsUbc9   61 RMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELL 
AaUbc9   61 RMIFKDDYPTSPPKCKFEPPLFHPNVYPSGTVCLSLLDEEKDWRPAITIKQILLGIQDLL 
 
HsUbc9  121 NEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAP-S 
AaUbc9  121 NEPNIKDPAQAEAYTIYCQNRLEYEKRVRAQARAMAATE 
#      ** 
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Figure 3.2 Conservation of Ubc9 between Ae. aegypti and H. sapiens. 
(A) The annotated amino acid sequence of the Ubc9 in Ae. aegypti was compared to 
the sequence of H. sapiens Ubc9, they were found to share  85% amino acid identity, 
catalytically active Cys93 is represented by a ‘#’, the residues which help regulate 
thioester bond formation Asp100 and Lys101 are indicated by ‘*’, and the amino acids 
PAQA, which has a high affinity for SCM sites are indicated by a bar. (B) Modelling 
the predicted structure of AaUbc9, (C) and comparing it to the resolved structure of 
HsUbc9 (PDB ID: 1A3S), indicated structural conservation between the orthologues. 
(D) 2.5 x 105 Ae. aegypti cells (A20, Aag2, AF5) or 1 x 105 H. sapiens cells (HFt; 
positive control) were seeded and incubated overnight. Cells were lysed into 100 µl 
and 10 µl cell lysate was resolved by SDS-PAGE and a Western blot was conducted 
with antibodies to HsUbc9 (lower blot). A Western blot probing for the expression of 
Actin was also conducted (upper blot) as a loading control. Molecular weight 
markers indicated. 
 
A20     Aag2      AF5          HFt D kDa 
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3.2.3. Conservation of SAE1/2 
The amino acid sequence of AaSAE1 and AaSAE2 was taken from the annotated 
sequence of Ae. aegypti, and compared to the amino acid sequence of H. 
sapiens SAE1/2 activating heterodimer (Appendix A: Amino acid sequence 
comparison between Hs and AaSAE1/2, and Hs and AaPIAS). The amino acid 
identity between HsSAE1/2 and AaSAE1/2 was lower than other components of 
the SUMOylation pathway, at 42% identity for SAE2, and 50% amino acid identity 
between the SAE1 orthologues. Structural models of the AaSAE1/2 heterodimer 
and structural comparisons with the HsSAE1/2 activating heterodimer revealed 
that even with an amino acid identity of 42% and 50%, the tertiary structure was 
still well conserved between species (Lois and Lima 2005) (Figure 3.3A; Figure 
3.3B). Due to the reduced amino acid identity, the antibody available against 
HsSAE2 did not appear to detect AaSAE2 at the predicted molecular size of ~80 
kDa (Figure 3.3C). There is a distinct band detected when Ae. aegypti cell 
lysate was tested at approximately 130 kDa (*, Figure 3.3C), however this is a 
far larger protein than AaSAE2 is predicted to be, and far larger than 
recombinant AaSAE2 resolved at (Figure 4.2). 
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Figure 3.3 Conservation of SAE1/2 between Ae. aegypti and H. sapiens. 
(A) Modelling the predicted structure of AaSAE1/2, (B) and comparing it to the 
resolved structure of HsSAE1/2 (PDB ID: 1Y8Q), indicated a high degree of structural 
conservation between the orthologues. (D) 2.5 x 105 Ae. aegypti cells (A20, Aag2, 
AF5) or 1 x 105 H. sapiens cells (HFt; positive control) were seeded and incubated 
overnight. Cells were lysed into 100 µl and 10 µl cell lysate was resolved by SDS-
PAGE and a Western blot was conducted with antibodies to HsSAE2 (upper blot). A 
Western blot probing for the expression of Actin was also conducted (lower blot) as 
a loading control. Molecular weight markers indicated. 
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3.2.4. Conservation of PIAS 
AaPIAS was located in the Ae. aegypti annotated genome and compared to the 
five H. sapiens PIAS homologues. There was a relatively low level of amino acid 
identity, in comparison to the other parts of the SUMOylation pathway: between 
32-37% (Appendix A: Amino acid sequence comparison between Hs and 
AaSAE1/2, and Hs and AaPIAS; Figure 3.4A). However, when the amino acid 
identity of the SP-RING domain was compared between AaPIAS and HsPIAS1-4, 
the degree of amino acid identity increased to 65-70% (Figure 3.4A). 
Furthermore, the active C371 was identified, predicted to be responsible for the 
ligase activity of the protein (Figure 3.4B). Structural modelling was conducted, 
and a comparison was conducted with HsPIAS2-α (Figure 3.4C; Figure 3.4D). 
Again, two different programmes predicted the overall structure of the protein 
was conserved, and the SP-RING domain of the PIAS orthologues has been 
indicated on the models. As the amino acid identity was predicted to be greatest 
throughout the entire protein with HsPIAS2-α, an antibody to HsPIAS2-α was used 
in an attempt to detect AaPIAS. Unfortunately, the antibody did not cross-react 
between the two species (Figure 3.4E). There is a faint band at the same 
molecular size as HsPIAS2-α (~85 kDa), however as it is not a distinct band, this 
could be non-specific, and it does not resolve at the expected molecular weight 
of AaPIAS (~70 kDa). 
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 % Amino acid identity 
 
AaPIAS whole 
protein 
AaPIAS SP-RING 
Domain 
HsPIAS1 35 70 
HsPIAS2-α 37 69 
HsPIAS2-β 36 69 
HsPIAS3 34 68 
HsPIAS4 32 65 
A 
B 
Continued on next page 
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Figure 3.4 Conservation of PIAS between Ae. aegypti and H. sapiens. 
(A) The annotated amino acid sequence of the Ae. aegypti PIAS was compared 
to the sequence of H. sapiens PIAS1-4, they were found to share  32-37% amino 
acid identity, although the catalytically active SP-RING domain contains 65-70% 
amino acid identity between the orthologues. (B) A schematic of the AaPIAS 
protein indicating the SP-RING domain and the catalytically active C371. (C) 
Modelling the predicted structure of AaPIAS using Phyre2, the SP-RING domain 
is highlighted in light blue, and the catalytically active C371, along with the 
flanking T370, and S372 are indicated; (D) the predicted structure of AaPIAS, 
made with Chimera 1.10.1 was compared to the resolves structure of HsPIAS2-α 
(PBD ID: 4FO9), The SP-RING domain of both orthologues are indicated in 
orange (HsPIAS2-α), and silver (AaPIAS), and the catalytically active C371 and 
flanking proteins are again indicated. (E) 2.5 x 105 Ae. aegypti cells (A20, Aag2, 
AF5) or 1 x 105 H. sapiens cells (HFt; positive control) were seeded and 
incubated overnight. Cells were lysed into 100 µl, 10 µl was resolved by SDS-
PAGE and a Western blot was conducted with antibodies to HsPIAS2-α (upper 
blot). A Western blot probing for the expression of Actin was also conducted 
(lower blot) as a loading control. Molecular weight markers indicated. 
E 
A20    Aag2    AF5      HFt kDa 
250 
130 
95 
70 
40 
Actin 
PIAS2 
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3.2.5. Confirmation of pathway expression 
In order to confirm the AaSUMOylation pathway was expressed, Ae. aegypti cells 
were assessed by LC-MS mass spectrometry for the presence of peptides to 
specific SUMO component proteins of the AaSUMOylation pathway. Samples were 
prepared and quantified (as described Section 2.2.7.3), and sent to 
collaborators in Dundee University for analysis by mass spectrometry (Table 3-
1). These data demonstrate that core component proteins of the AaSUMOyaltion 
pathway are constitutively expressed in Ae. aegypti cells. q-PCR analysis was 
also conducted on AaSUMO, AaUbc9, and AaPIAS on different tissues from Ae. 
aegypti mosquitoes (Figure 5.1). This also confirmed that the components of the 
SUMOylation pathway were expressed in different Ae. aegypti tissues.  
In the Table 3-1, the ‘Protein’ subheading indicates which protein the peptide 
sequence (‘Amino acid sequence’) is identified in. ‘Sequence unique to protein’ 
indicates if throughout the entire genome, the peptide sequence is only encoded 
in the ‘Protein’ identified, or if the peptide sequence is also encoded in other 
proteins. ‘Length’ details the number of amino acids in the peptide sequence, 
and ‘Start / End amino acid position’ indicates the position of the amino acid 
sequence within the protein.  
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Protein Amino acid sequence 
Sequence 
unique to 
protein 
Length 
Start 
amino 
acid 
position 
End 
amino 
acid 
position 
SUMOa/b 
KLMNAYCDR no 9 40 48 
LMNAYCDR no 8 41 48 
VLGQDNAVVQFK no 12 20 31 
SUMOa 
AGLSMQVVR no 9 49 57 
SEEKKDSKGSESEHINLK yes 18 2 19 
Ubc9 
CKFEPPLFHPNVYPSGTVCLSLL
DEEKDWRPAITIK 
no 36 75 110 
DDYPTSPPK no 9 66 74 
DHPFGFVAR no 9 19 27 
DHPFGFVARPVK no 12 19 30 
DWRPAITIK no 9 102 110 
FEPPLFHPNVYPSGTVCLSLLDEE
KDWRPAITIK 
no 34 77 110 
GTPWEGGLYK no 10 50 59 
KDHPFGFVAR no 10 18 27 
KDHPFGFVARPVK no 13 18 30 
KGTPWEGGLYK no 11 49 59 
MIFKDDYPTSPPK no 13 62 74 
NADGTLNLMTWECAIPGKK no 19 31 49 
QILLGIQDLLNEPNIK no 16 111 126 
Table 3-1 The SUMOylation pathway specific peptide sequences identified 
from Ae. aegypti cells by mass spectrometry.  
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QILLGIQDLLNEPNIKDPAQAEAY
TIYCQNR 
no 31 111 141 
SAE1 
ADTEELPK no 8 108 115 
AQQLNPMVELK no 11 97 107 
AQQLNPMVELKADTEELPK no 19 97 115 
AVTLLDDQVVK no 11 60 70 
AVTLLDDQVVKEADFCSQFLAPQ
DSLR 
no 27 60 86 
EADFCSQFLAPQDSLR no 16 71 86 
FRDDEKRDPLYSER no 14 240 253 
GFDVVCVIGANTEQLLR no 17 123 139 
ILIAGVNGLGAEIAK no 15 37 51 
KTDDFFKGFDVVCVIGANTEQLL
R 
no 24 116 139 
LWGLDSQK no 8 23 30 
LWGLDSQKR no 9 23 31 
NVILSGVK no 8 52 59 
RSGPALPLLR no 10 226 235 
SGPALPLLR no 9 227 235 
TELVTSTVK no 9 191 199 
TELVTSTVKR no 10 191 200 
TKTELVTSTVK no 11 189 199 
TKTELVTSTVKR no 12 189 200 
TLSYPAYQVLLDFDYK no 16 201 216 
TLSYPAYQVLLDFDYKAQSYAR no 22 201 222 
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TNRAEASLSR no 10 87 96 
VEANGIELTEQEAELYDR yes 18 2 19 
SAE2 
AAQIVGVFEPELQEK yes 15 2 16 
ALNMLNPDVILDGK no 14 467 480 
AQIFNIPR no 8 357 364 
AQIFNIPRK no 9 357 365 
ARVSNDDDDDDLIVIN no 16 627 642 
ASTSNNGAVDDDDDMCIVEEDAE
KPSTSDAGAGPSSSGSEKR 
no 42 573 614 
AYHDSITTSNYGVNFFQQFNLVL
NALDNR 
no 29 93 121 
CYVCAAKPEVTLK no 13 436 448 
DESSFDIVADPDSLKPK no 17 534 550 
DPGRDESSFDIVADPDSLKPK no 21 530 550 
EDEDQKTDDVQPSTSGQNGNSK yes 22 551 572 
ELRDDILIK no 9 458 466 
ESALSFNPNVK no 11 80 90 
GLTQCYECTPK no 11 156 166 
GTIVISSEEGETDCNNDK no 18 481 498 
GTIVISSEEGETDCNNDKK no 19 481 499 
GTIVISSEEGETDCNNDKKLEDLQ
IVDGCILK 
no 32 481 512 
HAMDFVAACANIR no 13 344 356 
HLFNQLFGESNEDEDVSPDTADP
EAGAEAGESALAAEANEK 
no 41 193 233 
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HLFNQLFGESNEDEDVSPDTADP
EAGAEAGESALAAEANEKGNVDR 
no 46 193 238 
ILVVGAGGIGCEILK no 15 22 36 
KLEDLQIVDGCILK no 14 499 512 
LAEGDHLVWDKDDK no 14 330 343 
LAEGDHLVWDKDDKHAMDFVAA
CANIR 
no 27 330 356 
LCLTADVPLIESGTAGYNGQVELI
KR 
no 26 130 155 
LEDLQIVDGCILK no 13 500 512 
LFYDDINYLLSMSNLWK no 17 259 275 
NLVLSGFQDIEIIDLDTIDVSNLNR no 25 37 61 
NQLFVPDR no 8 420 427 
NTPSEPIHCIVWAK no 14 179 192 
QFLFHKEHVGK no 11 62 72 
SMAGNIIPAIATTNAITAGVVVMH
AFR 
no 27 372 398 
SRTPPNPAKWDALEEDGEAAPT
DTVLR 
no 27 276 302 
TLNPPNPK no 8 428 435 
TPPNPAKWDALEEDGEAAPTDT
VLR 
no 25 278 302 
TPPNPAKWDALEEDGEAAPTDT
VLRDQK 
no 28 278 305 
TWAQQCGYDPEK no 12 243 254 
TWAQQCGYDPEKIFNK no 16 243 258 
VDDFVQNYELTVTVIHK no 17 513 529 
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VFGESITALKK no 11 315 325 
VLSLTESAK no 9 306 314 
VSNDDDDDDLIVIN no 14 629 642 
WDALEEDGEAAPTDTVLR no 18 285 302 
WDALEEDGEAAPTDTVLRDQK no 21 285 305 
PIAS 
GGQVHANGIVPIPYPEATPNPGY
PIHPDVK 
no 30 126 155 
GYAAACYLVR no 10 297 306 
IEHTIQVQLR no 10 212 221 
IQEGSFFFHLTPQQATDIATNR no 22 183 204 
KPTWNCPVCDK no 11 389 399 
LAFFDVLATLLKPATLVPSNTTQ
R 
no 24 159 182 
LCPLPNPIPTNKPGVEPK no 18 247 264 
LSSEDNEIQLHK no 12 421 432 
NVNKIEHTIQVQLR no 14 208 221 
QAAEFTELKDLVHQLR no 16 6 21 
RPPRPVNITPNVK no 13 265 277 
TNDSCTLDTPSKPVQK no 16 442 457 
VEVVSDDIEIITTDPPK no 17 458 474 
VPQGMYQQQYANAVQNDNR no 19 107 125 
VSDLQQLLGENNISR no 15 22 36 
VSLVCPLGK no 9 351 359 
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3.2.6. Summary 
This analysis demonstrates that the SUMOylation pathway is conserved in Ae. 
aegypti. Sequence analysis has shown a high conservation of the protein 
(summarised in Figure 3.5), and importantly, revealed the catalytically 
functional residues of the proteins are present, shown for AaPIAS in Figure 
3.4B). Modelling the structure of the AaSUMOylation proteins has revealed that 
they are very similar to their H. sapiens orthologues. Western blot analysis of 
Ae. aegypti cell lysate has also demonstrated that there are HMW SUMO 
conjugates in Ae. aegypti, demonstrating that the pathway is active. Antibody 
cross reaction also helps to demonstrate the amino acid sequence identity of the 
SUMO and Ubc9 orthologues. Finally, mass spectrometry analysis has also 
demonstrated that components of the AaSUMOylation pathway which we can’t 
detect by western blot (AaSAE1/2, and AaPIAS), are expressed in Ae. aegypti. 
Figure 3.5 A heatmap of amino acid identity between the Aa and Hs 
SUMOylation pathways 
The amino acid sequence of the AaSUMOylation and HsSUMOylation pathways 
were compared. Heatmap generated with Graphpad Prism 7.02, red 
demonstrates a greater percentage amino acid identity.  
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3.3. Viral proteins contain SUMO conjugation 
motifs 
It is hypothesised that any direct effect of SUMOylation on arbovirus replication 
in either H. sapiens or Ae. aegypti would likely be dependent on SUMO 
modification of viral proteins. Approximately 74% of experimentally confirmed 
SUMO modifications occur at SCMs (Yavuz and Sezerman 2014). Consequently, 
polyprotein sequences from different arbovirus families were analysed for the 
presence of SCM motifs to determine the potential relevance of SUMO 
modification in the regulation of arboviral replication.  
The published amino acid sequence of the proteins was analysed by the Joined 
Advances SUMOylation site and SIM Analyser (JASSA), an online SCM prediction 
tool (Beauclair, Bridier-Nahmias et al. 2015). Sites representing ‘Strong 
Consensus’ sequences were identified and are indicated with a bubble. ‘Weak 
Consensus’ sequences are depicted as vertical lines on the schematics. SCMs 
which are in a forward orientation are indicated in aqua, while sites in an 
inverse orientation are indicated in orange. 
 
3.2.1. SCM sites on BUNV proteins 
The Bunyamwera virus genome transcribes four proteins, these four proteins 
were analysed by JASSA to determine if they contained SCM sites. Multiple lysine 
residues were identified as potential targets of SUMO modification (Figure 3.6). 
Three of the ‘Strong Consensus’ sequences were located on the envelopment 
polyprotein, which is cleaved into the glycoproteins Gn and Gc, a non-structural 
protein NSm is also produced by the envelopment polyprotein. The three inverse 
‘Strong Consensus’ sites (‘EKKP’; ‘ETKV’, and ‘EPKI’) are all located on the Gc 
glycoprotein. The other three sites, also inverse SCMs, were located on the RNA-
directed RNA polymerase (RDRP) L protein (‘DYKV’; ‘DGKV’, and ‘EHKV’). Very 
few sites were identified as being capable of SUMO modification on the 
Nucleoprotein and non-structural NSs protein, none of which were identified as a 
‘Strong Consensus’ sequences. As the structure of the Gc glycoprotein, and the 
RDRP has not currently been resolved, no further analysis was conducted.  
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Figure 3.6 Predicted SUMO conjugation motifs on BUNV proteins 
The annotated amino acid sequence of BUNV proteins were assessed by JASSA 
for the presence of SUMO conjugation motifs.  Sites predicted as being a 
‘Strong Consensus’ sequence are represented as bubbles. ‘Weak Consensus’ 
sequences are annotated as vertical lines. Of the four proteins produced by the 
BUNV genome, only two possess ‘Strong Consensus’ motifs, located on the 
Envelopment polyprotein and the RNA Directed RNA Polymerase L. 
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3.2.2. SCM sites on SFV proteins 
The two polyprotein sequences from SFV and CHIKV were also analysed for the 
presence of SCMs with JASSA. SFV contained many sites amenable to SUMO 
modification, 10 of which were in the classical ‘Strong Consensus’ sequence 
(Figure 3.7A). Of these, seven were located on the non-structural polyprotein. 
Within the non-structural polyprotein, one site with the sequence ‘VKGE’ is 
located on the non-structural protein nsP1. Two SCM sites were found on nsP2 
(‘VKRE’; ‘ERKI’), and a further two SCM sites were located on nsP3 (‘EKKI’; 
‘VKCE’). Finally, the last two predicted SCMs were found on nsP4 (‘DVKI’; 
‘EVKI’). The three remaining ‘Strong Consensus’ sequences were located on the 
structural polypeptide; two of which were found within the capsid (which 
overlap each other in the sequence ‘VKHEGKV’) and one was located in the 
Envelope glycoprotein E2 (‘EGKP’) (Figure 3.7A).  
The resolved structure of the capsid protein was analysed to determine where 
the predicted SCM was located (Figure 3.7B; Figure 3.7C; Figure 3.7D). It was 
hypothesised that if the SCM was located on an internal section of the protein, it 
would be inaccessible as a target for SUMO modification. The resolved capsid 
structure revealed that the predicted SCM was found on a readily accessible part 
of the monomer, at the interface where monomers form multimers. As the 
resolved structure was not available for the Envelope glycoprotein E2 or the 
nsP1-4 proteins, the analysis was not continued for other potential SCMs in SFV. 
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Figure 3.7 Predicted SUMO conjugation motifs on SFV polyproteins 
The annotated amino acid sequence of SFV polyproteins were assessed by JASSA for 
the presence of SUMO conjugation motifs. (A) Sites predicted as being a ‘Strong 
Consensus’ sequence are represented as bubbles, ‘Weak Consensus’ sequences are 
annotated as vertical lines. Of the two polyproteins produced by the SFV genome, 
both possess multiple ‘Strong Consensus’ motifs. (B) The resolved structure of the 
Capsid (PDB ID: 1DYL) monomer, (C) trimer, (D) and a fully formed Capsid multimer 
are shown with the predicted ‘Strong Consensus’ motif indicated in red (Mancini, 
Clarke et al. 2000). 
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3.3.5. SCM sites on CHIKV proteins 
Further JASSA analysis with CHIKV indicated three potential SCMs on the 
structural polyprotein, and one further potential SCM on the non-structural 
polyprotein (Figure 3.8A). As the ‘VKHEGKV’ region was found to be conserved 
from SFV to CHIKV in the capsid protein this indicated that the site has an 
important and conserved role between alphaviruses. The other potential SCM 
site found on the structural polyprotein was a ‘PKGE’ motif located on the Spike 
Glycoprotein E2 (Figure 3.8B). This SCM appears to not be readily accessible, as 
it is located within a fold of the protein, and therefore unlikely to be exposed 
for SUMO modification. The potential SCM on the non-structural polyprotein 
(‘VKGE’) was located on the nsP2. As the resolved structure of nsP2 was 
available this was modelled where the ‘VKGE’ region was located and it was 
found to be also located on an exposed region of the protein (Figure 3.8C).  
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Figure 3.8 Predicted SUMO conjugation motifs on CHIKV polyproteins 
The annotated amino acid sequence of CHIKV polyproteins were assessed by JASSA 
for the presence of SUMO conjugation motifs. (A) Sites predicted as being a ‘Strong 
Consensus’ sequence are represented as bubbles, other ‘Weak Consensus’ sequences 
are annotated as vertical lines on the polyproteins. Of the two polyproteins 
produced by the CHIKV genome, there are a total of four ‘Strong Consensus’ motifs. 
(B) The ‘Strong Consensus’ motifs identified in A were assessed for which protein 
they are located on, using the resolved structure of CHIKV Envelope glycoprotein E2 
(PDB ID: 3N43) (Voss, Vaney et al. 2010), (C) and nsP2 (PDB ID: 3TRK), the SUMO 
conjugation motifs were identified and indicated in red. 
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3.3.6. SCM sites on ZIKV proteins 
The analysis was also conducted on flaviviruses. Here, analysis of Zika virus 
identified three potential SCMs on the polyprotein (Figure 3.9A). One (‘IKVE’) 
was located on the small envelope protein. However, while the sequence was 
found on the strain of ZIKV used in these studies (PE243; Table 2-3) this was not 
conserved between strains and therefore was not examined further. Another 
potential SCM (‘VKQD’) identified on NS3 was also not conserved between 
different ZIKV strains, and therefore no further examinations were conducted. 
The final potential SCM (‘VKYE’) was located on NS5. This SCM was found to be 
conserved, and so the potential SCM site was modelled on the resolved structure 
of NS5. This was found to be on an exposed region of the protein, indicating a 
potential site for SUMO modification (Figure 3.9B). 
  
S Stokes, 2018  172 
  
A 
B 
Figure 3.9 Predicted SUMO conjugation motifs on the ZIKV polyprotein 
The annotated amino acid sequence of ZIKV polyprotein was assessed by JASSA for 
the presence of SUMO conjugation motifs. (A) The 3 sites predicted to be a ‘Strong 
Consensus’ sequence are represented as bubbles, other ‘Weak Consensus’ sequences 
are annotated as vertical lines on the polyprotein. There are three ‘Strong 
Consensus’ sequences located on the ZIKV polyprotein. (B) The ‘Strong Consensus’ 
motifs identified in A were assessed for which protein they are located on, using the 
resolved structure of ZIKV NS5, the SUMO conjugation motifs were identified and 
indicated in red (PDB ID: 5KQR) (Coloma, Jain et al. 2016). 
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3.3.7. SCM sites on DENV proteins 
Previous studies have suggested an interaction between DENV and the 
SUMOylation pathway in H. sapiens (Chiu, Shih et al. 2007, Su, Tseng et al. 2016, 
Feng, Deng et al. 2018). DENV-2, the serotype utilised in previous studies which 
contain a large number of resolved structures to the proteins, was analysed 
revealing four potential SCM sites (Figure 3.10A). Of these four sites, two, 
‘VKWD’ and ‘PKNE’, were not conserved from the proteins NS2b and NS3, 
respectively. ‘VKKD’, also located on NS3, was conserved and the resolved 
structure was available (Figure 3.10B). This indicated that the lysines in the 
‘VKKD’ SCM are likely to be exposed, and consequently accessible for SUMO 
modification. Finally, the inverted ‘PFKE’ is located on the Non-structural 
protein 4B, however, the structure of the protein has not been resolved, and 
consequently, no further analysis was conducted on this site.  
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Figure 3.10 Predicted SUMO conjugation motifs on the DENV-2 virus polyprotein 
The annotated amino acid sequence of DENV polyprotein was assessed by JASSA for the 
presence of SUMO conjugation motifs. (A) The 4 sites predicted to be a ‘Strong 
Consensus’ sequence are represented as bubbles, other ‘Weak Consensus’ sequences 
are annotated as vertical lines on the polyprotein. (B) The ‘Strong Consensus’ motifs 
identified in A were assessed for which protein they are located on, using the resolved 
structure of DENV-2 NS3, the SUMO consensus motifs were identified and indicated in 
red (PDB ID: 4M9K) (Yildiz, Ghosh et al. 2013). Other ‘Strong Consensus’ motifs were 
either not conserved, or the resolved structures were not available for analysis. 
B 
A 
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3.3.8. Summary  
As summarised in Table 3-2, there are many potential sites of SUMO modification 
in arboviral proteins. While the resolved structure of many of these proteins is 
not available, for those which have been resolved indicate the SCM is frequently 
in an exposed location and consequently a potential target for SUMO 
modification. Su, Tseng et al. (2016) found that DENV-2 NS5 was a target of 
SUMO modification, unfortunately, this protein was not identified by this 
analysis, which is discussed further in Section 3.4 and may indicate that the list 
does not represent all potential targets of SUMO modification in the arboviral 
proteins, suggesting a potential role for E3 ligase specificity. 
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Virus Protein Resolved 
structure 
SCM sequence Exposed: 
Y/N 
BUNV 
Gc glycoprotein Not available EKKP / ETKV / EPKI 
 
RDRP Not available DYKV / DGKV / EHKV 
 
SFV 
Capsid protein Present 
(PDB ID: 1DYL) 
VKHEGKV Y 
Envelope 
glycoprotein 
Not available EGKP 
 
nsP1 Not available VKGE 
 
nsP2 Not available VKRE / ERKI 
 
nsP3 Not available EKKI / VKCE 
 
nsP4 Not available DVKI / EVKI 
 
CHIKV 
Capsid protein Present (as 
shown with SFV) 
VKHEGKV Y 
Spike 
glycoprotein 
Present 
(PDB ID: 3N43) 
PKGE N 
nsP2 Present 
(PDB ID: 3TRK) 
VKGE Y 
ZIKV 
Small envelope 
protein 
 
IKVE Not 
conserved 
NS3 
 
VKQD Not 
conserved 
NS5 Present 
(PDB ID: 5KQR) 
VKYE Y 
DENV 
NS2b 
 
VKWD Not 
conserved 
NS3 Not conserved / 
Present (PDB ID: 
4M9K) 
PKNE / VKKD Y 
NS4b Not available PFKE 
 
Table 3-2 Summary of the SCM sequences found on the relevant proteins of 
different arboviruses 
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3.4. Discussion  
All viruses manipulate the cell they infect in order to replicate efficiently. 
Unlike most other viruses, arboviruses need to manipulate two distinct cell 
types, the vertebrate and invertebrate host species. The SUMOylation pathway 
has previously been reported to influence arbovirus replication; however the 
studies to date only investigate the interaction of the SUMOylation pathway on 
Dengue Virus Serotype 2 (Chiu, Shih et al. 2007, Su, Tseng et al. 2016, Feng, 
Deng et al. 2018). The studies by Chiu, Shih et al. (2007), Su, Tseng et al. (2016) 
and Feng, Deng et al. (2018) have also only been conducted in mammalian cells 
and found both pro-viral and anti-viral roles for the SUMO pathway. 
Consequently, while there is an understanding of interactions occurring in 
mammalian cells, nothing is known about any interactions between the 
SUMOylation pathway and arboviruses in Ae. aegypti. There are also a very 
limited number of studies investigating the Ae. aegypti SUMOylation pathway, 
and previous studies have only looked at the amino acid sequence homology 
(Choy, Severo et al. 2013, Urena, Pirone et al. 2016). Consequently, as an initial 
step, the AaSUMOylation pathway was analysed for its similarity to the 
HsSUMOylation pathway.  
The analysis conducted here agrees with previous bioinformatic studies which 
demonstrate that the SUMO protein is conserved between H. sapiens and Ae. 
aegypti (Figure 3.1). Studies by Urena, Pirone et al. (2016), and Choy, Severo et 
al. (2013) both demonstrate that Ae. aegypti possesses the gene sequence of 
two SUMO homologues (Choy, Severo et al. 2013, Urena, Pirone et al. 2016). The 
study by Urena, Pirone et al. (2016) has also demonstrated that, based on the 
amino acid sequence, both AaSUMO proteins lack the SCM and should be unable 
to efficiently form poly-SUMO chains, work which agrees with the studies 
conducted here. Neither study, however, proceeded to investigate the tertiary 
structure of the AaSUMO proteins, nor did they examine if the proteins were 
expressed. Consequently, we show the novel findings that the SUMO protein 
shares a highly conserved tertiary structure, and demonstrated that the 
AaSUMOa protein in Ae. aegypti is expressed (Table 3-1; Figure 3.1). Our mass 
spectrometry analysis failed to identify peptide sequences specific to AaSUMOb. 
This could be because the AaSUMOb protein could be expressed in specific 
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tissues which weren’t studied, or AaSUMOb may lack a promoter sequence and 
so may be a pseudogene. 
Choy, Severo et al. (2013) also produced a phylogenetic tree of the annotated 
ubiquitin, ubiquitin-like conjugating enzymes, and activating enzymes, from a 
range of vector species. As their study focused on the generation of phylogenetic 
trees demonstrating how related the enzymes are between vector species, they 
did not look at the structure of the proteins. Here, we also demonstrate a 
shared amino acid identity, and proceed to show a similar tertiary structure of 
the predicted structure of AaUbc9 with the resolved structure of HsUbc9. This 
was also demonstrated with the predicted structure of AaSAE1/2 plotted against 
the resolved structure of HsSAE1/2. Finally, we validate the expression of 
AaSUMOa, AaUbc9, AaSAE1, and AaSAE2, by mass spectrometry and Western blot 
(Figure 3.2; Figure 3.3; Table 3-1).  
More studies have been conducted on AaPIAS, due to its widely known role as a 
regulator of the JAK-STAT pathway. Zou, Souza-Neto et al. (2011) analysed the 
amino acid sequence of AaPIAS and found conserved domains, including the SAP, 
PINIT, RING-finger like domain, and the Serine/Threonine-rich domain. Zou, 
Souza-Neto et al. (2011) also performed depletion studies and showed AaPIAS to 
be expressed in Ae. aegypti, we demonstrate AaPIAS to have a conserved 
tertiary structure and confirm AaPIAS expression by mass spectrometry (Figure 
3.4; Table 3-1). 
We have demonstrated that the pathway is conserved, and that the proteins are 
expressed in Ae. aegypti. Consequently, we assessed the potential effect of 
SUMO modification on arboviral proteins. For this a bioinformatics based 
approach was initially adopted. Previous studies have found predictive 
algorithms to be a suitable method of identifying potential sites of SUMO 
modification within cellular and viral proteins, and therefore the JASSA 
programme was utilised to help identify potential sites of SUMO modification on 
arboviral proteins (Handu, Kaduskar et al. 2015, Estruch, Graham et al. 2016, 
Iribarren, Di Marzio et al. 2018). 
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Representative model and clinically important arboviruses from three arboviral 
families were selected for analysis. All the arbovruses studied are known to be 
transmitted by Ae. aegypti. BUNV, a negative-strand RNA orthobunyavirus, was 
found to possess six potential SCM sites in the three proteins, and one 
polyprotein, which BUNV initially translates (Figure 3.6). Unfortunately, the 
resolved structure of the proteins was unavailable, and consequently, the 
analysis does not examine the location of the SCM sites on the proteins.  
JASSA analysis was also conducted on the alphavirus SFV, a positive-stranded 
RNA virus which appears to have 10 SCM sites throughout the two polyproteins it 
translates. Two sites were identified on the resolved capsid protein. These SCMs 
were located on an external surface, at the site where capsids form multimers 
(Figure 3.7). As SUMO modification has previously been reported to have roles in 
directing protein sub-cellular localisation (Matunis, Wu et al. 1998, Duprez, 
Saurin et al. 1999, Sachdev, Bruhn et al. 2001), this could potentially indicate a 
role for SUMO modification whereby SUMO modification transports the capsid 
monomers to the same location where they form multimers. Alternatively, it 
could indicate a role for SUMO in binding to the capsid monomers preventing the 
formation of multimers. CHIKV, another alphavirus, was also analysed (Figure 
3.8). Interestingly, two SCM sites in the capsid protein were conserved between 
SFV and CHIKV, which indicates a potentially important and conserved role for 
this region of the capsid protein. Other sites which were indicated as possessing 
SCMs were the Envelope glycoprotein E2 and the non-structural nsP2 protein. 
The SCM site on the Envelope glycoprotein does not appear to be readily 
accessible, and therefore unlikely to be a site of SUMO modification. The SCM on 
nsP2, however, is on the surface of the protein, and consequently could 
represent a target for SUMO modification (Figure 3.8). 
The polyprotein produced from the flavivirus ZIKV was assessed and found to 
contain three predicted SCM sites (Figure 3.9). Of these three, only one was 
located on a protein which had a resolved structure (NS5). This SCM was located 
on the surface of the protein, indicating that it is accessible for SUMO 
modification. The NS5 protein from many flaviviruses is well reported to localise 
to the nucleus of cells, a site of abundant SUMO modification within cells 
(Buckley, Gaidamovich et al. 1992, Miller, Sparacio et al. 2006, Hou, Cruz-Cosme 
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et al. 2017). DENV-2 was also assessed and found to possess four potential SCMs 
(Figure 3.10). The resolved structure was available for NS3. Here, the SCM was 
also found on a region of the protein accessible for SUMO modification. Previous 
studies have demonstrated DENV NS5 to be SUMO modified at the N-terminal 
(Su, Tseng et al. 2016). The JASSA analysis conducted here does not predict 
DENV NS5 to possess a ‘Strong Consensus’ SCM. Interestingly, however, the study 
by Su, Tseng et al. (2016) could not identify one lysine residue which was 
predominantly SUMO modified, and consequently hypothesised that SUMO could 
‘float’ in the N-terminal binding with any available lysine, as even after all 12 N-
terminal lysines were mutated, there was still SUMO binding to NS5. The analysis 
here does identify many ‘Weak Consensus’ sequences at the N-terminal of NS5 
which may be the SUMO modified section of NS5 that Su, Tseng et al. (2016) 
identified (Figure 3.10). Alternatively, it could indicate a necessity for E3 SUMO 
ligase activity in order to modify NS5.  
This work could be extended further to look at a bioinformatics comparison on 
the SENPs, which haven’t been addressed in this study. Furthermore, other non-
PIAS E3 ligases may be translated by Ae. aegypti, which could also influence the 
AaSUMOylation pathway, but have not been studied here. The analysis here 
could also extend to other strains of clinically important arboviruses, such as 
Japanese Encephalitis Virus, or Western Equine Encephalitis Virus, which may 
indicate how well conserved, and how important a SCM is on any individual 
arboviral protein.  
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of the Ae. aegypti and 
H. sapiens SUMOylation 
pathways 
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4.1. Overview 
Biochemical studies of the H. sapiens (Hs) SUMOylation pathway have revealed 
that the different HsSUMO homologues possess different biological functions 
within the cell. For instance, HsSUMO1 promotes ocular lens cell differentiation, 
while HsSUMO2/3 inhibits this cell differentiation. This is due to the SUMO 
isoforms having different effects on the stability of transcription factors (Gong, 
Ji et al. 2014). As HsSUMO2/3 possess an internal SCM at lysine 11 (Lys11; K11), 
both are capable of efficiently forming poly-SUMO chains, while HsSUMO1 
cannot. The formation of poly-SUMO chains is reported to have a variety of 
effects on proteins, including altering protein localisation, protein stability, and 
protein-protein interactions (Hardeland, Steinacher et al. 2002, Joseph, Tan et 
al. 2002, Pfander, Moldovan et al. 2005, Mullen and Brill 2008, Tatham, Geoffroy 
et al. 2008). As HsSUMO1 does not contain an internal SCM, HsSUMO1 
modifications generally occurs as mono-SUMOylation, or as a chain terminator 
events (Wang, Pan et al. 2002). 
AaSUMOa and –b both lack an internal SCM. Consequently, the amino acid 
sequence suggests AaSUMOa/b should share a biochemical function more 
equivalent to HsSUMO1 than HsSUMO3. This chapter investigates the biochemical 
function of the AaSUMOylation pathway component enzymes to determine if 
AaSUMO can form poly-SUMO chains in the absence of an SCM, utilising in vitro 
biochemical assays (Bencsath, Podgorski et al. 2002, Prudden, Pebernard et al. 
2007, Vethantham and Manley 2009, Boutell and Davido 2015, Yang, Campbell et 
al. 2018). 
The core components of the AaSUMOylation machinery were expressed using a 
bacterial expression system and purified as recombinant proteins, and in vitro 
biochemical studies conducted to investigate the biochemical properties of 
individual AaSUMOylation pathway component enzymes. Our data demonstrates 
that AaSUMO is biochemically more similar to HsSUMO1 than HsSUMO2/3 due to 
the lack of an internal SCM. Interestingly, however, when a catalytically active 
AaPIAS was included, AaSUMO efficiently formed poly-SUMO chains. The 
formation of AaSUMO chains being AaPIAS dependent indicates a potential 
regulatory mechanism for poly-SUMO chain formation in Ae. aegypti. We also 
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demonstrate that the biochemical activity of the SUMOylation proteins is highly 
conserved and functionally interchangeable between Ae. aegypti and H. sapiens. 
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4.2. Purification of the AaSUMOylation pathway 
In order to determine the biochemical properties of the AaSUMOylation pathway, 
the constituent proteins were cloned into vectors in frame with affinity tags. A 
bacterial expression system was adopted to purify recombinant proteins as 
bacteria do not possess a SUMOylation pathway. This reduces the likelihood of 
by-products being co-purified with biochemical activity that could influence in 
vitro SUMOylation assays. Many previous studies have utilised affinity tagged 
recombinant proteins for biochemical assays to characterise the biochemical 
propertied of the proteins demonstrating the validity for use in these studies 
(Derewenda 2004, Arnau, Lauritzen et al. 2006, Alontaga, Bobkova et al. 2012).  
Constituent proteins from the HsSUMOylation pathway were previously cloned 
into bacterial expression vectors in frame with either GST- or His-tags on the N-
termini of the proteins (Table 2-5). Corresponding proteins from the 
AaSUMOylation pathway were also cloned into bacterial expression vectors 
(Section 2.2.9). AaSUMO, AaUbc9, AaPIAS, and respective catalytically inactive 
mutants, and the SUMO chimaera were cloned to contain an in frame His-tag on 
the N-termini. Purification of AaSAE1/2 required an N-termini Strep.II tag on 
AaSAE2, as a His-tag resulted in dissociation of the heterodimer. It was 
hypothesised that AaSAE1/2 was unable to be purified by Ni-affinity 
chromatography due to the presence of non-conserved Histidine residues in 
AaSAE1 at positions 179/279/297/310, and AaSAE2 at position 66, which are 
located at the interaction interface of AaSAE1/2 (Appendix B: Purification of 
AaSAE1/2).  
Purification of recombinant proteins yielded predominantly pure samples, 
although some contained significant breakdown products (Figure 4.1; Figure 
4.2). Additionally, a catalytically inactive AaUbc9 (AaUbc9 C93S), and AaPIAS 
C371A, a chimaeric SUMO, and a chimaeric SUMO K11R mutant were also purified 
by Ni-affinity chromatography (Section 2.2.9; Appendix C: Purified AaUbc9 
C93S, the SUMO chimaera, and the SUMO chimaera K11).  A chimaeric SUMO 
protein, and K11R mutant, was produced to demonstrate that the lack of Lysine 
within an SCM in AaSUMO was responsible for lack of efficient poly-SUMO chain 
formation. If the addition of an SCM within AaSUMO did not resulted in the 
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efficient conjugation of poly-SUMO chains it would suggest another component 
of the AaSUMOylation pathway was preventing poly-AaSUMO chain formation.  
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Figure 4.1 Recombinant H. sapiens SUMOylation 
proteins 
Core proteins of the H. sapiens SUMOylation system 
were purified through Ni-affinity chromatography and 
resolved by SDS-PAGE with standardised concentrations 
of BSA. The gel was stained with Coomassie brilliant 
blue. Molecular weights indicated. * = His-SAE1, ** = 
GST-SAE2 
 
 
* 
** 
S Stokes, 2018  186 
  
Figure 4.2 Recombinant Ae. aegypti SUMOylation 
enzymes 
Core proteins of the Ae. aegypti SUMOylation system 
were purified through Ni-, or Biotin-affinity 
chromatography (SAE1/2). The proteins were resolved 
by SDS-PAGE with standardised concentrations of BSA. 
The gel was stained with Coomassie brilliant blue. 
Molecular weights indicated. * = SAE1, ** = Strep.II-
SAE2, # = His-AaPIAS, ##=His-AaPIAS C371A. 
 
AaSUMOylation pathway 
BSA (ng) 
55 
95 
kDa 
70 
130 
40 
35 
25 
15 
250 
* 
** ## # 
S Stokes, 2018  187 
4.3. Comparison of the biochemical properties of 
the Ae. aegypti and H. sapiens SUMOylation 
pathways 
4.3.1. Recombinant AaUbc9 forms a thioester 
bond with SUMO at a similar rate to 
recombinant HsUbc9 
Ubc9 is known to form a thioester bond with the terminal glycine residue of 
SUMO (Ubc9~SUMO) prior to modifying target substrates (Schwarz, Matuschewski 
et al. 1998, Tatham, Kim et al. 2003). The sequence similarity demonstrated 85% 
amino acid sequence identity (Figure 3.2A). Interestingly, previous work has 
implicated Asp100 and Lys101 as amino acids which influence the rate of thioester 
formation in HsUbc9. The presence of these amino acids has been shown to slow 
down the rate of thioester formation, but increase the rate of SUMO transfer to 
the substrate protein (Tatham, Chen et al. 2003). AaUbc9 encodes a Glu100 
instead of an Asp100 (Figure 3.2), which led us to hypothesise that the rate at 
which AaUbc9 forms thioester bonds should occur at a slightly faster rate 
compared to HsUbc9. 
Biochemical assays were conducted utilising recombinant proteins (300 ng 
HsSUMO3, 100 ng HsSAE1/2, and 100 ng Hs or AaUbc9). The proteins were mixed 
together in the presence of ATP, and incubated at 37˚C for the time course 
specified. The reactions were terminated with 3x BM –DTT (Table 2-8), which 
maintains the thioester bond. As indicated in Figure 4.3A, Ubc9~SUMO thioester 
conjugate resolved at the expected molecular weight. Furthermore, the addition 
of a catalytically inactive Ubc9, containing a C93S mutation, prevented thioester 
bond formation and therefore ensures that the band at the expected molecular 
weight represents Ubc9~SUMO. The formation of Ubc9~SUMO thioester was 
quantified, normalising to the background reading of the Coomassie stained gel 
at T0. Ubc9~SUMO thioester bond formation between HsSUMO and either Hs or 
AaUbc9 occurred at approximately the same rate (Figure 4.3B). These data 
demonstrate that thioester bond formation between HsSUMO3 and AaUbc9 
occurs at a similar rate to HsSUMO3 and HsUbc9, likely due to the high degree of 
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amino acid identity between the two Ubc9 orthologue proteins, indicating that 
these enzymes are biochemically indistinguishable in vitro. 
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Figure 4.3 Comparison of HsUbc9 and AaUbc9 rate of thioester formation  
Non-reducing biochemical Ubc9~SUMO thioester formation assays were conducted 
with 300 ng SUMO, 100 ng SAE1/2, 100 ng of either Aa or HsUbc9  in the presence 
of ATP and terminated at the specified time points. (A) Coomassie stained gel of 
the biochemical assay with either AaUbc9~ or HsUbc9~HsSUMO3 indicated. One 
reaction containing no Ubc9, and a functionally inactive AaUbc9 mutant were 
included as controls. Molecular weight and other recombinant proteins are 
indicated. (B) Mean signal intensity of Ubc9~HsSUMO3 from (A), with standard 
error bars shown. Curve plotted is nonlinear fit of data, as a specific binding with 
hill slope, with R2 values shown, produced with GraphPad Prism 7.02, N=3.  
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4.3.2. Recombinant AaSUMO is more 
biochemically comparable to HsSUMO1 than 
HsSUMO3 in an in vitro biochemical assay 
The HsSUMOylation pathway has been shown to be biochemically capable of 
forming poly-SUMO chains in vitro (Tatham, Jaffray et al. 2001). Using SAE2 and 
SUMO as substrates of SUMO modification, our assay compared the biochemical 
activity of the AaSUMOylation pathway with the HsSUMOylation pathway. Here, 
50 ng of SAE1/2, 50 ng of Ubc9, and 50 ng of SUMO were incubated together at 
28 ˚C. The reaction was terminated at the time points indicated with 3x BM 
(Table 2-8), the samples were resolved on an SDS-PAGE gel and a Western blot 
was conducted with antibodies raised against HsSUMO2/3, and HsSUMO1 when 
required. 
 AaSUMO doesn’t efficiently form mid-tier chains or HMW poly-SUMO chains, 
compared to HsSUMO3 (Figure 4.4A). The biochemical activity of AaSUMO is 
more comparable to that of HsSUMO1 (Figure 4.4B). However, AaSUMO does 
appear to be conjugated to AaSAE2 slightly more efficiently compared to 
HsSUMO1 conjugated to HsSAE2. The signal intensity of the HMW SUMO 
conjugates was quantified and normalised to unconjugated SUMO at T0. When 
the biochemical activity of the three SUMO proteins was compared, AaSUMO was 
observed to conjugate slightly more efficiently than HsSUMO1, but far less 
efficiently than HsSUMO3. The efficiency of SUMO conjugate formation of 
AaSUMO is therefore more similar to that of HsSUMO1 than HsSUMO3 (Figure 
4.4C). 
The assays comparing the biochemical activity of AaSUMO with HsSUMO3 (Figure 
4.5A) and HsSUMO1 (Figure 4.5B) were also conducted at 37 ˚C, in order to 
determine if the lower temperature was altering the efficiency of the 
HsSUMOylation pathway. However, as demonstrated in Figure 4.5C, AaSUMO 
remained more biochemically comparable to HsSUMO1, than HsSUMO3, 
regardless of temperature. Collectively, these data indicate that AaSUMO is 
biochemically more comparable to HsSUMO1 than HsSUMO3. This is likely due to 
the lack of an internal SCM, which is lacking in both HsSUMO1 and AaSUMO.  
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Figure 4.4 Comparison of Aa and Hs SUMOylation pathways activity at 28 ˚C 
Biochemical reactions comparing the activity of 50 ng SUMO, SAE1/2, and Ubc9 from 
the Aa and Hs SUMOylation pathways were incubated together at 28 ˚C prior to the 
reaction being terminated after the specified periods of time. (A) Comparison of the 
build-up of SUMO-SUMO dimers and HMW SUMO conjugates of either AaSUMO or 
HsSUMO3. Commercial poly-SUMO2 chains were also included to indicate sizes of 
SUMO chains. An antibody to HsSUMO2/3 was used to probe for Aa and HsSUMO3 
expression. (B) Comparison of the build-up of either AaSUMO or HsSUMO1 
conjugates. Antibodies to HsSUMO2/3 and HsSUMO1 were utilised to probe for 
HsSUMO1 and AaSUMO expression over time. (C) Graphical view of the build-up of 
SUMO-SUMO dimers and HMW SUMO conjugates from both (A) and (B), signal 
intensity quantified using a LiCor. Curve is Specific binding with hill slope nonlinear 
fit of data, mean, standard error, and R2 values shown, produced with GraphPad 
Prism 7.02. N≥3. 
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Figure 4.5 Comparison of Aa and Hs SUMOylation pathways activity at 37 
˚C 
Biochemical reactions comparing the activity of 50 ng SUMO, SAE1/2, and 
Ubc9 from the Aa and Hs SUMOylation pathways were incubated together at 
37 ˚C prior to the reaction being terminated after the specified periods of 
time. (A) Comparison of the build-up of SUMO-SUMO dimers and HMW SUMO 
conjugates of either AaSUMO or HsSUMO3. Commercial poly-SUMO2 chains 
were also included to indicate sizes of SUMO chains. An antibody to 
HsSUMO2/3 was used to probe for Aa and HsSUMO3 expression. (B) 
Comparison of the build-up of either AaSUMO or HsSUMO1 conjugates. 
Commercial poly-SUMO2 chains were also included to indicate sizes of SUMO 
chains. Antibodies to HsSUMO2/3 and HsSUMO1 were utilised to probe for 
HsSUMO1 and AaSUMO expression over time. (C) Graphical view of the build-
up of SUMO-SUMO dimers and HMW SUMO conjugates from both (A) and (B) 
signal intensity quantified using a LiCor. Curve is Specific binding with hill 
slope nonlinear fit of data, mean, standard error, and R2 values shown, 
produced with GraphPad Prism 7.02. N≥3. 
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4.3.3. A chimaeric SUMO protein efficiently 
forms HMW SUMO conjugates 
This work has demonstrated a biochemical difference between the AaSUMO 
protein and HsSUMO3 utilising a combination of both bioinformatics and 
biochemical assays (Section 3.2.1; Section 4.3.2). The lack of efficient AaSUMO 
poly-SUMO chain formation was hypothesised to be due to the lack of an internal 
SCM in AaSUMO. A chimaeric SUMO protein was synthesised made from the N-
terminal of HsSUMO3 and the C-terminal of AaSUMO. The N-terminal of the 
chimaeric protein consisted of the sequence MSEEKPKEGVKTEN, from HsSUMO3, 
containing the SCM VKTE (shown in aqua). The C-terminal consisted of amino 
acid residues 14-91 from AaSUMO. This resulted in a SUMO protein which could 
efficiently form poly-SUMO chains. A mutant chimaeric SUMO protein was also 
synthesised and purified which contained a K11R mutation, ablating the internal 
SCM (Figure 4.6A). This ensured AaSUMO possessed the SCM and a control which 
cannot efficiently form poly-SUMO chains.  
A similar biochemical experiment was set up utilising 50 ng chimaeric or K11R 
mutant SUMO protein, 50 ng Ubc9, and 50 ng SAE1/2. The samples were resolved 
on an SDS-PAGE gel, and probed with an antibody to HsSUMO2/3 (Figure 4.6B). 
As demonstrated, the chimaeric SUMO formed HMW SUMO conjugates more 
efficiently than the K11R mutant chimaera. The signal intensity was quantified, 
normalised to the concentration of unconjugated SUMO at T0. The resulting 
graph demonstrates that the SUMO chimaera formed HMW conjugates far more 
efficiently than the SUMO chimaera K11R mutant, due to the presence of the 
lysine within the SCM (Figure 4.6C).  
Together, these data demonstrate that a K11 within an SCM is necessary for the 
efficient formation of poly-AaSUMO chains.  
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Figure 4.6 Comparison of SUMO chimaera with a K11R chimaera mutant 
Biochemical reactions comparing the activity of 50 ng SUMO chimaera, SUMO 
chimaera K11R, SAE1/2, and Ubc9 from the AaSUMOylation pathway was 
incubated together at 28 ˚C prior to the reaction being terminated after the 
specified periods of time. (A) A schematic of the SUMO chimaera, and SUMO 
chimaera K11R mutant which demonstrates what the protein is made from and 
where the K11R mutation is. (B) Comparison of the build-up of SUMO-SUMO 
dimers and HMW SUMO conjugates when the SUMO chimaera was used 
compared to the SUMO chimaera K11R mutant at time points indicated post 
initiation of reaction. An antibody to HsSUMO2/3 was used to probe for SUMO 
expression. Commercial poly-SUMO2 chains were also included to indicate 
sizes of SUMO chains. Molecular mass markers are shown. (C) Signal intensity 
of SUMO conjugates from (B) was detected with a LiCor, normalised to 
unconjugated SUMO at T0. Mean results were plotted on a graph with standard 
error bars, n≥3, nonlinear fit of data was plotted as Specific binding with hill 
slope with R2 values shown produced with GraphPad Prism 7.02. 
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4.3.4. AaPIAS enhances rate of HMW SUMO 
conjugate formation  
In H. sapiens, the family of PIAS proteins are well reported to efficiently 
increase the rate of poly-SUMO chain formation (Eisenhardt, Chaugule et al. 
2015). This is due to the catalytically active SP-RING domain. AaPIAS shares a 
relatively well conserved SP-RING domain and a conserved catalytically active 
Cys371 (Section 3.2.4). Consequently, we sought to identify if PIAS shared a 
similar biochemical function in the SUMOylation pathway of Ae. aegypti as in H. 
sapiens. Wild type and catalytically inactive mutant AaPIAS (AaPIAS C371A; CA) 
were cloned into a bacterial expression vector and purified (Figure 4.2). Upon 
addition of 10 ng of AaPIAS or AaPIAS C371A to the SUMOylation assay mixture at 
28 ˚C, there was a rapid build-up of HMW SUMO conjugates in a SP-RING 
dependent manner (Figure 4.7A). Assays were quantified and plotted (Figure 
4.7B). These data demonstrate that biochemically active AaPIAS is required to 
efficiently form poly-AaSUMO chains in vitro. 
Equivalent reaction samples were sent for mass spectrometry analysis by 
collaborators at the University of Dundee (Section 2.2.3.1; Figure 4.8A). Mass 
spectrometry analysis revealed that every AaSUMOa lysine residue can act as an 
acceptor site for SUMO modification in vitro (Figure 4.8B), with the most 
prominent lysine residues being K5/6/9/40 (Figure 4.8C). These residues are 
predominantly located around the N-terminus of AaSUMO (Figure 4.8D). Further 
analysis of the effect of AaPIAS on the formation of SUMO dimers or poly-SUMO 
chains indicated that AaPIAS does not appear to influence acceptor site 
preference (Figure 4.8E), but rather rate of accumulation (Figure 4.7A).  
Together this demonstrates that AaSUMO is capable of forming poly-SUMO 
chains, but it only efficiently occurs in the presence of an AaPIAS. This could 
potentially indicate an additional level of regulation on the formation of poly-
SUMO chains in Ae. aegypti, compared to H. sapiens. Although the formation of 
poly-SUMO chains in Ae. aegypti mosquitoes has not been investigated, and the 
potential biological effects of poly-SUMO chain formation indicates an exciting 
new avenue of research.  
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Figure 4.7 Comparison of PIAS activity with a catalytically inactive PIAS mutant 
Biochemical reactions comparing the activity of 50 ng SUMO, SAE1/2, Ubc9, and 10 ng 
AaPIAS or AaPIAS C371A from the AaSUMOylation pathway was incubated together at 28 
˚C prior to the reaction being terminated after the specified periods of time. (A) A 
representative biochemical assay demonstrating the difference in the build-up of HMW 
SUMO conjugates when the AaPIAS was used against the AaPIAS C371A mutant at time 
points of 0, 5, 15, 30, or 60 minutes post initiation of the reaction at 28 ˚C. 
Membranes were probed with an antibody to H. sapiens SUMO2/3 for expression of 
SUMO. Commercial poly-SUMO2 chains were also included to indicate sizes of SUMO 
chains. Molecular weight is indicated. (B) Signal intensity of SUMO-SUMO dimers and 
HMW SUMO conjugates from (A) was quantified with a LiCor, normalised to 
unconjugated SUMO at T0. Mean of n≥3 repeats calculated and plotted as a nonlinear 
curve with specific binding with hill slope by Graphpad Prism 7.02, with standard error 
and R2 values indicated. 
AaPIAS AaPIAS C371A 
 0     5     15   30    60     0      5     15    30    60              Time (min) 
55 
95 
kDa 
70 
130 
40 
35 
25 
15 
250 
HMW SUMO 
conjugates 
Unconjugated 
SUMO 
SUMO dimers 
0 20 40 60 80
0
10
20
30
Time (min)
R
e
la
ti
v
e
 s
ig
n
a
l 
in
te
n
s
it
y
 (
T
0
)
28 C
+ AaPIAS C371A
+ AaPIAS
R
2
=0.57
R
2
=0.67
Curve = Nonlinear fit of data (Specific binding with hill slope)
S Stokes, 2018  200 
 
 
 
 
 
D 
A 
B 
C 
Continued on next page 
S Stokes, 2018  201 
  
Figure 4.8 Mass spectrometry analysis reveals which lysine’s SUMO is binding 
to. 
Biochemical assays were conducted prior to being sent to collaborators at the 
University of Dundee for analysis by mass spectrometry. (A) Coomassie gel showing 
in vitro conjugation assay products from reactions either lacking AaPIAS (-) or 
including an active (WT) or inactive (CA) AaPIAS. Schematic that explains the 
sample processing and mass spectrometry analysis using a branched peptide 
database. (B) Sequence alignment of the Ae. aegypti and H. sapiens SUMO 
orthologues. Sequence identity is shown by grey boxes and SUMO-1 secondary 
structure shown above with arrow showing strands, and box showing helices. The 
ubiquitin-like domain is indicated by the broken blue box. AaSUMOa lysine residues 
are shown in red and the position indicated. (C) Summary of mass spectrometry 
data associated with identified SUMO-SUMO branched peptides from the samples 
shown in (A). Data are aggregated for all samples and separated by lysine 
acceptor. (D) A model of the AaSUMOa protein with the lysine residues which are 
most likely to be SUMO modified, as identified in (C) indicated. (E) Slice-specific 
peptide intensity data separated by lysine acceptor. Data are % total intensity of 
all branched peptides found in each slice.  
E 
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4.4. Biochemical activity of the pathways is 
conserved between species 
As the orthologous proteins are well conserved at an amino acid and structural 
level, we hypothesised that the biochemical activity of the proteins should be 
sufficiently conserved to enable the individual Ae. aegypti SUMOylation proteins 
to substitute for H. sapiens SUMOylation pathway constituent proteins. If so, this 
would demonstrate that the proteins share a high degree of biochemical 
conservation as well. The assays were conducted at 37 ˚C as described in 
Section 2.2.3.1. 
 
4.4.1. AaSUMO can be utilised by the 
HsSUMOylation pathway 
AaSUMOa shares 68% amino acid identity with HsSUMO2, and possesses a similar 
tertiary structure (Section 3.2.1). In order to determine if AaSUMO is capable of 
being conjugated by the HsSUMOylation pathway, 100 ng SAE1/2, 100 ng Ubc9, 
and 300 ng either AaSUMO, or HsSUMO2 were incubated together. Additional 
samples were also included which lacked either SUMO, or HsUbc9, to 
demonstrate that the HMW bands represent genuine SUMO conjugates. The 
samples were terminated at the specified times, resolved by SDS-PAGE, and the 
gel was Coomassie stained (Figure 4.9). This analysis revealed that AaSUMO can 
be utilised by the HsSUMOylation machinery, to be conjugated to the GST-
HsSAE2, although conjugation of AaSUMO does not appear to be as efficient as 
HsSUMO2. This is likely explained by the lack of SCM on AaSUMO, as previously 
described (Section 4.3.2; Section 4.3.3). 
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60   60   60    1     5    15    30   45   60    1     5   15    30   45   60  Time (min) 
HsSUMO2 AaSUMO 
His-AaSUMO 
GST-HsSAE2 
HMW SUMO 
conjugates 
His-HsUbc9 
His-HsSUMO2 
Figure 4.9 AaSUMO is biochemically active with HsSUMOylation machinery 
100 ng HsUbc9, 100 ng HsSAE1/2, and 300 ng either AaSUMO or HsSUMO2 were 
incubated together at 37 ˚C for varying lengths of time. Samples including no 
SUMO or no Ubc9 were included as controls. The reaction was terminated and 
the samples were resolved on an SDS-PAGE gel. The gel was stained by 
Coomassie and demonstrates that over time there is a build-up of HMW SUMO 
conjugates when AaSUMO was incubated. This shows that the AaSUMO protein is 
functionally interchangeable with HsSUMO. N=2. 
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4.4.2. AaUbc9 can be utilised in the 
HsSUMOylation pathway with HsSUMO2 
AaUbc9 shares 85% amino acid identity with HsUbc9, a conserved active site 
(C93), and a conserved tertiary structure (Figure 3.2). As a consequence, it was 
hypothesised that AaUbc9 should be able to efficiently conjugate HsSUMO2 after 
activation by HsSAE1/2. The biochemical conservation of AaUbc9 was tested 
against HsUbc9, to determine if AaUbc9 is able to be substituted for HsUbc9 in 
the HsSUMOylation pathway. An experiment utilising 300 ng HsSUMO2, 100 ng 
HsSAE1/2, and either 100 ng AaUbc9 or HsUbc9 was set up, the reactions were 
terminated at the times stated, samples were then resolved by SDS-PAGE, and 
Coomassie stained. AaUbc9 was found to be capable of efficiently conjugating 
HsSUMO2 to GST-HsSAE2 (Figure 4.10).  
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HsUbc9 AaUbc9 
GST-HsSAE2 
HMW SUMO 
conjugates 
His-Hs/AaUbc9 
His-HsSUMO2 
Figure 4.10 AaUbc9 is biochemically active with HsSUMOylation machinery 
300 ng HsSUMO2, 100 ng HsSAE1/2, and 100 ng either AaUbc9 or HsUbc9 were 
incubated together at 37 ˚C for varying lengths of time. A sample including no 
Ubc9 was included as a control. The reaction was terminated and the samples 
were resolved on an SDS-PAGE gel. The gel was stained by Coomassie and 
demonstrates that over time there is a build-up of HMW SUMO2 conjugates 
when AaUbc9 was incubated. This shows that AaUbc9 is functionally 
interchangeable with HsUbc9. N=2. 
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4.4.3. AaSAE1/2 utilise in HsSUMOylation 
pathway 
Due to the relatively low degree of amino acid identity between HsSAE1/2 and 
AaSAE1/2 (50% and 42%, for SAE1 and SAE2 respectively) compared to the rest of 
the SUMOylation pathway (Section 3.2.3), it was unlikely that AaSAE1/2 would 
work to the same efficiency as HsSAE1/2 when used in the HsSUMOylation 
pathway. However, the active Cys173 is still conserved (Appendix A: Amino acid 
sequence comparison between Hs and AaSAE1/2, and Hs and AaPIAS), and the 
tertiary structure of the proteins is also well conserved (Section 3.2.3), 
therefore it was hypothesised that AaSAE1/2 could still activate HsSUMO 
orthologues. An experiment utilising either 100 ng AaSAE1/2 or HsSAE1/2, with 
300 ng HsSUMO2, and 100 ng HsUbc9 was conducted and terminated at specified 
times. The samples were then resolved by SDS-PAGE, and Coomassie stained. 
The results reveal that AaSAE1/2 is capable of activating HsSUMO2 that AaSAE2 
can act as a substrate for HsSUMO2 modification (Figure 4.11).  
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90   1    5   15  30   45   60   90    1     5    15    30   45   60   90  Time (min) 
AaSAE1/2 HsSAE1/2 
GST-HsSAE2 
HMW SUMO 
conjugates 
His-HsUbc9 
His-HsSUMO2 
Strep.II-AaSAE2 
Figure 4.11 AaSAE1/2 is biochemically active with HsSUMOylation 
machinery 
300 ng HsSUMO2, 100 ng HsUbc9, and 100 ng either AaSAE1/2 or HsSAE1/2 were 
incubated together at 37 ˚C for varying lengths of time. A sample including no 
SAE1/2 was included as a control. The reaction was terminated and the 
samples were resolved on an SDS-PAGE gel. The gel was stained by Coomassie 
and demonstrates that over time there is a build-up of HMW SUMO2 conjugates 
when AaSAE1/2 was incubated. This shows that the AaSAE1/2 heterodimer is 
functionally interchangeable with the HsSAE1/2 heterodimer. N=1. 
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4.4.4. AaPIAS can enhance rate of HsSUMO3 
chain formation 
AaPIAS was also tested for its ability to be utilised by the HsSUMOylation 
pathway. As described in Section 3.2.4, AaPIAS only shares 32% - 37% amino acid 
identity with the orthologous proteins, however, the SP-RING domain does share 
a higher degree of amino acid identity (between 65% - 70%). The activity of 
AaPIAS was tested against the activity of the catalytically inactive mutant. The 
experiment was conducted with 300 ng HsSUMO2, 100 ng HsUbc9, 100 ng 
HsSAE1/2 and either 20 ng AaPIAS, or AaPIAS C371A. Reactions were terminated 
at the specified times, resolved by SDS-PAGE, and Coomassie stained. AaPIAS 
can be seen to efficiently form HMW conjugates, compared to AaPIAS C371A, 
while utilising HsSAE1/2, HsUbc9, and HsSUMO2 (Figure 4.12). Within 15 
minutes, the E3 ligase activity of AaPIAS efficiently forms a build-up of HMW 
SUMO conjugates indicative of poly-SUMO chain formation. In the absence of a 
catalytically functional SP-RING domain, the same build-up of HMW SUMO 
conjugates is not present until the 90 minute time point. This also demonstrates 
that even though the overall amino acid identity between AaPIAS and the H. 
sapiens orthologues is 32% - 37%, AaPIAS is still able to interact with HsSUMO2, 
HsUbc9, and HsSAE2. 
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AaPIAS AaPIAS C371A 
His-HsSUMO2 
His-HsUbc9 
GST-HsSAE2 
HMW SUMO 
conjugates 
Figure 4.12 AaPIAS is biochemically active with HsSUMOylation machinery 
300 ng HsSUMO2, 100 ng HsUbc9, 100 ng HsSAE1/2 and either 20 ng AaPIAS, or 
AaPIAS C371A, were incubated together at 37 ˚C for varying lengths of time. 
Samples including no Ubc9 and no PAIS were included as controls. The reaction 
was terminated and the samples were resolved on an SDS-PAGE gel. The gel was 
stained by Coomassie. This demonstrates that a functional SP-RING domain 
results in an efficient increase in HMW HsSUMO2 conjugates. N=1. 
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4.5. Discussion 
Protein modification by the SUMOylation pathway is known to have a wide 
variety of important biological functions in many species of eukaryotes. A large 
body of work has been produced in H. sapiens demonstrating the effect of mono- 
or poly-SUMO modification. Likewise, there has been a large body of work 
conducted in yeast (Saccharomyces cerevisiae; S. cerevisiae) and in D. 
melanogaster. This work has revealed important functions of SUMO modification, 
including protein sub-cellular localisation and protein stability (Desterro, 
Rodriguez et al. 1998, Miteva, Keusekotten et al. 2010).  
It is well known that in the HsSUMOylation pathway, Ubc9 forms a thioester bond 
with SUMO through the Sulphur atom in the R group of the cysteine amino acid 
(Tatham, Chen et al. 2003, Tatham, Kim et al. 2003). It was hypothesised that 
AaUbc9 would also form a thioester bond with SUMO, due to the conserved 
active site (C93); a mutant which is incapable of forming thioester bonds was also 
purified as a control (Appendix C: Purified AaUbc9 C93S, the SUMO chimaera, 
and the SUMO chimaera K11). As AaUbc9 encodes a Glutamic acid (E100) instead 
of an Aspartic acid (D100), we expected the rate of AaUbc9~SUMO formation to 
be up to 1.3-fold greater than HsUbc9~SUMO (Tatham, Chen et al. 2003). 
However, these results demonstrate that the C93 in AaUbc9 does form thioester 
bonds with SUMO at a comparable rate to HsUbc9 irrespective of the presence of 
E100 instead of D100 (Section 4.3.1). This is likely due to the similarity between 
the structure of Aspartic acid and Glutamic acid resulting in a predominantly 
similar phenotype. 
As AaSUMO is lacking an internal SCM, it was hypothesised it should not be able 
to efficiently form poly-SUMO chains (Section 3.2.1). Utilising the recombinant 
proteins described in Section 4.2, the ability of AaSUMO to form poly-SUMO 
chains in an in vitro assay was assessed. When comparing the build-up of HMW 
SUMO conjugates between the AaSUMOylation pathway and the HsSUMOylation 
pathway, there are a range of similarities and differences with both HsSUMO1 
and HsSUMO3 (Figure 4.4; Figure 4.5). These results show that conducting the 
assay at either 28 ˚C or 37 ˚C have no effect on the activity of the 
AaSUMOylation pathway; we also found that AaSUMO and HsSUMO1 / HsSUMO3 
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all form SUMO-SUMO dimers within 5-15 minutes, and all SUMO orthologues 
studied are capable of SUMO modifying SAE2. SUMO modification of SAE2 has 
previously been reported to result in the localisation of SAE2 out of the nucleus, 
and altering enzyme activity (Truong, Lee et al. 2012, Truong, Lee et al. 2012). 
As AaSAE2 also appears to be a substrate for SUMO modification, it seems likely 
that SUMO modification of AaSAE2 results in a similar phenotype, although 
further studies would be needed to confirm this in vivo. There are also notable 
differences in the biochemical activity of AaSUMO and HsSUMO3, demonstrated 
in Figure 4.4 and Figure 4.5. This includes the ability of HsSUMO3 to efficiently 
form mid-tier SUMO chains, and the formation of a ‘smear’, typically indicative 
of poly-SUMO chains, at the top of the blot of HMW SUMO conjugates. The mid-
tier and HMW chains are also both absent when HsSUMO1 is utilised. Together, 
this demonstrates that the biochemical activity of AaSUMO is more comparable 
to HsSUMO1, compared to HsSUMO3. This also demonstrates that AaSUMO cannot 
efficiently form poly-SUMO chains at either 28 ˚C or 37 ˚C. Furthermore, as the 
rate of Ubc9~SUMO thioester bond formation is equivalent between species, it 
rules out a lack of poly-SUMO chain formation being due to different activity of 
Ubc9, and further implicates the lack of SCM in the inability to form poly-SUMO 
chains. SUMO1 has been reported to form chains on low affinity sites when large 
concentrations of Ubc9 are added in vitro, and it is possible that any poly-
HsSUMO1 chains, or poly-AaSUMO chains formed in this assay could be due to the 
concentration of Ubc9 (Matic, van Hagen et al. 2008). This could be confirmed 
by titrating in lower concentrations of Ubc9 and performing mass spectrometry 
analysis to determine if one lysine is predominantly modified. 
To confirm that the SCM would result in the formation of poly-SUMO chains, a 
chimaeric SUMO protein was produced and purified, which contained the SCM 
from HsSUMO3, replacing the first 14 amino acids of the AaSUMO protein, 
including the SCM (Section 4.3.3). The chimaeric SUMO formed chains of HMW 
SUMO conjugates more efficiently than a chimaeric mutant which contained a 
mutation in lysine 11 (K11R), the primary substrate for SUMO chain formation 
(Tatham, Jaffray et al. 2001). The chimaeric protein is capable of efficiently 
forming HMW SUMO conjugates when compared to the chimaera K11R (Figure 
4.6). This shows that the lack of a lysine within an internal SCM prevents SUMO 
chains from efficiently forming in Ae. aegypti.  
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Upon addition of the E3 ligase, AaPIAS, however, there was a rapid build-up of 
HMW SUMO chains forming (Figure 4.7). The activity of AaPIAS was compared to 
AaPIAS C371A, which clearly demonstrated a rapid increase in HMW SUMO 
conjugates forming. The SP-RING domain of PIAS proteins are widely known to be 
the catalytically active site for enhancing SUMO conjugation (Hochstrasser 2001, 
Hay 2005). This work demonstrates that the AaSUMOylation pathway is capable 
of forming poly-AaSUMO chains, but only when an AaPIAS is available. This 
indicates that the important biological functions of poly-SUMO chains are also 
utilised in Ae. aegypti. Previous work by Urena, Pirone et al. (2016), on Blattella 
germanica (B. germanica) and D. melanogaster suggested that insect SUMO 
proteins could not form poly-SUMO chains. The evidence here indicates that 
AaSUMO can form poly-SUMO chains in vitro, but requires the presence of an 
AaPIAS for this to occur efficiently. The in vitro biochemical evidence Urena, 
Pirone et al. (2016) presented on B. germanica did not include the activity of a 
PIAS protein. They also found that ectopic expression of HsSUMO3 had a 
deleterious effect on D. melanogaster development, which suggests that poly-
SUMO chain formation is tightly regulated in insects. Further mass spectrometry 
analysis also indicates that AaSUMO can form chains on any internal lysine, 
although chains are predominantly formed on K5/6/9/40. These lysine residues 
are all expected to be located on a readily accessible region of the N-terminal of 
the protein (Figure 4.8).  
Previous studies have looked at the conservation of the SUMOylation pathway by 
ectopically expressing tagged Drosophila SUMOylation proteins in human cells, 
and determining that they could be conjugated to human proteins (Lehembre, 
Badenhorst et al. 2000). In this study, we sought to further characterise the 
conservation of the Aa- and Hs-SUMOylation pathways in an in vitro based assay. 
Much previous work on the biochemistry of the H. sapiens and S. cerevisiae 
SUMOylation pathways have been conducted using in vitro biochemical assays 
(Tatham, Jaffray et al. 2001, Bencsath, Podgorski et al. 2002, Yang, Campbell et 
al. 2018). It was hypothesised that due to the shared amino acid sequence, 
tertiary structure, and enzyme active sites, the biochemical function of the 
proteins should be conserved as well (Section 3.2.1; Section 3.2.2; Section 
3.2.3; Section 3.2.4). Biochemical conservation could be observed by 
substituting the orthologous proteins, as previously demonstrated (Urena, Pirone 
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et al. 2016). Here, we have demonstrated in vitro that AaSUMO, AaUbc9, 
AaSAE1/2, or AaPIAS can function as a substitute for their H. sapiens orthologues 
(Figure 4.9; Figure 4.10; Figure 4.11; Figure 4.12). For Ubc9 and SAE1/2, 
there appears to be a difference in the activity of the enzymes. This could be 
due to deviation between reactions as only one repeat was undertaken. Other 
causes could be due to the buffering conditions during protein purification, 
which were originally optimised for the HsSUMOylation pathway. HsUbc9 and 
HsSAE1/2 also evolved to activate and conjugate the HsSUMO proteins, so a 
difference in the activity may be due to a lower affinity between AaUbc9 or 
AaSAE1/2 with HsSUMO. This could be further explored by investigating the 
activity of the HsSUMO proteins, HsUbc9, or HsSAE1/2, in the AaSUMOylation 
pathway, experiments that there was not time to conduct here. 
Other ways this work could be extended is by examining the functional 
phenotype of SENPs. Previous work in S. cerevisiae has indicated that SENPs 
have different roles in maturing SUMO or in deSUMOylating proteins (Di Bacco, 
Ouyang et al. 2006, Eckhoff and Dohmen 2015). Further studies could also be 
conducted to perform a poly-SUMO chain pull down on Ae. aegypti cell lysate, to 
determine if Ae. aegypti produce poly-SUMO chains in vivo. Mass spectrometry 
analysis could then be conducted to attempt to determine which proteins are 
modified by, or interact with poly-SUMO chains. Furthermore, confirming these 
phenotypes with recombinant and endogenous AaSUMOb would help to 
demonstrate if AaSUMOb is biochemically and biologically similar to AaSUMOa, or 
if there are undiscovered roles for the two proteins. 
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5. AaSUMOylation 
pathway suppresses 
arbovirus replication 
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5.1. Overview 
The SUMOylation pathway is known to regulate the expression of a variety of 
genes, including those involved in cellular immunity in species ranging from H. 
sapiens to D. melanogaster. For instance, the immune proteins 14-3-3ε, Imd, and 
STAT92E have all been shown to be a substrate of SUMO modification in D. 
melanogaster (Handu, Kaduskar et al. 2015). The function of SUMO modification 
of these proteins has not yet been determined; however it is likely that 
SUMOylation of STAT92E suppresses the activation of STAT, in a similar 
mechanism to SUMOylation of H. sapiens STAT proteins. Due to the importance 
of SUMOylation in the regulation of immune pathways, the SUMOylation pathway 
is a prominent target for virus manipulation in order to restrict the immune 
response and promote replication from the outset of infection. Moreover, 
previous work with arboviruses in H. sapiens cells suggests that various 
components of the SUMOylation pathway interact directly with DENV proteins to 
the benefit or detriment of viral replication. Studies by Chiu, Shih et al. (2007) 
suggest that Ubc9 can SUMO modify the viral E protein at various lysine residues, 
although no biological function of this modification was determined. Over-
expression of Ubc9 has also been shown to suppress DENV replication, indicating 
an antiviral role for Ubc9 during DENV infection (Chiu, Shih et al. 2007). This was 
supported by more recent studies by Feng, Deng et al. (2018) who depleted Ubc9 
by siRNAs and found an increase in viral RNA expression (Feng, Deng et al. 2018). 
In contrast to this, studies by Su, Tseng et al. (2016) have shown that the N-
terminal of DENV NS5 is a substrate for SUMO modification, which stabilizes NS5 
to suppress induction of STAT2 antiviral signalling. Consequently, this study 
indicates a proviral role for SUMO modification during DENV infection (Su, Tseng 
et al. 2016). To date, no virology has been conducted on the effect of the 
SUMOylation pathway on arbovirus replication in Ae. aegypti.  
This chapter aims to address the expression pattern of the AaSUMOylation 
pathway in different organs and cells within Ae. aegypti, and to determine if 
there is a biologically functional requirement for the AaSUMOylation pathway 
during arboviral replication. Previous studies have investigated the expression of 
the SUMOylation pattern in a range of tissues of multiple species by q-PCR 
analysis and microscopy studies (Bohren, Nadkarni et al. 2004, Hu and Chen 
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2013, Bocksberger, Karch et al. 2014, Liang, Lee et al. 2016). These studies have 
revealed different patterns of expression of SUMO in different organs of 
invertebrates. For instance, in the salivary glands of D. melanogaster, SUMO is 
predominantly nuclear, localising to the chromosome arms, chromocentre, and 
chromosome telomeres within the nucleus (Nie, Xie et al. 2009, Bocksberger, 
Karch et al. 2014). To our knowledge, no studies have investigated the 
expression of SUMO in Ae. aegypti. Consequently, q-PCR and microscopy studies 
were conducted to reveal the ubiquitous, but differential, expression of SUMO in 
different Ae. aegypti tissues. dsRNA was utilised to deplete mRNA transcripts 
encoding SUMO, Ubc9, PIAS, or LacZ as a non-target negative control. Arboviral 
infections were conducted with arboviruses encoding an internal luciferase 
reporter protein to measure any effect on viral replication, as conducted 
previously (Tamberg, Lulla et al. 2007, Dietrich, Shi et al. 2017, Royle, Donald et 
al. 2017). q-PCR analysis was done on viral genome to ensure luciferase 
expression correlated with viral replication, and depletion of the SUMOylation 
pathway was not altering viral translation. These studies were conducted in 
mosquitoes in vivo, to determine the effect of SUMO depletion on the replication 
of ZIKV, and in vitro with BUNV, SFV, and ZIKV. Together, these studies reveal 
that the AaSUMOylation pathway has an overall suppressive effect on arbovirus 
replication in a virus-dependent manner.  
Throughout this chapter, in vivo experiments were conducted by Floriane Almire 
and Dr Emilie Pondeville.  
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5.2. Expression of the AaSUMOylation pathway 
SYBR Green q-PCR was undertaken to determine the level of transcript 
expression of AaSUMO, AaUbc9, and AaPIAS relative to the carcass in four tissues 
known to support arboviral replication. The midgut is known to be the first 
barrier to arboviral replication, as it constitutes the first cells arboviruses need 
to establish replication in. Haemocytes, the mosquito immune cells, can 
transport the arbovirus around the mosquito once they are infected and are 
believed to be a key amplifying site for arboviruses. The ovaries are the site of 
replication essential for vertical transmission of the arbovirus, and the salivary 
glands are the site of replication prior to being injected into a new host (Hardy, 
Houk et al. 1983).  
Dissection of the female adult mosquitoes was conducted by Floriane Almire and 
Dr Emilie Pondeville. RNA extraction, and cDNA synthesis was undertaken by F. 
Almire. Mosquitoes were non-blood fed prior to harvesting and analysis. 
Throughout the course of this chapter, the mosquito midgut is referred to as the 
gut. The term tissues are used to mean both perfused mosquito cells 
(haemocytes) and dissected mosquito organs (salivary glands, gut, and ovaries). 
 
5.2.1. Q-PCR analysis shows the AaSUMOylation 
pathway is differentially expressed in Ae. 
aegypti tissues  
Q-PCR analysis was conducted to examine the expression of mRNA transcripts in 
the tissues mentioned. Primers were designed to SUMO, Ubc9, or PIAS and 
primers to the ribosomal S7 gene were used as an endogenous control to 
standardise expression of the gene of interest across tissues (Table 2-6). Melt 
curves were conducted to ensure primer dimers were not interfering with the 
analysis (Appendix E: Melt curve analysis of q-PCR primers). Results were 
normalised to the carcass, material which consists of the abdomen after the gut 
and ovaries have been removed. The results show that SUMO, Ubc9, and PIAS 
mRNA are all expressed throughout these Ae. aegypti tissues. These results show 
that the SUMOylation pathway is expressed in the haemocytes and the ovaries, 
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as approximately 20-25 fold more SUMO mRNA is expressed compared to the 
carcass (Figure 5.1). SUMO mRNA expression in the gut and salivary glands is 
also greater than the carcass, but only by approximately 3–6 fold.  
 
Figure 5.1 Q-PCR of SUMOylation pathway transcript expression in Ae. 
aegypti tissues 
SYBR Green q-PCR was conducted on cDNA synthesised with random 
hexamers on RNA extracted from Ae. aegypti salivary glands, gut, ovaries, 
haemocytes, and carcass. Transcript expression of SUMO, Ubc9, and PIAS 
was examined. Levels of mRNA were normalised to ribosomal S7, using 
the threshold cycle (ΔΔCT) method and expressed relative to the carcass, 
which consists of the abdomen after the gut and ovaries have been 
removed. The results demonstrate the SUMOylation pathway is most 
abundantly expressed in the ovaries and haemocytes, but still have a 
higher level of expression in the salivary glands and gut relative to the 
carcass. Means of relative quantitation (RQ) and standard deviations (SD) 
shown, n=3, plotted with GraphPad Prism 7.02 
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5.2.2. AaSUMO is expressed in all Ae. aegypti 
tissues studied 
Confocal microscopy studies were conducted on the tissue samples. Here, DAPI 
stain is used to detect nucleic acids (blue), Phalloidin 488 stain is used to detect 
F-actin (green), and an antibody to SUMO2/3 are used to detect SUMO 
expression (red). Confocal microscopy was undertaken by Floriane Almire. 
Controls staining with no primary antibody were also performed for each 
replicate, where no signal was detected (Appendix D: No primary antibody 
controls of SUMO expression in Ae. aegypti tissues). 
 
5.2.2.1. AaSUMO is expressed in the 
haemocytes  
Ae. aegypti haemocytes are known to be a key site of arboviral amplification 
within the vector species, and are therefore a crucial target for arboviral 
infection. Investigation into the expression of SUMO by confocal microscopy 
revealed that all forms of haemocytes studied express SUMO. Undifferentiated 
prohaemocytes (Figure 5.2A), and differentiated granulocytes (Figure 5.2B) 
both express SUMO in a predominantly punctate nuclear distribution. This 
punctate distribution is commonly found in H. sapiens cells due to extensive 
SUMO modification of PML nuclear bodies (PML-NB) (Kamitani, Nguyen et al. 
1998). 
AF5 cell culture was also assessed for SUMO expression. AF5 cells are derived 
from Aag2s, a larval Ae. aegypti haemocyte cell line (Table 2-1) (Barletta, Silva 
et al. 2012, Varjak, Maringer et al. 2017). These cells expressed a similar 
pattern of staining to the haemocytes isolated from Ae. aegypti, as punctate 
nuclear structures. Interestingly, these structures are more defined in AF5 cells 
than in the haemocytes. There was also some cells which did not express SUMO 
in nuclear punctate structures, these cells are likely to be expressing a diffuse 
nuclear staining pattern which was not detected under these conditions.  
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Figure 5.2 Confocal microscopy of SUMO expression in Ae. aegypti 
haemocytes 
Haemocytes were extracted from adult Ae. aegypti and stained with DAPI 
(nuclei, in blue), phalloidin 488 (F-actin, in green), and αSUMO2/3 primary 
antibody (red).  (A) Undifferentiated prohaemocytes and (B) differentiated 
granulocytes both displayed the greatest extent of SUMO staining within the 
nuclei. (C, D) 3x104 AF5 cells were seeded in each well of an ibidi slide and 
incubated overnight. Images were taken on a Zeiss LSM 880 microscope with a 
63X (A and B) or 40X (C and D) oil-immersion objective and are representative of 
n=≥3. Scale bar represents 20 µm. 
A B 
C D 
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5.2.2.2. AaSUMO is expressed in the salivary 
glands 
Ae. aegypti salivary glands are a key site for arboviral replication prior to 
infecting a naïve host. SUMO staining was therefore conducted on the salivary 
glands; however, the majority of the staining appears to be localised to fat 
bodies. The distal-lateral lobe (Figure 5.3A), proximal-lateral, and median lobe 
(Figure 5.3B) are imaged. Surrounding these organs are fat bodies (arrows), 
which express SUMO to the greatest levels. 
 
 
  
Figure 5.3 Confocal microscopy of SUMO expression in Ae. aegypti salivary 
glands 
Salivary glands were extracted from adult Ae. aegypti and stained with DAPI 
(nuclei, in blue), phalloidin 488 (F-actin, in green), and αSUMO2/3 primary 
antibody (red).  (A) Distal lateral lobe, (B) proximal-lateral lobes, and median 
lobe stained for SUMO expression (circled). Arrows indicate likely fat bodies. 
Images were taken on a Zeiss LSM 880 microscope with 40X oil-immersion 
objective and are representative n=≥3. Scale bar represents 20 µm. 
 
A B 
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5.2.2.3. AaSUMO is expressed in the gut 
The gut acts as the first site of arboviral infection in Ae. aegypti, and therefore 
acts as a prominent antiviral barrier to incoming arboviruses. Within the gut, 
SUMO appears to be predominantly localised to the nuclei of cells (Figure 5.4). 
Without cell specific markers it is impossible to be certain which cells of the 
midgut are being stained, however, they are likely to be a combination of stem 
cells, enteroendocrine cells, and enterocytes.  
 
 
  
Figure 5.4 SUMO expression in the Ae. aegypti gut by confocal 
microscopy 
The gut was extracted from adult female Ae. aegypti and stained 
with DAPI (nuclei, in blue), phalloidin 488 (F-actin, in green), and 
αSUMO2/3 primary antibody (red).  A combination of stem cells, 
enteroendocrine cells, and enterocytes are shown and likely 
examples are indicated, with SUMO predominantly localised to 
the nucleus. Images were taken on a Zeiss LSM 880 microscope 
with 40X oil-immersion objective and are representative of n=≥3. 
Scale bar represents 20 µm. 
Enteroendocrine 
cells 
Enterocytes  
Stem cells 
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5.2.2.4. AaSUMO is expressed in the ovaries 
Upon investigation of Ae. aegypti ovaries, SUMO was found to be expressed in 
differential patterns in different sites. In the oviduct, SUMO is expressed 
predominantly in the nuclei (Figure 5.5A). In the ovarian sheath, SUMO again 
appears to be primarily expressed in the nuclei, the DAPI stained nuclei which 
are not expressing punctate SUMO structures are likely epithelial somatic 
follicular cells, which surround the egg chamber but are located below the 
ovarian sheath (Figure 5.4; Figure 5.5B) (Dr Emilie Pondeville, personal 
communications). Figure 5.5C and Figure 5.5D show the primary vitellogenic 
follicle, and the germarium within an ovariole. Interestingly, within these 
tissues, SUMO expression is primarily cytoplasmic. The most abundant staining 
appears in the cytoplasm of the germarium and secondary follicles. Also within 
the germarium there is further staining of the nuclei of stem germ cells, which 
give rise to new follicles (Nicholson 1921). There is also prominent cytoplasmic 
SUMO expression in the follicular cells surrounding the future oocyte (Figure 
5.5C). Within the nurse cells, there is a build-up of SUMO expression at the 
perinuclear region of the nuclei (arrows), similar to what has previously been 
observed in D. melanogaster ovaries (Hashiyama, Shigenobu et al. 2009). 
Furthermore, SUMO expression within the follicular cells surrounding the primary 
follicle is predominantly cytoplasmic. The differential expression of SUMO in the 
tissues studied here strongly indicates a cellular and tissue specific role for 
SUMO modification in Ae. aegypti.   
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Figure 5.5 Expression of SUMO in Ae. aegypti ovaries  
Ovaries were extracted from adult Ae. aegypti and stained with DAPI (nuclei, in 
blue), phalloidin 488 (F-actin, in green), and αSUMO2/3 primary antibody (red). 
(A) Oviduct, (B) ovarioles encased by the ovarian sheath, (C, D) and ovarioles 
containing the primary vitellogenic follicle (circled in C) and secondary follicle 
and germarium (circled in D). Within the ovaries, SUMO is found predominantly 
localised in the cytoplasm, while in the ovarian sheath, and oviduct SUMO is 
primarily localised in the nuclei. Arrows indicate SUMO signal accumulating in 
the perinuclear region of nurse cells. Images were taken on a Zeiss LSM 880 
microscope with 40X oil-immersion objective and are representative of n=≥3. 
Scale bar represents 20 µm.   
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5.3. Depletion of AaSUMO in vivo does not 
significantly enhance ZIKV replication 
In order to determine the overall effect of AaSUMO during arbovirus replication, 
SUMO mRNA expression was depleted through dsRNA knock down. A negative 
control dsRNA was also produced against the bacterial LacZ. dsRNA was injected 
into 10 female adult Ae. aegypti, which were subsequently harvested and 
assessed for SUMO mRNA expression by q-PCR. Two strains of Ae. aegypti were 
tested for depletion efficiency, Liverpool and Paea strains. A trial dsRNA knock 
down was conducted which resulted in no deaths amongst the mosquitoes 
(Figure 5.6A), and approximately 70% depletion in the Liverpool strain, and 92% 
depletion in the Paea strain (Figure 5.6B; Figure 5.6C). Experiments were 
continued with the Paea strain of Ae. aegypti, as these achieved a better level 
of depletion and are more susceptible to ZIKV infection in vivo (Dr Emilie 
Pondeville, personal communications). Ae. aegypti depleted of SUMO mRNA 
were then infected with ZIKV-nl (Table 2-3). Three biological replicates 
indicated a trend that SUMO mRNA depletion resulted in a greater replication of 
ZIKV, but the phenotype was not statistically significant (P=0.7969). This is likely 
due to the overall variance of ZIKV-nl in the mosquito population (Figure 5.7A), 
discussed further in Section 5.6.  
To determine if there was a correlation between the samples expressing high or 
low levels of luciferase and SUMO mRNA depletion, three individual mosquitoes 
with the highest luciferase expression, and the three with the lowest luciferase 
expression from each replicate were combined and assessed. The dsSUMO 
treated samples (blue) had consistently lower SUMO mRNA expression by q-PCR 
than the dsLacZ control (brown) treated samples (Figure 5.7B). Notably, there 
was a wide variation in the basal expression of SUMO mRNA within the dsLacZ 
treated samples, indicating that SUMO mRNA expression varies between 
individuals. Analysis was also conducted on ZIKV RNA to ensure that the samples 
expressing high or low levels of luciferase correlated with levels of viral RNA 
replication. The samples with high concentrations of luciferase expression 
consistently had higher levels of viral RNA, compared to the samples expressing 
low concentrations of luciferase, indicating that the luciferase expression was an 
accurate indicator of viral replication (Figure 5.7C).  
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As stated, there appears to be a large degree of variation between SUMO 
expression between individual mosquitoes (Figure 5.7B). There are also other 
variables to consider within individuals treated with dsRNA, including the 
variation between which tissues are depleted of SUMO mRNA and which tissues 
are amplifying the arbovirus at the time point of harvest. For instance, if the 
dsRNA is targeting SUMO mRNA in the ovaries, salivary glands, and fat bodies, 
but haemocytes are the primary amplifying cell type, then any effect of SUMO 
depletion may be diminished (Xi, Ramirez et al. 2008, Ramirez, Souza-Neto et 
al. 2012, Carissimo, Pondeville et al. 2015).  
As a consequence of the difficulty in controlling these variables in vivo, in vitro 
depletion studies were performed to directly assess the influence of SUMOylation 
on arbovirus replication. This approach enabled a greater range of arboviruses to 
be tested, and a greater selection of components in the SUMOylation pathway to 
be analysed for their respective biological phenotype.  
  
S Stokes, 2018  227 
 
Figure 5.6 SUMO transcript expression levels achieved by q-PCR after 
dsRNA knockdown 
(A) Survival rates of 10 female Ae. aegypti Liverpool or Paea strain 
mosquitoes treated with dsRNA to target SUMO or LacZ (negative control). 
(B) Ae. aegypti (Liverpool) SUMO mRNA levels were determined by SYBR 
Green q-PCR. Values were normalised to ribosomal S7 using ΔΔCT and 
expressed relative to the normalised levels in the LacZ treated wells. 
Results represent RQ mean with RQ Min/Max shown. (C) Ae. aegypti (Paea) 
SUMO mRNA levels were determined by SYBR Green q-PCR by Floriane 
Almire. Values were normalised to ribosomal S7 using Standard Curve, and 
expressed relative to the normalised levels in the LacZ treated wells. 
Results represent RQ mean. All graphs produced with GraphPad Prism 7.02 
(n=1). 
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Figure 5.7 Effect of knocking down SUMO expression on ZIKV replication in 
Ae. aegypti mosquitoes 
Female Ae. aegypti mosquitoes were treated with dsRNA to SUMO or LacZ and 
fed blood containing 1.04x107 pfu/ml ZIKV-nl, supplemented with 2 mM ATP. 
Mosquitoes which fed were isolated and harvested for analysis 7 days post blood 
feeding. (A) Nano-Luciferase readings were analysed by a luminometer, and 
readings are indicated. Black lines show the medians; blue lines represent 
individual data points, lengths are proportional to frequency of occurrence; 
polygons represent the estimated density of the data. Mann-Whitney U 
statistical test was conducted on >100 mosquitoes from three independent 
experiments. (B) Samples expressing the three highest and three lowest 
luciferase readings were combined from the dsLacZ and dsSUMO treated 
conditions from each biological replicate were assessed for levels of depletion 
by SYBR Green q-PCR by Floriane Almire. RQ values indicated as individual 
points, the mean and standard deviation are shown. Samples were normalised to 
a dsLacZ treated sample at random. (C) The samples from (B) were assessed for 
relative levels of ZIKV RNA by SYBR Green q-PCR by Floriane Almire. Mean 
calculated from RQ values and standard deviation shown plotted on GraphPad 
Prism 7.02. Samples were normalised to the dsLacZ treated high luciferase 
sample from replicate 3. 
 
C 
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5.4. dsRNA can deplete expression of the 
AaSUMOylation pathway in AF5 cells 
Due to the previously mentioned variables in mosquitoes we cannot control for, 
dsRNA was used to deplete SUMO, Ubc9, and PIAS mRNAs in AF5 cells. AF5 cells 
are a single cell clonal population of Aag2 cells, which are likely derived from 
haemocytes (Barletta, Silva et al. 2012). Haemocytes are known to be an 
amplifying tissue for arboviral replication and to express SUMO (Franz, Kantor et 
al. 2015) (Figure 5.1; Figure 5.2). Samples were treated with the desired dsRNA 
for 72 hours, followed by a 48 hour infection with an arbovirus encoding a 
luciferase protein at a low MOI (0.05 pfu/cell). Samples were subsequently 
harvested either for q-PCR or luciferase analysis. Q-PCR analysis confirmed that 
the mRNA transcripts were consistently depleted by 72% – 82% for the different 
mRNAs of interest by 72 hours post transfection (Figure 5.8A). One sample was 
taken to assess the effect of dsRNA treatment on SUMO and Ubc9 expression by 
Western blot. This demonstrated that there were fewer HMW SUMO conjugates 
in the samples treated with dsRNA to SUMO, Ubc9, or PIAS relative to the non-
target control. Ubc9 did not appear to decrease in concentration by Western 
blot (Figure 5.8B).  
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Figure 5.8 Depletion of the AaSUMOylation pathway by q-PCR and Western 
blot 
AF5 cells were treated with dsRNA against the indicated cellular transcripts for 
72 hours, followed by infection for 48 hours at an MOI of 0.05 pfu/cell. (A) Bar 
graph shows mRNA levels of Ago2, SUMO, Ubc9, and PIAS, determined by SYBR 
Green q-PCR. Values were normalised to ribosomal S7 using ΔΔCT and expressed 
relative to the normalised levels in the non-target (LacZ) treated wells. Results 
represent RQ means, with SD bars shown, produced with GraphPad Prism 7.02 
(n=15). (B)  A representative Western blot was conducted to determine the 
effect of RNA depletion on protein expression. Membranes were probed with 
antibodies to SUMO2/3, Ubc9, or Actin as a loading control. Molecular mass 
markers are shown 
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5.5. Interaction of the AaSUMOylation pathway 
and arboviruses in vitro  
AF5 cells were treated with dsRNA to SUMO, Ubc9, PIAS, Ago2 as a positive 
control, or LacZ as a non-target control. Cells were infected with a virus 
encoding an internal luciferase protein as detailed in Table 2-3. SYBR Green q-
PCR was also conducted to determine if depletion of the SUMO pathway was 
affecting viral translation or viral replication. Luciferase expression and viral 
RNA levels were normalised to the non-target LacZ control. 
 
5.5.1. Depletion of the AaSUMOylation 
pathway enhances replication of BUNV 
In order to assess the effect of the AaSUMOylation pathway on BUNV replication, 
depleted AF5 cells were infected at a low MOI (0.05) with BUNV-nl (Table 2-3). 
Nano-Luciferase readings were taken as five biological repeats, each in 
triplicate. These readings demonstrate that depletion of SUMO, Ubc9, or PIAS 
significantly enhances the replication of BUNV-nl by approximately two- to 
three-fold, on par with the positive control, Ago2 (Figure 5.9A). Q-PCR was 
conducted in parallel on the viral complementary RNA (cRNA). Only depletion of 
Ubc9 resulted in a statistically significant increase in BUNV cRNA levels, with a 
mean increase of approximately 2.2-fold, compared to between 1.2- and 1.6-
fold increases when Ago2, SUMO, or PIAS was depleted (Figure 5.9B). These 
results indicate that depletion of components of the AaSUMOylation pathway 
may be affecting viral transcription and translation differently. Alternatively, 
depletion of SUMO or PIAS may be weakly effecting viral replication, yet the 
depletion still has a significant effect on viral luciferase levels. This would also 
be true for the positive control, Ago2, which may alternatively indicate that the 
q-PCR may not be sensitive enough to detect the changes in viral cRNA levels. 
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Figure 5.9 Effect of depletion of the AaSUMOylation pathway on BUNV replication 
AF5 cells were treated with dsRNA against SUMO, Ubc9, PIAS, Ago2 (positive 
control), or bacterial LacZ (non-target control; Ctrl) for 72 hours. Cells were then 
infected with BUNV-nl (MOI 0.05 pfu/cell) for 48 hours. (A) Samples were harvested 
and assessed for Nano-Luciferase expression, readings were normalised to the non-
target control, triplicate samples were taken, n=5, mean and Standard deviation 
from biological repeats presented. (B) Viral complementary RNA (cRNA) levels were 
assessed by SYBR Green q-PCR. Values were normalised to ribosomal S7 using ΔΔCT 
and expressed relative to the normalised levels in the non-target control. Results 
represent RQ mean, with standard deviation bars shown (n=5). Graphs were 
produced with GraphPad Prism 7.02, two-way ANOVA statistics utilised, ns = not 
significant, ** indicates p=<0.01, **** indicates p= <0.001 
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5.5.2. Depletion of the AaSUMOylation 
pathway enhances replication of SFV 
In order to assess the effect of the AaSUMOylation pathway on SFV replication, 
the depleted AF5 cells were infected at a low MOI (0.05 pfu/cell) with SFV-Ffluc 
(Table 2-3). Firefly-luciferase readings were taken as five biological repeats, 
each in triplicate. These readings demonstrate that depletion of SUMO, and 
especially Ubc9, but not PIAS, significantly enhanced the replication of SFV-
Ffluc. Mean viral luciferase expression increased by two- and five-fold for SUMO 
and Ubc9 depleted cells, respectively, in comparison to the control (Figure 
5.10A). Q-PCR was conducted on the viral RNA levels harvested. Here, q-PCR 
results demonstrated a similar, but more pronounced, phenotype as observed 
with the luciferase readings. Mean viral RNA levels increased by six- and ten-fold 
for SUMO and Ubc9 depleted cells, respectively, compared to the control. This 
demonstrates that depletion of SUMO or Ubc9, but not PIAS significantly 
enhanced replication of SFV-Ffluc (Figure 5.10B). This indicates that 
endogenous Ae. aegypti SUMO and Ubc9 both suppress the replication of SFV, 
while PIAS does not, although it is also possible that the AaPIAS depletion levels 
need to be more thorough to see a significant effect.  
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Figure 5.10 Effect of depletion of the AaSUMOylation pathway on SFV replication 
AF5 cells were treated with dsRNA against SUMO, Ubc9, PIAS, Ago2 (positive 
control), or bacterial LacZ (non-target control; Ctrl) for 72 hours. Cells were then 
infected with SFV-FFluc (MOI of 0.05) for 48 hours. (A) Samples were harvested and 
assessed for Firefly-Luciferase expression, readings were normalised to the non-
target control, triplicate samples were taken, n=5, mean and standard deviation 
from biological repeats presented. (B) Viral RNA levels were assessed by SYBR Green 
q-PCR. Values were normalised to ribosomal S7 using ΔΔCT and expressed relative to 
the normalised levels in the non-target control. Results represent RQ mean, with 
standard deviation bars shown (n=5). Graphs were produced with GraphPad Prism 
7.02, two-way ANOVA statistics utilised, ns indicates not significant, * indicates 
p=<0.05, ** indicates p=<0.01, **** indicates p= <0.001 
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5.5.3. Depletion of the AaSUMOylation 
pathway enhances replication of ZIKV 
When testing the effect of the AaSUMOylation pathway on the replication of 
ZIKV, depleted AF5 cells were infected at a low MOI (0.05 pfu/cell) for 48 hours 
with ZIKV-nl (Table 2-3). Samples were then harvested for q-PCR or luciferase 
analysis. Nano-Luciferase expression demonstrates that depletion of SUMO, 
Ubc9, or PIAS resulted in a small, but consistent, increase in viral replication of 
approximately 1.5-fold (Figure 5.11A). When investigating the viral RNA levels 
by q-PCR, viral RNA levels also increased following depletion of the SUMOylation 
pathway. Interestingly, q-PCR had a higher proportional increase in viral RNA 
than observed by luciferase 1.5-fold up to a three-fold increase in viral RNA 
levels when PIAS was depleted (Figure 5.11B). 
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Figure 5.11 Effect of depletion of the AaSUMOylation pathway on ZIKV replication 
AF5 cells were treated with dsRNA against SUMO, Ubc9, PIAS, Ago2 (positive control), 
or bacterial LacZ (non-target control; Ctrl) for 72 hours. Cells were then infected 
with ZIKV-nl (MOI 0.05 pfu/cell) for 48 hours. (A) Samples were harvested and 
assessed for Nano-Luciferase expression, readings were normalised to the Ctrl, 
triplicate samples were taken, n=5 mean and standard deviation from biological 
repeats presented. (B) viral RNA levels were assessed by SYBR Green q-PCR. Values 
were normalised to ribosomal S7 using ΔΔCT and expressed relative to the normalised 
levels in the non-target control (n=5). Results represent RQ mean, with standard 
deviation bars shown (n=5). Graphs were produced with GraphPad Prism 7.02, two-
way ANOVA statistics utilised, ns = not significant, ** indicates p=<0.01, **** indicates 
p= <0.001 
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5.6. Discussion  
Component enzymes of the SUMOylation pathway are known to be differentially 
expressed in different tissues and organs from a range of species (Bohren, 
Nadkarni et al. 2004, Hu and Chen 2013, Liang, Lee et al. 2016). To date, 
however, little work has been reported in insects. Early studies in D. 
melanogaster indicated that SUMO and Ubc9 were expressed in a variety of 
tissues, although no comparison of relative expression levels have been reported 
(Lehembre, Badenhorst et al. 2000). Experiments by Hu and Chen (2013), in 
Cynoglossus semilaevis indicated that Ubc9 mRNA was expressed to the greatest 
extent in the reproductive organs, followed by the blood cells. According to 
open source data from the Human Protein Atlas 
(https://www.proteinatlas.org/), in H. sapiens, Ubc9 protein is predominantly 
expressed in reproductive organs and tissues involved in the immune system 
(including the lymph nodes and tonsils). SUMO1, SUMO2, and SUMO3 are 
expressed to a relatively high level in tissues involved in the immune system, 
endocrine tissues, reproductive tissues, and adipose tissues (Uhlen, Oksvold et 
al. 2010, Uhlen, Fagerberg et al. 2015). We hypothesised that different organs in 
Ae. aegypti would have different requirements for SUMO modification and 
consequently, tissues would express varying levels of SUMO, Ubc9 and PIAS. 
Collectively, the data presented in this study does correlate with what has been 
previously reported, despite comparing vertebrate to invertebrates. We show 
that the SUMOylation pathway is expressed to the greatest extent in the 
reproductive organs (ovaries) and immune cells (haemocytes), whereas there is a 
relatively low level of SUMO expression in the gut, relative to the carcass 
(Figure 5.1). Consequently, we sought to assess the expression of SUMO in a 
range of Ae. aegypti tissues.  
To our knowledge, there aren’t any studies investigating the expression of 
SUMOylation pathway component proteins in D. melanogaster haemocytes. 
Consequently, comparisons are drawn with H. sapiens cells. In H. sapiens cells, 
SUMO expression is predominantly localised to the nucleus due to the extensive 
SUMO modification of PML-NBs (Kamitani, Nguyen et al. 1998). The staining seen 
in Figure 5.2 displays a similar phenotype to H. sapiens cells, and could indicate 
a PML-like protein expressed in the nuclei that is also extensively SUMO-
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modified. Studies on the expression of SUMO in the salivary glands of D. 
melanogaster found SUMO localised to the nuclei, likely localised to the 
chromosome arms, chromocentre, and chromosome telomere (Nie, Xie et al. 
2009, Bocksberger, Karch et al. 2014). In our microscopy, we cannot confidently 
detect SUMO in the nuclei of salivary gland cells, due to the presence of fat 
bodies (Dr Emilie Pondeville, personal communications; Figure 5.3). However, it 
seems likely that SUMO would localise to the same region of the salivary glands, 
as they are relatively closely related insect species. Further studies would be 
needed to confirm this using specific cellular markers at a higher resolution. To 
our knowledge, no published studies exist investigating the expression of SUMO 
in the midgut of D. melanogaster. In the studies we have conducted, SUMO 
appears to be localised to the nucleus of specific cells (Figure 5.4). Without cell 
specific markers, it is impossible to say with certainty which cells have the 
greatest abundance of SUMO expression. However, due to the location and size 
of the nucleus, cells with the greatest abundance of SUMO expression are 
believed to be enterocytes, enteroendocrine cells, and stem cells (Dr Emilie 
Pondeville, personal communications).  
Studies investigating the expression of SUMO during the development of D. 
melanogaster ovaries found that SUMO was primarily localised to the nuclei of 
the germ cells. After the ovaries had developed primary vitellogenic follicles, 
SUMO staining was predominantly localised to the nuclei of oocytes and also 
found at the perinuclear region of the nurse cells (Hashiyama, Shigenobu et al. 
2009). In our samples, Ae. aegypti SUMO is primarily expressed in the cytoplasm 
of the ovarioles, although there is a similar accumulation of SUMO expression at 
the perinuclear region of the nurse cells and oocyte (Figure 5.5). There is also 
extensive cytoplasmic SUMO expression in the follicular cells, similar to what has 
previously been observed in D. melanogaster. The most predominant SUMO 
expression appears to be localised to the cytoplasm of the germarium, which 
were not analysed in D. melanogaster. The expression pattern of SUMO in Ae. 
aegypti ovaries strongly suggests that there is a shared biological function during 
egg development as in D. melanogaster. Previous studies have demonstrated 
that within D. melanogaster Ftz-f1, a nuclear receptor involved in lipid uptake, 
is only expressed in the presence of SUMO, and Ftz-f1 is itself a substrate of 
SUMO modification. Furthermore, Ftz-f1 has also been shown to be expressed in 
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the ovaries of Ae. aegypti, indicating that Ftz-f1 could be a substrate of SUMO 
modification in Ae. aegypti ovaries, although studies would be required to 
confirm this (Zhu, Chen et al. 2003, Talamillo, Herboso et al. 2013).  
Some genes which alter in expression include genes involved in the antiviral 
immune response. For instance, 14-3-3ε, has been shown to be upregulated 
following a blood meal, 14-3-3ε is also a known target of SUMO modification in 
D. melanogaster (Bottino-Rojas, Talyuli et al. 2015, Handu, Kaduskar et al. 
2015). Due to the known regulation of cellular immunity by SUMO in other 
species, it was hypothesised that SUMO modification could influence the 
replication of arboviruses in Ae. aegypti. Initially, these studies were attempted 
in vivo. However, while we were able to detect a trend that ZIKV replication 
increased following treatment with dsRNA, the trend was not statistically 
significant. Previous studies have encountered similar problems with not being 
able to detect a significant effect in vivo (Troupin, Londono-Renteria et al. 
2016). This is potentially due to the virus upregulating the gene expression in 
vivo but not in vitro, or effect of the larger number of variables that are 
challenging to control or account for. For instance, as the dsRNA is injected into 
Ae. aegypti it is impossible to say which cells and tissues were depleted of SUMO 
to the greatest extent. As the midgut acts as the first site of arboviral 
replication in the mosquito, a greater depletion in the midgut may result in a 
more pronounced phenotype, compared to a greater depletion achieved in the 
salivary glands. This could be the case even if the overall level of SUMO mRNA 
appears to be depleted to a similar extent (Figure 5.6). Furthermore, the range 
of SUMO mRNA expression in the dsLacZ treated samples also indicates that the 
basal level of SUMO significantly varies between individual populations or 
individuals within the population of mosquitoes (Figure 5.7B). Consequently, 
there is no way of knowing which individuals in the control population may have 
more or less SUMO expression prior to infection, which may distort the statistical 
analysis of results.  
The difficulty in controlling the variables in adult Ae. aegypti led to a greater 
emphasis on in vitro depletion and infection work. This also enabled other 
components of the AaSUMOylation pathway to be examined for any effect on 
arboviral replication of SFV, BUNV, or ZIKV. Following successful depletion of 
S Stokes, 2018  242 
AaSUMO, AaUbc9, or AaPIAS, we show that depletion of the AaSUMOylation 
pathway results in a significant increase in the expression of BUNV luciferase and 
RNA expression (Figure 5.8; Figure 5.9). Depletion of AaSUMO and AaUbc9 also 
resulted in a significant increase in the replication of SFV (Figure 5.10). 
Interestingly, AaPIAS depletion did not enhance replication of SFV, which 
indicates a virus specific role for AaPIAS in suppressing arbovirus replication, 
although this could be due to the depletion not being effective enough for a 
phenotype to be observed with SFV. Alternatively, it could indicate that some 
substrates for SUMO modification do not require PIAS to enhance the rate of 
conjugation, or it could indicate that SUMO and Ubc9 are suppressing SFV 
replication independent of SUMO conjugation. When ZIKV was infected in cells 
depleted of AaSUMO, AaUbc9, or AaPIAS, ZIKV replication was significantly 
enhanced (Figure 5.11). 
Due to potential differences in the protein half-life of AaSUMO, AaUbc9, or 
AaPIAS, we cannot say what levels of protein depletion were achieved for 
AaPIAS, as we do not possess an antibody which cross reacts with AaPIAS. By 
Western blot AaUbc9 does not appear to be depleted (Figure 5.8B), this is likely 
due to protein stability, as the mRNA levels have been depleted by ~70%. 
Furthermore, as a Western blot for SUMO was only conducted at the end of the 
experiment, after harvesting, it is unknown how efficiently AaSUMO protein was 
depleted from cells.    
Time limitations resulted in the mechanism of action not being determined. 
However, in D. melanogaster SUMO is well-known to modify proteins involved in 
cellular immunity, including 14-3-3ε, the Imd protein, Casp, STAT92E, or Hop  
(Bhaskar, Smith et al. 2002, Gronholm, Ungureanu et al. 2010, Handu, Kaduskar 
et al. 2015). Furthermore, previous studies in Ae. aegypti which depleted the 
expression of PIAS suggested that mosquitoes became more resistant to DENV 
infection. Five antimicrobial peptides (four Cecropin A-like genes and one 
Defensin 1-like gene), were found to be down-regulated in mosquito cell cultures 
which had JAK-STAT activated (by depleting PIAS expression) (Souza-Neto, Sim 
et al. 2009). The study by Souza-Neto, Sim et al. (2009) implicates a broad role 
for the JAK-STAT pathway in suppressing DENV replication, although they do not 
examine the possibility that PIAS is also acting as a SUMO E3 ligase on separate 
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immune proteins, as other antimicrobial peptides could be up-regulated when 
PIAS was endogenously expressed.  
These results support the hypothesis that SUMO is differentially expressed in the 
Ae. aegypti tissues that we investigated. This is likely due to proteins expressed 
in specific tissues possessing different requirements for SUMO modification. 
AaSUMOylation pathway expression is broadly in line with what has previously 
been reported in H. sapiens and D. melanogaster. Furthermore, due to differing 
effects from depletion of the AaSUMOylation pathway on the arboviruses 
studied, the AaSUMOylation pathway is capable of suppressing the replication of 
BUNV, SFV, and ZIKV, in a virus specific manner.  
The underlying mechanism of suppression is not clear, and requires further 
investigation. Infected cell lysate was analysed by mass spectrometry (data not 
shown), however this proved unsuccessful in identifying any SUMO modified viral 
proteins. It was also unable to identify cellular substrates of SUMO modification 
that had changed in response to infection. Time constraints meant that this 
experiment was not repeated or optimised further, but future work could 
optimise this experiment to attempt to identify a mechanism of suppression. 
Experiments, such as cell viability assays, should be conducted to confirm cell 
health following depletion of the SUMOylation pathway. Further studies would 
also be required to determine if the SUMOylation pathway was having positive 
and negative roles at different stages of arbovirus replication, rather than just 
determine an overall phenotypic effect. If there was a pro-viral effect at any 
stage of the virus replication cycle, it could open opportunities for small 
molecule inhibitors to be developed. Other arboviruses and other vectors could 
also be studied to determine if the SUMOylation pathway has a broad antiviral 
effect on all arboviruses in their vector species. Future studies could also 
investigate the expression of SUMO in Ae. aegypti tissues following a blood meal. 
In vivo, the expression of proteins and the structure of tissue are well known to 
change following a blood meal; it would therefore be interesting to determine if 
SUMO expression also changes (Perrone and Spielman 1988, Kato, Dasgupta et al. 
2002, Sodja, Fujioka et al. 2007). Finally, repeating the in vivo depletion studies 
and assessing how effective the depletion, along with viral levels in different 
S Stokes, 2018  244 
tissues could indicate a statistically significant, or tissue specific role for SUMO 
modification in arbovirus replication.  
Collectively, the data presented here suggests that the SUMOylation pathway 
acts to suppress arbovirus replication. As no substrates were identified, we 
cannot say for certain if the suppression is due to SUMO modification of target 
proteins, or if the constituent proteins are interacting with the viral proteins 
through novel mechanisms. Although, as depletion of any component of the 
AaSUMOylation pathway results in a significant increase in BUNV and ZIKV 
replication, it seems likely that SUMO conjugation, requiring the entire pathway, 
is suppressing replication of these viruses.  
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6. HsSUMOylation 
pathway suppresses 
arbovirus expression 
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6.1. Overview 
Published studies examining the role of host SUMOylation during arbovirus 
infection have focused on the influence of the HsSUMOylation pathway during 
DENV infection, which found opposing roles for the HsSUMOylation pathway. 
Chiu, Shih et al. (2007) found that over expression of Ubc9 had an antiviral 
effect on the replication of DENV, due to Ubc9 interacting with the E protein, 
potentially through Lys51 and Lys241 suggesting that Ubc9 was antiviral. This was 
supported by a recent study which used siRNAs to deplete expression of Ubc9 
and found an increase in DENV viral RNA (Feng, Deng et al. 2018). Su, Tseng et 
al. (2016) however, conducted studies which used stably tranfected shRNAs to 
deplete expression of Ubc9, and found a decrease in DENV replication, 
suggesting a proviral effect of endogenous Ubc9. The mechanism they 
characterised indicated that SUMO2/3 modified the N-terminal of DENV capsid 
protein, promoting its stability and enhancing replication. Consequently, it is 
still unclear if SUMO conjugation has an overall proviral or antiviral role during 
flavivirus infection in H. sapiens cells. Furthermore, nothing is known about the 
influence of the HsSUMOylation pathway on arboviruses from other viral families.  
This chapter aims to determine if the HsSUMOylation pathway is capable of 
influencing the replication of alphaviruses, flaviviruses, and orthobunyaviruses. 
A depletion system was utilised as for Ae. aegypti cells (Section 5.4) to 
determine the effect of the HsSUMOylation pathway during arboviral replication. 
An immortalised Human fibroblast cell line (HFt) was utilised in these studies, as 
arboviruses are known to initially amplify in fibroblast cells at the inoculation 
site (Vogel, Kell et al. 2005). Furthermore, HFt’s are known to possess a 
competent immune response to viral infection (Smith, Goddard et al. 2013). 
SUMO1, SUMO2/3, and PIAS1 mRNA was targeted for depletion by lentiviral 
transduction and expression of targeted or non-targeting (control) short hairpin 
RNAs (shRNA). Utilisation of shRNA expressing lentiviruses is a well-established 
approach for targeting host SUMOylation proteins in human fibroblast cells 
(Brown, Conn et al. 2016, Conn, Wasson et al. 2016, Alandijany, Roberts et al. 
2018). Viral luciferase assays were conducted as described in Section 5.5. In cell 
Western blot assays (ICWB) were conducted to monitor the initiation and 
development of ZIKV infection. ICWB has the advantage of being readily 
S Stokes, 2018  247 
quantifiable due to the use of near-infrared probes, more reproducible, and 
quicker than Western blots (Aguilar, Zielnik et al. 2010, Hoffman, Moerke et al. 
2010). Cell stains can be utilised as a loading control to ensure a similar number 
of cells are present for each depleted cell line. ICWBs have also been used 
previously to determine the effect of depletion on viral plaque numbers (Sklan, 
Staschke et al. 2007).  
 
6.2. Lentiviral transduction with shRNAs depletes 
expression of components of the SUMOylation 
pathway in HFt cells 
Previous studies have utilised shRNA to target host mRNAs which decrease 
expression of components of the HsSUMOylation pathway to determine the 
effect of that protein, either direct or indirect, on viral replication (Brown, Conn 
et al. 2016, Conn, Wasson et al. 2016, Su, Tseng et al. 2016). Only the study by 
Su, Tseng et al. (2016) utilises shRNAs targeting Ubc9 (also known as UBE2I) to 
determine the effect on DENV2 replication. Their study was conducted in 
alveolar adenocarcinoma (A549) cells. 
Here, diploid HFt cells were stably transduced with lentiviruses expressing 
shRNAs targeting SUMO1, SUMO2/3, or PIAS1 (shSUMO1, shSUMO2/3, or shPIAS1, 
respectively). To ensure lentiviral transduction was not affecting the phenotype, 
parallel HFt cells were transduced with lentiviruses containing a non-targeting 
shRNA (shCtrl). At passage 3, samples were validated for mRNA abundance and 
protein expression by q-PCR and Western blot, respectively (Figure 6.1A; Figure 
6.1B; Figure 6.1C; Figure 6.1D). All subsequent viral experiments were 
conducted on cells at passage 3 or 4 to ensure cells maintained a similar level of 
depletion over the course of the study. Q-PCR demonstrates that there is a 
reduced amount of targeted mRNA remaining. A total of 96% depletion was 
achieved when SUMO1 was depleted relative to the shCtrl sample, while 80% and 
79% depletion was achieved when SUMO2/3 or PIAS1 were depleted. Western 
blot also indicates that expression of all the proteins was reduced compared to 
the shCtrl sample. 
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Figure 6.1 Depletion of SUMOylation pathway from HFt cells 
HFt cells were transduced with lentivirus vectors expressing short-hairpin RNA 
(shRNA) targeting SUMO1 (shSUMO1), SUMO2/3 (shSUMO2/3), PIAS1 (shPIAS1), or 
a non-target control (shCtrl). (A) Bar graph shows mRNA levels of SUMO1, 
SUMO2/3, and PIAS1 in the stably transduced lentivirus cell lines. Levels of mRNA 
were determined using TaqMan system of qPCR. Values were normalised to 
GAPDH mRNA as an endogenous control using cycle threshold (ΔΔCT), and 
expressed relative to shCtrl. Results represent the mean of three relative 
quantitation (RQ) plus standard deviation. Western blot for expression of (B) 
SUMO1, (C) SUMO2/3, (D) and PIAS1, with a loading control (lower blot) from 
whole cell lysates. Membranes were probed with antibodies to SUMO1, SUMO2/3, 
or PIAS1 to determine level of protein depletion, and antibodies to Actin as the 
loading control. Molecular weights indicated.  
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6.3. Depletion of components of the 
HsSUMOylation pathway enhances arbovirus 
expression in vitro 
As depletion of the AaSUMOylation pathway increased the replication of BUNV, 
SFV, or ZIKV, it was hypothesised that the HsSUMOylation pathway would also 
influence arbovirus replication, as this pathway is well conserved. To assess the 
effect of the HsSUMOylation pathway on arbovirus replication, three parallel cell 
lines depleted of SUMO1, SUMO2/3, and PIAS1 were infected with arboviruses 
containing a luciferase reporter protein at a range of MOIs (0.5, 0.1, and 0.05) 
for 24 hours (SFV) or 48 hours (ZIKV and BUNV). Luciferase readings were taken 
over three biological repeats. When the cells were infected with BUNV-nl, 
luciferase expression increased significantly in cell lines depleted of SUMO1 or 
PIAS1 (Figure 6.2A). Interestingly, upon infection of the cells with SFV-Ffluc, 
neither SUMO1 nor SUMO2/3 depletion had a significant effect on Ffluc 
expression. However, depletion of PIAS1 led to a significant 8.4-fold increase in 
Ffluc expression (Figure 6.2B).  
Studies of the flavivirus DENV, in H. sapiens cells have found contradictory roles 
for the HsSUMOylation pathway (Chiu, Shih et al. 2007, Su, Tseng et al. 2016, 
Feng, Deng et al. 2018). ZIKV, another flavivirus, was shown to be suppressed by 
the AaSUMOylation pathway (Section 5.5.3). It was therefore hypothesised that 
the HsSUMOylation pathway would also influence ZIKV replication. Consequently, 
using H. sapiens HFt cells depleted of SUMO1, SUMO2/3, or PIAS1, the effect of 
the HsSUMOylation pathway on ZIKV was determined. Luciferase assays of ZIKV-
nl expression in cells depleted of PIAS1 resulted in a significant; approximately 
five fold, increase in luciferase expression (Figure 6.2C). This phenotype was 
corroborated by an ICWB conducted which showed more plaques forming in cells 
depleted of PIAS1 compared to the shCtrl treated cells (Figure 6.2D). Average 
plaque forming efficiency (PFE) experiments from ICWBs indicated that SUMO1 
depleted cells have two plaques while PIAS1 depleted cells have approximately 
six plaques, while infected shCtrl cell monolayers didn’t produce any plaques 
(Figure 6.2E). PFE and luciferase analysis on the effect of SUMO2/3 depletion on 
ZIKV expression shows no statistically significant effect. Although, luciferase 
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assays indicate that ZIKV expression in cells depleted of SUMO2/3 is lower than 
control cells (Figure 6.2C).  
Collectively, these results indicate that the HsSUMOylation pathway is capable of 
suppressing arbovirus replication. This predominantly occurs through the actions 
of HsPIAS1. Depletion of PIAS1 results in a significant increase in the luciferase 
expression of all arboviruses studied here. This could be due to a shared 
mechanism, or through a mechanism which is specific to each arbovirus. 
Furthermore, depletion of SUMO1, but not SUMO2/3, suppresses the replication 
of BUNV, which shows that a target protein needs to be modified specifically by 
SUMO1. Due to time limitations these observations could not be pursued further.  
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Figure 6.2 Effect of depletion of the HsSUMOylation pathway on arbovirus 
expression 
Cells were transduced with lentiviruses targeting SUMO1, SUMO2/3, PIAS1 mRNA, 
or a non-target control (Ctrl). Cells were infected with either BUNV expressing a 
Nano-Luciferase reporter (BUNV-nl), SFV expressing a Firefly Luciferase reporter 
(SFV-Ffluc), a clinical strain of ZIKV (ZIKV-wt), or ZIKV expressing a Nano-
Luciferase reporter (ZIKV-nl). Infections occurred at a MOI of 0.5, 0.1, or 0.05 for 
48 hours (BUNV and ZIKV) or 24 hours (SFV) before the samples were harvested. 
(A) BUNV-nl, (B) SFV-Ffluc and (C) ZIKV-nl readings were normalised to the Ctrl 
samples, and the mean of five technical repeats was taken and plotted for each of 
the three biological replicates on a Log2 graph. Statistics were conducted on 
GraphPad Prism 7.02 using a 2-way ANOVA, ns indicates not significant; * = p≤0.05, 
**** = p≤0.001. (D) ICWB of cells depleted of the SUMOylation pathway and either 
mock infected, or infected with ZIKV-wt at an MOI of 0.5. Upon harvesting, cells 
were fixed and probed with antibodies against ZIKV NS3-protein (green) and 
CellTag 700 stain was included as a loading control (red). N=2. (E) The number of 
plaques produced in (D) was counted, and plotted in Graphpad Prism 7.02 showing 
the mean number of plaques and standard deviation. N=2. 
E 
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6.4.  Discussion 
The HsSUMOylation pathway has previously been shown to positively or 
negatively influence viral replication for a range of viruses (reviewed in Wilson 
(2012), Lowrey, Cramblet et al. (2017)). This may occur through direct 
modification of the viral proteins, or as a consequence of modifying other 
cellular proteins, for instance transcription factors. Previous studies indicate 
that the SUMOylation pathway has a proviral and antiviral effect on DENV 
replication. However, both of these studies interpreted the effect of 
SUMOylation based on Ubc9 (overexpression or depletion), and neither of these 
studies looked at other arboviruses. Consequently, our knowledge is limited as to 
the overall relevance of SUMOylation in the replication of arboviruses in human 
cells. Given that our previous data indicates that the AaSUMOylation pathway 
can influence arbovirus replication from different arboviral families, and that 
the SUMOylation pathways are well conserved (Section 3.2; Section 5.5), we 
hypothesised that the HsSUMOylation pathway should also influence the 
replication of these arboviruses. 
This hypothesis was tested through the depletion of SUMO1, SUMO2/3, and PIAS1 
from HFt cells, an immortalised H. sapiens fibroblast cell line which possesses a 
competent innate immune response (Smith, Goddard et al. 2013, Alandijany, 
Roberts et al. 2018). Depletion levels ranged from ~95% for SUMO1, to ~80% for 
SUMO2/3 or PIAS1 (Figure 6.1). When cells depleted of components of the 
SUMOylation pathway were infected with BUNV-nl, SUMO1 and PIAS1 depletion 
both appeared to significantly increase the luciferase expression. When PIAS1 
was depleted, luciferase expression increased by two-fold, and when SUMO1 was 
depleted luciferase expression increased by four-fold (Figure 6.2A). Firefly-
Luciferase data indicates that PIAS1 depletion also significantly enhances the 
expression of SFV, while depletion of SUMO1 and SUMO2/3 had no significant 
effect (Figure 6.2B). By luciferase analysis, cells infected with ZIKV after being 
depleted of PIAS1 experienced a significant increase in luciferase expression 
(Figure 6.2C). A similar phenotype is demonstrated by ICWB, as more plaques 
are visible in cells depleted of PIAS compared to the control (Figure 6.2D). 
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This work correlates with work by Guo, Chen et al. (2017), which found that 
replication of the flavivirus HCV was restricted by PIAS2. PIAS2 was found to 
reduce HCV core, NS3, and NS5A levels through the proteasome pathway (Guo, 
Chen et al. 2017). Furthermore, studies on PIAS1 and PIAS4 with Herpes Simplex 
Virus-1 (HSV-1) found that HSV-1 is also restricted by the PIAS1 and PIAS4 
homologues (Brown, Conn et al. 2016, Conn, Wasson et al. 2016). Together, 
these studies indicate an antiviral role for the PIAS family of proteins 
independent of its role as an inhibitor of activated STAT, and negative regulator 
of innate immunity.  
Furthermore, previous studies by Su, Tseng et al. (2016), suggest that SUMO 
modification of DENV NS5 increases protein stability, and therefore is proviral. 
The studies by Su, Tseng et al. (2016) were conducted by depleting Ubc9 
expression. The experiments conducted here depleted expression of SUMO1 or 
SUMO2/3, and while the luciferase readings when SUMO2/3 was depleted were 
consistently lower than the non-target control sample (Figure 6.2C), the effect 
was not statistically significant. This could be due to a number of reasons, for 
instance the ~20% mRNA expression remaining in the SUMO2/3 depleted cells, 
may be enough to protect the viral protein from degradation. Alternatively, 
SUMO2/3 has previously been reported to be able to substitute for loss of SUMO1 
function in the development of mice, consequently it is possible that in this 
assay SUMO1 is substituting for loss of SUMO2/3 (Zhang, Mikkonen et al. 2008). 
Furthermore, cells are known to possess a supply of unconjugated SUMO, 
therefore depletion levels need to be extensive enough to reduce both the 
supply of unconjugated SUMO and HMW SUMO conjugates. If depletion levels are 
not extensive enough, a biological phenotype of SUMO2/3 in arboviral infection 
may be missed. Other previous reports have utilised overexpression, or depletion 
of Ubc9 to implicate Ubc9 in being antiviral against DENV (Chiu, Shih et al. 2007, 
Feng, Deng et al. 2018). In order to confirm the validity of either previous study, 
future work would need a greater depletion of the individual SUMO homologues, 
Ubc9, and could include the activating enzyme, SAE1/2, to determine if it is the 
SUMO modification, or interaction with Ubc9 which is producing the pro- or anti-
viral phenotype.  
S Stokes, 2018  257 
Further ICWB analysis was attempted for lentivirus-sh depleted cells which were 
infected with SFV-eGFP, or a wild type BUNV (data not shown). During this 
analysis all infections were left for 48 hours, this resulted in ZIKV plaques being 
visible, but small. It is likely that if the ZIKV infected cells were left for longer 
more plaques would be visible. Conversely, cultures infected with SFV-eGFP 
were lysed by the end of the infection period. Depleted cell cultures infected 
with BUNV did produce readily detectable plaques; however there was not a 
noticeable difference between the shCtrl and other treated cells, which would 
make drawing comparisons difficult.  
Collectively, these data indicate that the HsSUMOylation pathway is capable of 
suppressing the replication of a range of arboviruses. SUMO1 depletion 
significantly enhanced BUNV luciferase expression, while PIAS1 appears to have a 
wide ranging antiviral effect which is capable of suppressing BUNV, SFV, and 
ZIKV. Due to time limitations, the studies here are primarily relying on luciferase 
expression to infer replication, and consequently further studies investigating 
viral RNA are required to confirm these phenotypes alter viral replication. Other 
studies, such as mass spectrometry analysis to identify SUMO substrates and 
introducing lysine mutations, would also be required to decipher the underlying 
mechanism of action.  
  
S Stokes, 2018  258 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Discussion 
  
S Stokes, 2018  259 
7.1. Overview 
This thesis had three initial objectives: to determine the homology between the 
Ae. aegypti and H. sapiens SUMOylation pathways; to characterise the 
biochemical properties of the Ae. aegypti SUMOylation pathway; and to 
determine if the SUMOylation pathway affected the replication of Semliki Forest 
Virus, Bunyamwera virus, or Zika virus within the transmitting vector species Ae. 
aegypti. Bioinformatic analysis indicated that the Ae. aegypti and H. sapiens 
SUMOylation pathways were well conserved. The biochemical properties of the 
AaSUMOylation pathway demonstrated that there was significant overlap 
between homologous proteins of both species, to the extent that the 
AaSUMOylation proteins were biochemically interchangeable with the 
HsSUMOylation pathway. Furthermore, this analysis indicated that AaSUMO 
required a catalytically active AaPIAS in order to efficiently form poly-SUMO 
chains. Finally, it was identified that components of the Ae. aegypti and H. 
sapiens SUMOylation pathways can suppress arbovirus replication in an arbovirus 
dependent manner.  
 
7.2. Conservation of the sequence, structure, 
biochemical function, and expression of the Aa- 
and Hs-SUMOylation pathways  
The SUMOylation pathway is known to be important for a wide array of 
important biological processes throughout the cell, including cellular immunity, 
cell cycle progression, and the cell stress response. Consequently, SUMO 
modification is known to be well conserved between various species, including 
H. sapiens, D. melanogaster, and S. cerevisiae (Matunis, Coutavas et al. 1996, 
Lehembre, Badenhorst et al. 2000). Our mass spectrometry analysis of Ae. 
aegypti cell culture demonstrates that SUMO, along with the constituent 
proteins of the SUMOylation pathway are expressed (Table 3-1). Bioinformatics 
and computational modelling show that the amino acid sequence and tertiary 
structure of SUMO, the E2 conjugating enzyme (Ubc9), and activating 
heterodimer (SAE1/2), were well conserved (Figure 3.2; Figure 3.3).  
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There is only one known PIAS in Ae. aegypti,  in contrast to five known HsPIAS 
homologues. The HsPIAS homologues can have different functions in the cell, as 
they are able to act as a ligase for SUMO conjugation on specific target proteins 
(Chung, Liao et al. 1997, Liu, Liao et al. 1998, Reindle, Belichenko et al. 2006). 
As there is only one AaPIAS, it seems likely that there is not the same degree of 
E3-target protein specificity. More work has been conducted on AaPIAS, than 
AaSUMO, AaUbc9, or AaSAE1/2, because of the biological homology of PIAS as an 
inhibitor of activated STAT. Previous studies have mapped the biologically 
functional domains of AaPIAS, which identified the SP-RING domain, along with 
the SAP, PINIT, and S/T variable domains (Zou, Souza-Neto et al. 2011). Our 
work has also identified the SP-RING domain of AaPIAS to be conserved, and 
found that AaPIAS possessed a conserved tertiary structure, even though the 
amino acid sequence identity was only between 32% - 37% (Figure 3.4). Previous 
studies have also investigated the function of AaPIAS as an inhibitor of the Ae. 
aegypti JAK-STAT pathway, and found that depletion of PIAS activated the JAK-
STAT signalling, demonstrating a conserved biological function for PIAS in Ae. 
aegypti and H. sapiens. The greatest variation in biochemical activity came from 
the SUMO homologue. Although the amino acid sequence and predicted tertiary 
structure of SUMO is well conserved with HsSUMO3, AaSUMO lacks the SCM in the 
N-terminus of SUMO (Figure 3.1). As a consequence, AaSUMO functions 
biochemically more similarly to HsSUMO1. This aligns with previous reports, 
which found that most eukaryotic organisms express both SUMO1 and a SUMO2/3 
paralogue. Insects, however, do not possess a SUMO1 paralogue, and the 
SUMO2/3 paralogue(s) lack the SCM (Choy, Severo et al. 2013, Urena, Pirone et 
al. 2016). This suggests that insect SUMO does not have the ability to efficiently 
form poly-SUMO chains without the presence of an E3 ligase, indicating an extra 
degree of regulation in insects. 
The biochemical function of the homologous SUMOylation pathways is well 
conserved. The recombinant proteins are biochemically similar enough that they 
can substitute one another. HsSAE1/2 and HsUbc9 can activate and conjugate 
AaSUMO to form HMW SUMO conjugates (Figure 4.9). AaSAE1/2 can also activate 
HsSUMO2, and AaUbc9 is capable of conjugating HsSUMO2 into HMW SUMO 
conjugates, to form poly-SUMO chains (Figure 4.10; Figure 4.11). These 
demonstrated that the biochemical properties of the SUMOylation pathways are 
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well conserved and function interchangeably. These studies were only 
undertaken to determine if the biochemical properties were conserved, 
consequently there is a low number of replicates. For these experiments, the 
analysis was conducted by Coomassie staining of SDS-PAGE gels. This has the 
advantage of being able to observe the relative abundance of all proteins within 
reaction mixtures. However, care must be taken to ensure the protein which is 
being observed is the protein of interest. Throughout this study, no work was 
conducted on Ae. aegypti deSUMOylating enzymes (SENPs), further studies are 
required to determine the structure, biological function, organ  localisation, and 
number of AaSENP homologues. 
The expression pattern of SUMO throughout Ae. aegypti also indicates a 
conserved pattern of expression between species. Analysis of the open source 
Human Protein Atlas (https://www.proteinatlas.org/), and studies on the fish 
species Cynoglossus semilaevis, also indicate that the SUMO homologues and 
Ubc9 are abundantly expressed in the reproductive organs and immune related 
organs (Uhlen, Oksvold et al. 2010, Hu and Chen 2013, Uhlen, Fagerberg et al. 
2015). Our data also shows that the AaSUMOylation pathway is primarily 
expressed within the reproductive tissues and the haemocytes of adult female 
Ae. aegypti (Figure 5.1). Further work to develop greater insight into the 
expression of SUMO within different organs of Ae. aegypti could be conducted by 
dissecting the specific Ae. aegypti organs and conducting proteomic analysis to 
try to identify SUMO conjugated proteins. If SUMO modification of homologous 
proteins is conserved between species it would suggest a conserved biological 
function within organs.  
 
7.3. Biochemical properties of the AaSUMOylation 
pathway 
Biochemical studies have previously been used to provide detailed biological 
insights into host SUMOylation pathways (Muller, Hoege et al. 2001, Tatham, 
Jaffray et al. 2001, Gong, Ji et al. 2014). Utilising affinity tag protein 
purification, the components of the AaSUMOylation pathway have been purified 
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(Figure 4.2) and biochemically characterised for the first time. The assays 
revealed that the biochemical properties of the homologous pathways appear to 
be broadly similar. Ubc9 is capable of forming thioester bonds with SUMO at 
comparable kinetic rates (Figure 4.3). No studies were conducted to determine 
the rate of thioester formation on SAE2. This was because SAE1/2 has a known 
ability to autoSUMOylate (Truong, Lee et al. 2012). However, future studies 
could be conducted in parallel non-reducing and reducing environments to 
compare the rate of SAE2~SUMO thioester formation. The primary difference 
between the H. sapiens and Ae. aegypti SUMOylation pathway is from the 
biochemical properties conferred by AaSUMO. AaSUMO is biochemically more 
comparable to HsSUMO1, as both lack an internal SCM, even though AaSUMO 
shares more amino acid identity with HsSUMO3 (Figure 3.1; Figure 4.4; Figure 
4.5; Figure 4.6). Our studies show that AaSUMO can still form chains, but this 
process only occurs efficiently when in the presence of an AaPIAS (Figure 4.7).  
Poly-SUMO chain formation is widely known to be important for a myriad of 
cellular processes in species ranging from H. sapiens to S. cerevisiae (Tatham, 
Jaffray et al. 2001, Bylebyl, Belichenko et al. 2003, Ulrich 2008). The conserved 
ability to form poly-SUMO chains, as demonstrated by the formation of HMW 
SUMO conjugated proteins (Figure 4.7), indicates that poly-SUMO chains are 
likely to also have an important biological function in Ae. aegypti. Previous 
studies have shown the D. melanogaster SUMO (DmSUMO) cannot form poly-
SUMO chains due to the lack of SCM (Urena, Pirone et al. 2016). Here, we show 
that AaSUMO cannot form poly-SUMO chains unless an E3 ligase, such as an 
AaPIAS, is present (Figure 4.7). Consequently, based on our studies, it seems 
likely that insects including Ae. aegypti and D. melanogaster can form chains, 
but only under tightly regulated circumstances with the presence of an E3 ligase 
such as PIAS.  
Mass spectrometry analysis of our samples indicated that poly-SUMO chains could 
form on any lysine residue on the AaSUMO protein, although lysine 5, 6, 9, and 
40 were primary acceptors for SUMO-SUMO conjugation (Figure 4.8). In H. 
sapiens and S. cerevisiae, the primary site of SUMO conjugation is within an SCM. 
It is likely that if this analysis was repeated including the SUMO chimaera, the 
Lysine 11 would be the primary site of SUMO conjugation as it is located in an 
SCM. Furthermore, in vitro assays can force the formation of poly-HsSUMO1 
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chains by increasing the concentration of Ubc9 incubated in the assay (Matic, 
van Hagen et al. 2008). Perhaps one possible avenue for investigations would 
have been to titrate in lower concentrations of the SAE1/2 and Ubc9, to identify 
the lowest concentrations of protein required to conjugate SUMO in the 
timeframe of the assay. A lower concentration of SAE1/2 and Ubc9 would 
increase the chance of SUMO conjugating to substrates with a higher affinity, 
and may have helped to identify if there is a preference for a specific SUMO 
lysine. A pull down specific for SUMO-chains could also have conclusively proven 
poly-SUMO chain formation in vivo. Poly-SUMO chains are important in H. sapiens 
cells for a range of biological properties, including protein localisation, protein 
stability, and protein-protein interactions. If insects cannot form poly-SUMO 
chains in vivo, it raises many questions about how these functions are performed 
in insect cells.  
 
7.4. The SUMOylation pathway is broadly antiviral 
to arboviruses 
Many studies have implicated components of the SUMOylation pathway as having 
a proviral or antiviral effect through depletion experiments (Brown, Conn et al. 
2016, Conn, Wasson et al. 2016, Su, Tseng et al. 2016, Guo, Chen et al. 2017, 
Feng, Deng et al. 2018). SUMO depletion experiments are crude, as they do not 
distinguish between different targets of SUMO modification, so it becomes hard 
to determine if a phenotype is directly or indirect (Lyst and Stancheva 2007). It 
does, however, demonstrate whether the SUMO pathway has an overall proviral 
or antiviral effect on arbovirus replication within the cell. Previous studies have 
also used dsRNA to deplete expression of targets proteins, such as Ago2, or 
PIWI4, in Ae. aegypti or Ae. aegypti cell culture to determine the effect of the 
target protein on arbovirus replication (Schnettler, Donald et al. 2013, 
McFarlane, Arias-Goeta et al. 2014, Dietrich, Shi et al. 2017, Varjak, Maringer et 
al. 2017).  
Initially, in adult Ae. aegypti mosquitoes, SUMO mRNA was depleted by dsRNA 
injection, and the mosquitoes were infected with ZIKV-nl (Figure 5.6). No 
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significant effect was found on luciferase expression (Figure 5.7). However, 
there are a large number of variables which could not be controlled for that may 
alter the infectivity of ZIKV in the mosquitoes. These include variations in which 
tissues are being depleted and which are becoming infected. For instance, the 
dsRNA could be predominantly depleting SUMO mRNA in the ovaries and salivary 
glands, which together account for over 50% of SUMO mRNA (Figure 5.1). If, 
however, at the end of the experiment ZIKV was primarily replicating in the 
haemocytes and midgut, the SUMO levels would not have been altered in the 
relevant tissues. Consequently, we opted to deplete expression of SUMO, Ubc9, 
or PIAS in Ae. aegypti cell culture, where there are fewer variables, and 
subsequently infected with the alphavirus SFV, orthobunyavirus BUNV, or 
flavivirus ZIKV (Figure 5.8). Studies were later conducted in H. sapiens cells. 
Lentiviruses expressing short hairpin RNA was transfected into fibroblast cells, to 
deplete expression of SUMO1, SUMO2/3, or PIAS1 (Figure 6.1). Following 
successful depletion, cells were infected with SFV, ZIKV, or BUNV and changes in 
luciferase readings were assessed. 
When SFV replication was assessed in depleted Ae. aegypti cells, depletion of 
AaSUMO or AaUbc9 resulted in a significant increase in viral luciferase expression 
and viral RNA levels, indicating that endogenous AaSUMO and AaUbc9 suppress 
arbovirus replication. When AaPIAS was depleted there was no significant effect 
on viral replication (Figure 5.10). There are many potential mechanisms this 
could be due to. The capsid protein of SFV contains two readily accessible 
overlapping SCMs (Figure 3.7). One possibility could be that the capsid 
monomers could be SUMO modified, interfering with the formation of the capsid 
during virus assembly. Depletion of SUMO or Ubc9 would hypothetically reduce 
the amount of SUMO conjugation on the capsid, and therefore reduce the 
amount of interference, increasing viral assembly and replication. This would 
need to be investigated experimentally. Mass spectrometry analysis could 
indicate if the capsid was a target of SUMO modification, and mutation of 
acceptor sites in the SFV capsid could demonstrate if SUMO modification was 
altering viral replication.  Alternatively, many other proteins SFV encodes also 
contain an SCM, including the envelope glycoprotein, nsP1, nsP2, nsP3, or nsP4. 
SUMO binding to any of these proteins could alter viral protein activity or 
stability, this could also be investigated through mass spectrometry and 
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mutational studies to determine target, and function of SUMO modification. An 
alternative hypothesis would be that the increased replication is due to SUMO 
modification of immune proteins which could normally suppress SFV replication. 
As the SUMO pathway is suppressed, the immune proteins would not be 
modified, and SFV could theoretically replicate to higher titres. Again, this 
would need to be confirmed experimentally; potentially through mass 
spectrometry analysis of SUMO modified immune proteins in uninfected and 
infected cells. Interestingly, and in contrast to Ae. aegypti, H. sapiens cells 
depleted of SUMO1 or SUMO2/3 showed no significant effect on viral luciferase 
expression. However, there was a significant increase in viral luciferase when 
HsPIAS1 was depleted (Figure 6.2). This could suggest that the SUMO 
modification hypothesised in Ae. aegypti does not occur in H. sapiens. 
Alternatively, the H. sapiens SUMO homologues could possess redundant or 
overlapping functional roles with each other. This could be examined 
experimentally by depleting expression of Ubc9 or SAE1/2, and determining if 
the SUMO conjugation alters viral luciferase expression.  
When the effect of the depletion on BUNV replication was assessed, AaSUMO, 
AaUbc9, or AaPIAS depletion all increased the replication of BUNV (Figure 5.9). 
Furthermore, depletion of HsSUMO1 or HsPIAS1 also increased luciferase 
expression of BUNV (Figure 6.2). This indicates a conserved role for the 
SUMOylation pathway in suppressing BUNV replication between host and vector 
species. As depletion of HsSUMO2/3 did not result in a statistically significant 
increase in luciferase expression, modification specifically by HsSUMO1 seems 
likely. Two potential targets of this modification are the Gc protein, or the 
RDRP, both of which contain three SCM sites (Figure 3.6). As the resolved 
structure of these proteins is not available, it is currently impossible to say if the 
SCMs are accessible to SUMO modification, or to postulate on a potential 
mechanism of action. Interestingly, SUMO1, Ubc9, PIAS1, and PIAS2β have all 
been implicated in the transport of the ribonucleocapsid (RNC) of other 
Bunyavirales (Seoul and Hantaan viruses) to the Golgi prior to viral packaging 
(Lee, Yoshimatsu et al. 2003, Maeda, Lee et al. 2003). Due to the overall 
antiviral effect on BUNV, the findings suggest that either BUNV RNC may be 
transported to the Golgi via a different mechanism to Hantaan virus or Seoul 
virus, or alternatively, modification by SUMO may still transport the RNC to be 
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packaged, but there may also be an overall more significant antiviral effect on 
another part of the virus replication cycle. This would result in the overall 
antiviral effect from SUMO1 that these studies show. 
Depletion of AaSUMO, AaUbc9, or AaPIAS in Ae. aegypti resulted in a small but 
consistent significant increase in ZIKV replication (Figure 5.11). This could be 
due to modification of NS5, which contain a readily accessible SCM (Figure 3.9). 
Alternatively, as described for SFV, SUMO could be modifying immune related 
proteins which normally function to suppress ZIKV replication. As the 
AaSUMOylation pathway has been depleted, cellular immune proteins may not 
be modified, and consequently ZIKV replication could increase. In contrast to 
this, in H. sapiens cells, HsSUMO1 and HsSUMO2/3 depletion did not have any 
significant effect on viral replication (Figure 6.2). This could be explained if the 
level of depletion in H. sapiens cells were not as effective as Ae. aegypti. 
Alternatively, there may be redundancy between the function of HsSUMO1 and 
HsSUMO2/3. Another possibility is that ZIKV could have evolved a mechanism to 
replicate without being affected by SUMO modification in H. sapiens cells, 
potentially due to the evolutionary divergence between the HsSUMOylation and 
AaSUMOylation pathways. The flavivirus DENV has been shown to be SUMO 
modified at the N-terminal of NS5 to increase protein stability, the study could 
not identify one specific lysine residue that was modified. Consequently, they 
hypothesised that SUMO ‘floats’ around the N-terminus of the protein and could 
modify any of the available lysine residues, as even mutation of all 12 lysine 
residues in the N-terminal resulted in a weak SUMOylated band (Su, Tseng et al. 
2016). Our study does not provide evidence to support this mechanism occurring 
with ZIKV. However, it could be due to redundancy between HsSUMO1 and 
HsSUMO2/3 modification.  
Surprisingly, regardless of the arbovirus utilised, when HsPIAS1 was depleted 
there was a statically significant increase in viral luciferase expression (Figure 
6.2). It seems likely that this indicates a novel biological antiviral function for 
PIAS1, independent of and in contrast to its reported function as an inhibitor of 
STAT and negative regulator of the IFN response (Liu, Liao et al. 1998, Liu, Mink 
et al. 2004). The majority of PIAS functions are related to SUMO, so it is likely 
that the antiviral activity found here is also related to SUMO modification 
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(Rytinki, Kaikkonen et al. 2009). This could occur through its activity as an E3 
ligase, for instance by SUMO modifying a transcription factor, and activating it or 
altering the subcellular localisation, or by SUMO modifying a viral protein 
targeting it for proteasome degradation. PIAS2 was recently found to target the 
HCV core, NS3, and NS5A proteins for proteasome degradation in a ubiquitin 
independent manner, and therefore act as an antiviral protein during HCV 
infection (Guo, Chen et al. 2017). It is possible that PIAS1 acts in a similar 
mechanism against a range of arboviral proteins. Alternatively, PIAS1 has also 
been reported to associate with PML-NBs through SIM dependent mechanisms, 
resulting in the SUMO-1 modification of PML-NBs and enhancing the antiviral 
properties of this protein complex (Brown, Conn et al. 2016). Previous studies 
have found that PML-NBs suppress the replication of DENV2, and consequently it 
is possible that PML-NBs also suppress the replication of other arboviruses, and 
that this activity could be enhanced by PIAS1 mediated SUMO modification 
(Giovannoni, Damonte et al. 2015).  PIAS4 has also been previously shown to be 
an intrinsic antiviral protein to HSV-1, through SIM-dependent and SIM-
independent mechanisms, PIAS4 localises to sites of genome entry and to 
replication compartments, and suppress viral replication (Conn, Wasson et al. 
2016).  
Collectively, these results indicate that the interplay between the SUMOylation 
pathway in the host and vector, following arbovirus infection is context 
dependent. Future work should focus on determining the mechanism of action. 
This could be achieved through mass spectrometry analysis to determine if any 
viral proteins are being SUMO modified; it could also demonstrate other immune 
related proteins being SUMO modified in response to infection with an arbovirus. 
It is likely there is a combination of proviral and antiviral roles for SUMO 
modification during arbovirus replication. More studies should be conducted to 
decipher mechanisms to determine if there is a potential for genetically 
engineered mosquitoes which may help target any proviral roles for SUMO 
modification. In turn, this may help to restrict arboviral replication to reduce 
the burden of arboviral disease.  
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7.5. Concluding remarks  
The SUMOylation pathway is a conserved and vital form of protein modification 
found in all eukaryotic organisms studied to date, including Ae. aegypti. The 
formation of poly-SUMO chains in Ae. aegypti requires an AaPIAS, due to the lack 
of an internal SCM within AaSUMO. This indicates an extra regulatory step for 
the AaSUMOylation pathway, which is less prevalent in other species that 
express a SUMO with an internal SCM. Constituent AaSUMOylation pathway 
enzymes are expressed throughout Ae. aegypti, albeit in a tissue dependent 
manner. The AaSUMOylation pathway has also been shown to contribute to the 
suppression of arbovirus replication from three distinct viral families in an 
arbovirus dependent manner. Furthermore, work in H. sapiens cell lines 
indicates a novel and important function for PIAS1 in restricting the replication 
of a range of arboviruses. 
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AaSAE1 and HsSAE1 
 
AaSAE1    1 MVEA--NGIELTEQEAELYDRQIRLWGLDSQKRLRAARILIAGVNGLGAEIAKNVILSGV 
HsSAE1    1 MVEKEEAGGGISEEEAAQYDRQIRLWGLEAQKRLRASRVLLVGLKGLGAEIAKNLILAGV 
 
 
AaSAE1   59 KAVTLLDDQVVKEADFCSQFLAPQDSLRTNRAEASLSRAQQLNPMVELKADTEELPKKTD 
HsSAE1   61 KGLTMLDHEQVTPEDPGAQFLIRTGSVGRNRAEASLERAQNLNPMVDVKVDTEDIEKKPE 
 
 
AaSAE1  119 DFFKGFDVVCVIGANTEQLLRIDGVCREAGIKFFAADLWGMFGFSFADLQEHNFAEDVVK 
HsSAE1  121 SFFTQFDAVCLTCCSRDVIVKVDQICHKNSIKFFTGDVFGYHGYTFANLGEHEFVEEKTK 
 
 
AaSAE1  179 HKIVSKPHEKTKTE----L---VTSTVKRTLSYPAYQVLLDFDYKAQSYARKLKRSGPAL 
HsSAE1  181 VAKVSQGVEDGPDTKRAKLDSSETTMVKKKVVFCPVKEALEVDWSSEKAKAALKRTTSDY 
 
 
AaSAE1  232 PLLRVLQKFRDDEKRDPLYSEREADLQKLLKIRDEV------AADLIPDNAFLHVFAQIS 
HsSAE1  241 FLLQVLLKFRTDKGRDPSSDTYEEDSELLLQIRNDVLDSLGISPDLLPEDFVRYCFSEMA 
 
 
AaSAE1  286 PAAAIVGGAVAHEIIKTVSQKEAPHHNVFLFDPESCCGFIESIGVDA 
HsSAE1  301 PVCAVVGGILAQEIVKALSQRDPPHNNFFFFDGMKGNGIVECLGP-K 
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* 
AaSAE2 and HsSAE2 
 
AaSAE2    1 MAAQIVGVFEPELQEKISNSKILVVGAGGIGCEILKNLVLSGFQDIEIIDLDTIDVSNLN 
HsSAE2    1 MA--LSRGLPRELAEAVAGGRVLVVGAGGIGCELLKNLVLTGFSHIDLIDLDTIDVSNLN 
 
 
AaSAE2   61 RQFLFHKEHVGKSKANVARESALSFNPNVKIKAYHDSITTSNYGVNFFQQFNLVLNALDN 
HsSAE2   59 RQFLFQKKHVGRSKAQVAKESVLQFYPKANIVAYHDSIMNPDYNVEFFRQFILVMNALDN 
 
 
AaSAE2  121 RAARNHVNRLCLTADVPLIESGTAGYNGQVELIKRGLTQCYECTPKAAQKTFPGCTIRNT 
HsSAE2  119 RAARNHVNRMCLAADVPLIESGTAGYLGQVTTIKKGVTECYECHPKPTQRTFPGCTIRNT 
 
 
AaSAE2  181 PSEPIHCIVWAKHLFNQLFGESNEDEDVSPDTADPEAGAEAGES-ALAAEANEKGNVDRV 
HsSAE2  179 PSEPIHCIVWAKYLFNQLFGEEDADQEVSPDRADPEAAWEPTEAEARARASNEDGDIKRI 
 
 
AaSAE2  240 NTRTWAQQCGYDPEKIFNKLFYDDINYLLSMSNLWKSRTPPNPAKWDALEEDGEAAP--- 
HsSAE2  239 STKEWAKSTGYDPVKLFTKLFKDDIRYLLTMDKLWRKRKPPVPLDWAEVQSQGEETNASD 
 
 
AaSAE2  297 --TD-T-VLRDQKVLSLTESAKVFGESITALKKDFEKLAEGDHLVWDKDDKHAMDFVAAC 
HsSAE2  299 QQNEPQLGLKDQQVLDVKSYARLFSKSIETLRVHLAEKGDGAELIWDKDDPSAMDFVTSA 
 
 
AaSAE2  353 ANIRAQIFNIPRKSRFEVKSMAGNIIPAIATTNAITAGVVVMHAFRVLKGELDKCKSVYM 
HsSAE2  359 ANLRMHIFSMNMKSRFDIKSMAGNIIPAIATTNAVIAGLIVLEGLKILSGKIDQCRTIFL 
 
 
AaSAE2  413 RLRPNARNQLFVPDRTLNPPNPKCYVCAAKPEVTLKVDTKNVTVKELRDDILIKALNMLN 
HsSAE2  419 CALDPPNPNCYVCASKPEVTVRLNVHKVTVLTLQDKIVKEKFAMVANKQPNPRKKLLVP- 
 
 
AaSAE2  473 PDVI-LDGKGTIVISSEEGETDCNNDKKLEDLQIVDGCILKVDDFVQNYELTVTVIHKDP 
HsSAE2  478 PDVQIEDGKGTILISSEEGETEANNHKKLSEFGIRNGSRLQADDFLQDYTLLINILHSED 
 
 
AaSAE2  532 GRDESSFDIVA-DPDSLKPKEDEDQKTDDVQPSTSGQNGNSKASTSNNGAVDDDDDMCIV 
HsSAE2  538 LGKDVEFEVVGDAPEKVGPKQAEDA-A---KSITNGSDDGAQPS---TSTAQEQDDVLIV 
 
 
AaSAE2  591 EEDAEKPSTSDAGAGPSSSGSEKRKIEDSEGPSTKKARVSNDDDDDDLIVIN 
HsSAE2  591 DSDEEDS-SNNADVSEE-ERSRKRKLDEKENLSAKRSRIEQKEELDDVIALD 
 
* catalytically active cysteine (Lois and Lima 2005)   
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AaPAIS and HsPIAS 
 
AaPIAS     1 MRKTRQVAEFTELKDLVHQLRVSDLQQLLGENNISRSGRKSELIERVLILVRQNISV-LK 
HsPIAS1    1 ------MADSAELKQMVMSLRVSELQVLLGYAGRNKHGRKHELLTKALHLLKAGCSPAVQ 
HsPIAS2α   1 ------MADFEELRNMVSSFRVSELQVLLGFAGRNKSGRKHDLLMRALHLLKSGCSPAVQ 
HsPIAS2β   1 ------MADFEELRNMVSSFRVSELQVLLGFAGRNKSGRKHDLLMRALHLLKSGCSPAVQ 
HsPIAS3    1 ------MAELGELKHMVMSFRVSELQVLLGFAGRNKSGRKHELLAKALHLLKSSCAPSVQ 
HsPIAS4    1 -----MAAELVEAKNMVMSFRVSDLQMLLGFVGRSKSGLKHELVTRALQLVQFDCSPELF 
 
 
AaPIAS    60 YKVRDLHKKAQEETELLKQAAETPVITTQPIQPPPPVLPPEPPVISRVPQGMYQQQYANA 
HsPIAS1   55 MKIKELYRRRFPQKIMTPADLS-----IPNVHSSP--MPAT----L-SPSTIPQLTYDGH 
HsPIAS2α  55 IKIRELYRRRYPRTLEGLSDLSTIKSSVFSLDGGS--SPVEPDLAVAGIHSLPSTSVTPH 
HsPIAS2β  55 IKIRELYRRRYPRTLEGLSDLSTIKSSVFSLDGGS--SPVEPDLAVAGIHSLPSTSVTPH 
HsPIAS3   55 MKIKELYRRRFPRKTLGPSDLS-----LLSLPPGT--SPVG------SPGPLAPIP---- 
HsPIAS4   56 KKIKELYETRYAKKNSEPAPQP-----HRPLDPLT--MHSTYD----RAGAVPRTPLAGP 
 
 
AaPIAS   120 VQNDNRGGQVHANGIVPIPYPEATPNPGYPIHPDVKLKKLAFFDVLATLLKPATLVPSNT 
HsPIAS1  103 PASSPLLPVSLLGPKHELELPHLT-SALHPVHPDIKLQKLPFYDLLDELIKPTSLASD-N 
HsPIAS2α 113 SPSSPVGSVLLQDTKPTFEMQQPS-PPIPPVHPDVQLKNLPFYDVLDVLIKPTSLVQS-S 
HsPIAS2β 113 SPSSPVGSVLLQDTKPTFEMQQPS-PPIPPVHPDVQLKNLPFYDVLDVLIKPTSLVQS-S 
HsPIAS3   98 --PTLLAPGTLLGPKREVDMH--P-PLPQPVHPDVTMKPLPFYEVYGELIRPTTLAST-S 
HsPIAS4  105 NIDYPVLYGKYLNGLG-------R-LPAKTLKPEVRLVKLPFFNMLDELLKPTELVPQ-N 
 
 
AaPIAS   180 TQRIQEGSFFFHLTPQQATDIATNRDIRNVNKIEHTIQVQLRFCLLETSCEQEDYFPPNI 
HsPIAS1  161 SQRFRETCFAFALTPQQVQQISSSMDIS-GTKCDFTVQVQLRFCLSETSCPQEDHFPPNL 
HsPIAS2α 171 IQRFQEKFFIFALTPQQVREICISRDFLPGGRRDYTVQVQLRLCLAETSCPQEDNYPNSL 
HsPIAS2β 171 IQRFQEKFFIFALTPQQVREICISRDFLPGGRRDYTVQVQLRLCLAETSCPQEDNYPNSL 
HsPIAS3  152 SQRFEEAHFTFALTPQQVQQILTSREVLPGAKCDYTIQVQLRFCLCETSCPQEDYFPPNL 
HsPIAS4  156 NEKLQESPCIFALTPRQVELIRNSRELQPGVKA---VQVVLRICYSDTSCPQEDQYPPNI 
 
 
AaPIAS   240 VVKVNNKLCPLPNPIPTNKPGVEPKRPPRPVNITPNVKLSPLVANHIAVSWCTEYNRGYA 
HsPIAS1  220 CVKVNTKPCSLPGYLPPTKNGVEPKRPSRPINITSLVRLSTTVPNTIVVSWTAEIGRNYS 
HsPIAS2α 231 CIKVNGKLFPLPGYAPPPKNGIEQKRPGRPLNITSLVRLSSAVPNQISISWASEIGKNYS 
HsPIAS2β 231 CIKVNGKLFPLPGYAPPPKNGIEQKRPGRPLNITSLVRLSSAVPNQISISWASEIGKNYS 
HsPIAS3  212 FVKVNGKLCPLPGYLPPTKNGAEPKRPSRPINITPLARLSATVPNTIVVNWSSEFGRNYS 
HsPIAS4  213 AVKVNHSYCSVPGYYPSNKPGVEPKRPCRPINLTHLMYLSSAT-NRITVTWG-NYGKSYS 
 
 
AaPIAS   300 AACYLVRKLTSSQLLQRMKTKGVKPADYTRALIKEKLNEDADCEIATTMLKVSLVCPLGK 
HsPIAS1  280 MAVYLVKQLSSTVLLQRLRAKGIRNPDHSRALIKEKLTADPDSEIATTSLRVSLLCPLGK 
HsPIAS2α 291 MSVYLVRQLTSAMLLQRLKMKGIRNPDHSRALIKEKLTADPDSEIATTSLRVSLMCPLGK 
HsPIAS2β 291 MSVYLVRQLTSAMLLQRLKMKGIRNPDHSRALIKEKLTADPDSEIATTSLRVSLMCPLGK 
HsPIAS3  272 LSVYLVRQLTAGTLLQKLRAKGIRNPDHSRALIKEKLTADPDSEVATTSLRVSLMCPLGK 
HsPIAS4  271 VALYLVRQLTSSELLQRLKTIGVKHPELCKALVKEKLRLDPDSEIATTGVRVSLICPLVK 
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AaPIAS   360 MRMATPCRSSTCSHLQCFDASLYLQMNERKPTWNCPVCDKAAIYDNLVIDGYFQEVLASN 
HsPIAS1  340 MRLTIPCRALTCSHLQCFDATLYIQMNEKKPTWVCPVCDKKAPYEHLIIDGLFMEIL--- 
HsPIAS2α 351 MRLTIPCRAVTCTHLQCFDAALYLQMNEKKPTWICPVCDKKAAYESLILDGLFMEIL--- 
HsPIAS2β 351 MRLTIPCRAVTCTHLQCFDAALYLQMNEKKPTWICPVCDKKAAYESLILDGLFMEIL--- 
HsPIAS3  332 MRLTVPCRALTCAHLQSFDAALYLQMNEKKPTWTCPVCDKKAPYESLIIDGLFMEIL--- 
HsPIAS4  331 MRLSVPCRAETCAHLQCFDAVFYLQMNEKKPTWMCPVCDKPAPYDQLIIDGLLSKIL--- 
 
 
AaPIAS   420 KLSSEDNEIQLHKDGSWSTHVKTNDSCTLDTPSKPVQKVEV--VSD-DIEIITTDPPKSS 
HsPIAS1  397 KYCTDCDEIQFKEDGTWAPMRSKKEVQEVS--ASY-NGVDGCLSSTLEHQVASHHQSSNK 
HsPIAS2α 408 NDCSDVDEIKFQEDGSWCPMRPKKEAMKVS--SQPCTKIES--SSVLSKPCSVTVASEAS 
HsPIAS2β 408 NDCSDVDEIKFQEDGSWCPMRPKKEAMKVS--SQPCTKIES--SSVLSKPCSVTVASEAS 
HsPIAS3  389 SSCSDCDEIQFMEDGSWCPMKPKKEASEVC--PPPGYGLDG----L-QYSPVQGGDPSEN 
HsPIAS4  388 SECEDADEIEYLVDGSWCPIRAEKERS--C--SPQ-------------GAILVLGPSDAN 
 
 
AaPIAS   477 INQASVISSSEPSSTTAPSSDTVDLTLSDSDDDLPL-KRKTVTRAAAGG--Q 
HsPIAS1  454 N-------------KKVEVIDLTIDSSSDEEEEEPSAKRTCPSLSPTS-P-L 
HsPIAS2α 464 K-------------KKVDVIDLTIESSSDEEEDPPA-KRKCIFMSETQS--S 
HsPIAS2β 464 K-------------KKVDVIDLTIESSSDEEEDPPA-KRKCIFMSETQS--S 
HsPIAS3  442 K-------------KKVEVIDLTIESSSDEEDLPPT-KKHCSVTSAAIPALP 
HsPIAS4  431 G-----------------LLPAPSVNGSGALGSTGG-GGPVGSMENGK---P 
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Appendix B: Purification 
of AaSAE1/2  
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Initially, a Ni2+ affinity purification was used on AaSAE1/2, with a 6xHis tag 
cloned in frame with either AaSAE1 or AaSAE2. During purification the 
heterodimer appeared to dissociate, and consequently there was a bias towards 
the protein which possesses the 6xHis tag. Optimisation studies revealed that 
this is due to the imidazole concentration, used for elution which induced 
heterodimer dissociation. Further analysis of the modelled structure of AaSAE1/2 
revealed non-conserved histidine residues at the interface of AaSAE1 and 
AaSAE2, which are likely the cause of the dissociation. We hypothesise that the 
imidazole competitively binds to the histamine residues at the interface of 
AaSAE1 and AaSAE2, leading to heterodimer dissociation. Consequently, the 
AaSAE1/2 heterodimer was cloned into a Strep.II tag vector, interestingly, when 
the Strep.II tag was cloned onto the N-terminal of AaSAE1, the heterodimer was 
inactive (data not shown). However, when the Strep.II tag was cloned onto the 
N-terminal of AaSAE2, a functional heterodimer was produced that was utilised 
for the rest of the biochemical studies. 
SAE1 
SAE2 
55 
40 
35 
70 
95 
kDa 
 1       2.5       5              1       2.5      5       µl sample loaded 
 Purification of 6x His AaSAE1/2 through Nickel affinity chromatography 
Coomassie stained SDS-PAGE gel of purified AaSAE1/2, containing a 6xHis tag 
on the N-terminal of either the SAE2 protein (left), or the SAE1 protein 
(right). Regardless of which protein was tagged, the heterodimer dissociated 
during purification.  
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 SAE2 
 SAE1 
  0      50      100     150       200      250       300    mM imidazole 
kDa 
55 
40 
35 
70 
95 
130 
25 
15 
250 
Imidazole titration performed during purification of 6xHis-
AaSAE1/AaSAE2 
Coomassie stained SDS-PAGE gel of 6xHis-AaSAE1/AaSAE2 samples 
grown and purified using increasing concentrations of imidazole in 
the elution buffer.  As the concentration of imidazole increased, 
the ratio of 6xHis-AaSAE1 to AaSAE2 became more skewed in favour 
of 6xHis-AaSAE1. 
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Histidine residues at the AaSAE1/2 interface  
(A) The predicted structure of AaSAE1/2 was modelled and histidine residues 
(pink, labelled) located around the AaSAE1 (light sea green), AaSAE2 
(cornflower blue) interface were identified. (B) 180˚ rotation on the Y-axis 
focusing on the interface of AaSAE1 and AaSAE2. 
B   
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Appendix C: Purified 
AaUbc9 C93S, the 
SUMO chimaera, and 
the SUMO chimaera 
K11R  
  
S Stokes, 2018  308 
In order to characterise biochemical properties of proteins in the AaSUMOylation 
pathway, catalytically inactive, and chimaeric proteins were produced. A 
catalytically inactive AaUbc9 (Ubc9 C93S) was produced and cloned as described 
(Section 2.2.1.10; Section 2.2.9.3), and purified through the 6xHis tag (Section 
2.2.2.2). A chimaeric SUMO protein and a chimaeric SUMO containing a K11R 
mutation were also synthesised, cloned as described and purified through 6xHis 
tag (Section 2.2.9.2; Section 2.2.2.2). 
 
 
 
 
 
 
110 
80 
60 
50 
40 
30 
1      2.5   5     125   250   500  
BSA (ng 
loaded) 
Ubc9 C93S 
(µl loaded) 
A   
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Purification of chimaeric proteins, and proteins containing point mutations  
Coomassie stained SDS-PAGE gel of 6xHis purified (A) Ubc9 C93S, (B) SUMO 
chimaera, and (C) SUMO chimaera K11R. BSA standards included to determine 
concentration. Molecular weight markers indicated. 
130 
95 
55 
40 
25 
15 
    1    2.5       5     125   250   500  
BSA (ng 
loaded) 
SUMO 
chimaera 
(µl loaded) 
70 
35 
B
   1    2.5     5       125    250   500  
BSA (ng 
loaded) 
SUMO chimaera 
K11R (µl loaded) 
C  
kDa 
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Appendix D: No 
primary antibody 
controls of SUMO 
expression in Ae. 
aegypti tissues 
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Confocal microscopy of tissues stained with no primary antibody 
 
Non blood-fed adult female Ae. aegypti had cells and organs dissected. Confocal 
microscopy was conducted without primary (αSUMO2/3) antibody, tissues were 
stained with DAPI (nuclei, blue), and Phalloidin 488 (F-actin, green), secondary 
antibody Alexa Fluor 568 goat anti-mouse IgG was diluted 1:1000 (red). 
Experiment was conducted on haemocytes (A), salivary glands (B), midgut (C), 
and ovaries (D). Images were acquired on a Zeiss LSM 880 confocal microscope 
with 40x or 63x oil-immersion lens using the same settings as the samples 
incubated with a primary antibody. Scale bar represents 20 µm. 
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Appendix E:  
Melt curve analysis  
of q-PCR primers 
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A 
RNA was harvested from either mosquito AF5 cells or Ae. aegypti organs, cDNA 
was synthesised and  q-PCR analysis was conducted. Subsequent melt curves 
were conducted to ensure no primer dimers were interfering with analysis. (A) 
melt curves following q-PCR of primers targeting the ribosomal S7, (B) melt 
curves following q-PCR of primers targeting SUMO, (C) melt curves following q-
PCR of primers targeting Ubc9, and (D) melt curves following q-PCR of primers 
targeting PIAS. 
B 
C D 
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“Have no fear of perfection – you’ll never reach it”  
– Salvador Dali 
